Original Article
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
N Engl J Med 2006; 355:2542-2550December 14, 2006
- Abstract
Background
Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been shown to benefit patients with a variety of cancers.
Methods
Between July 2001 and April 2004, the Eastern Cooperative Oncology Group (ECOG) conducted a randomized study in which 878 patients with recurrent or advanced non–small-cell lung cancer (stage IIIB or IV) were assigned to chemotherapy with paclitaxel and carboplatin alone (444) or paclitaxel and carboplatin plus bevacizumab (434). Chemotherapy was administered every 3 weeks for six cycles, and bevacizumab was administered every 3 weeks until disease progression was evident or toxic effects were intolerable. Patients with squamous-cell tumors, brain metastases, clinically significant hemoptysis, or inadequate organ function or performance status (ECOG performance status, >1) were excluded. The primary end point was overall survival.
Results
The median survival was 12.3 months in the group assigned to chemotherapy plus bevacizumab, as compared with 10.3 months in the chemotherapy-alone group (hazard ratio for death, 0.79; P=0.003). The median progression-free survival in the two groups was 6.2 and 4.5 months, respectively (hazard ratio for disease progression, 0.66; P<0.001), with corresponding response rates of 35% and 15% (P<0.001). Rates of clinically significant bleeding were 4.4% and 0.7%, respectively (P<0.001). There were 15 treatment-related deaths in the chemotherapy-plus-bevacizumab group, including 5 from pulmonary hemorrhage.
Conclusions
The addition of bevacizumab to paclitaxel plus carboplatin in the treatment of selected patients with non–small-cell lung cancer has a significant survival benefit with the risk of increased treatment-related deaths. (ClinicalTrials.gov number, NCT00021060.)
Media in This Article
Figure 1
Enrollment, Randomization, and Follow-up of Patients in the Study.Figure 2
Kaplan–Meier Estimates of Overall Survival (Panel A) and Progression-free Survival (Panel B).Article Activity
- Article
In the United States, lung cancer affects approximately 171,000 people annually and is the leading cause of cancer-related deaths.1 Approximately 85% of these patients have non–small-cell lung cancer. The Eastern Cooperative Oncology Group (ECOG) conducted a randomized clinical trial comparing four platin-based, two-drug chemotherapy regimens in more than 1100 patients.2 The median survival was 8 months, with no significant differences in overall survival among the groups. Although modest progress has been made with the use of chemotherapy in patients with metastatic non–small-cell lung cancer, additional treatment options are needed.
Angiogenesis is one of the hallmarks of cancer.3 Vascular endothelial growth factor (VEGF), an endothelial-cell–specific mitogen, is the major regulator of angiogenesis in normal and malignant tissue.4,5 Increased expression of VEGF has been found in most tumors in humans, including non–small-cell lung cancers, and in many instances, it is associated with increased risks of recurrence, metastasis, and death.6-9 Preclinical studies have shown that a murine monoclonal antibody against VEGF can inhibit the growth of human tumor xenografts when given alone or with chemotherapy.10-13 A humanized variant of this antibody (bevacizumab [Avastin, Genentech]) has clinical activity in human cancer and increases survival when added to standard chemotherapy in metastatic colon cancer.14
A randomized phase 2 study, involving patients with advanced non–small-cell lung cancer who had not previously received chemotherapy, compared paclitaxel and carboplatin alone with paclitaxel and carboplatin plus bevacizumab, with bevacizumab at a dose of 7.5 mg or 15 mg per kilogram of body weight intravenously every 3 weeks.15 In the group receiving the higher dose of bevacizumab, as compared with the two other groups, the median time to disease progression was significantly longer. However, of the 66 patients who received bevacizumab, life-threatening pulmonary hemorrhage occurred in 6, including four fatal events. Serious hemorrhagic events appeared to be more common among patients with predominantly squamous-cell carcinomas. These preliminary results prompted the present phase 3 study, which was designed to investigate whether the addition of bevacizumab to paclitaxel and carboplatin improves survival in patients with metastatic non–squamous-cell, non–small-cell lung cancer.
Methods
Patients
Between July 2001 and April 2004, we conducted a randomized study in which 878 patients with recurrent or advanced non–small-cell lung cancer (stage IIIB or IV) were assigned to paclitaxel and carboplatin chemotherapy alone (paclitaxel–carboplatin group) (444 patients) or paclitaxel and carboplatin plus bevacizumab (paclitaxel–carboplatin–bevacizumab group) (434 patients). Eligible patients were required to have histologically or cytologically confirmed, newly diagnosed stage IIIB (malignant pleural effusion) or stage IV cancer or recurrent non–small-cell lung cancer for which they had not received chemotherapy. Other inclusion criteria were measurable or nonmeasurable disease as defined by the Response Evaluation Criteria in Solid Tumors (RECIST),16 an ECOG performance status of 0 or 1, and adequate hematologic, hepatic, and renal function (including urinary excretion of ≤500 mg of protein per day).
Exclusion criteria were histologic evidence of predominantly squamous-cell cancer; hemoptysis (1/2 tsp or more per event — a criterion added after a grade 5 pulmonary hemorrhage occurred in a patient with pretreatment hemoptysis); central nervous system (CNS) metastases (to reduce concern about possible CNS hemorrhage); pregnancy or lactation; a history of documented hemorrhagic diathesis or coagulopathy; therapeutic anticoagulation; regular use of aspirin (>325 mg per day), nonsteroidal antiinflammatory agents, or other agents known to inhibit platelet function; radiation therapy within 21 days before enrollment or major surgery within 28 days before enrollment; clinically significant cardiovascular disease; and medically uncontrolled hypertension.
Laboratory Correlates
Plasma VEGF levels were measured at baseline in the initial 166 consecutive patients (79 in the paclitaxel–carboplatin group and 87 in the paclitaxel–carboplatin–bevacizumab group) by means of an enzyme-linked immunosorbent assay. Each sample was assayed in duplicate.
Study Design
Treatment assignments were designed to achieve a balance between the two study groups in permuted blocks with stratification according to measurable versus nonmeasurable disease, prior radiation therapy versus no prior radiation therapy, prior weight loss of less than 5% versus 5% or more, and non–small-cell lung cancer, stage IIIB, with pleural effusion versus stage IV or recurrent disease. The primary end point was overall survival. Prespecified stopping rules were based on toxic effects.
Patients were randomly assigned to receive paclitaxel at a dose of 200 mg per square meter of body-surface area and carboplatin at a dose calculated to produce an area under the concentration–time curve of 6.0 mg per milliliter per minute, administered intravenously on day 1, or paclitaxel and carboplatin plus bevacizumab at a dose of 15 mg per kilogram given intravenously on day 1.15 Chemotherapy was repeated every 21 days for a total of six cycles unless there was evidence of disease progression or intolerance of the study treatment. Patients in the paclitaxel–carboplatin–bevacizumab group continued to receive bevacizumab monotherapy every 3 weeks until evidence of disease progression or unacceptable toxic effects developed.
The protocol was approved by the institutional review boards of all participating institutions and was carried out in accordance with the Declaration of Helsinki, current Food and Drug Administration Good Clinical Practices, and local ethical and legal requirements. ECOG designed and coordinated the study and was responsible for all aspects of the data collection and analysis; the authors made the decision to publish the data. The authors assume responsibility for the overall content and integrity of the manuscript and vouch for the accuracy and completeness of the reported data; their views do not necessarily represent the official views of the National Cancer Institute (NCI). Bevacizumab (Cancer Chemotherapy National Service Center code 704865) was provided by Genentech and distributed by the NCI.
Assessments
After the baseline evaluation, tumor status was assessed every 6 weeks for 24 weeks, then every 9 weeks for the remainder of the treatment period, and then every 12 weeks after the completion of treatment. Responses were assessed using RECIST and required confirmation at least 4 weeks after initial documentation.
Assessments of toxic effects were made according to the common toxicity criteria (version 2) of the NCI. Because of concern about pulmonary hemorrhage, any serious bleeding event (grade 3 or higher) was reported to ECOG and the study chairman within 24 hours after its occurrence.
Statistical Analysis
The original study design called for the enrollment of a total of 640 patients, with the final analyses to be performed after 500 deaths had occurred. The design included two planned suspensions of recruitment for the safety analysis after a total of 112 patients had been enrolled and then after a total of 336 patients had been enrolled and planned interim analyses of survival after 218 and 350 deaths had occurred. The plan to suspend recruitment after enrollment of 336 patients was eliminated in August 2003, on the basis of the recommendation by the data monitoring committee; in January 2004, the planned enrollment was increased to 842 patients, with a planned final analysis after 650 deaths had occurred, to target a smaller treatment effect than that in the original study design. The increase in accrual was based on a recommendation by the ECOG Lung Committee, which was unaware of the results of the efficacy analysis. The revised design yielded an 80.5% power of the study to detect a hazard ratio for death of 0.80 in the group treated with chemotherapy plus bevacizumab, with the use of a one-sided test and an overall type I error of 2.5%.
The design specified interim analyses after 286 deaths had occurred (44%) and after 455 deaths had occurred (70%), with stopping rules both for a demonstrated difference between the study groups and for a demonstrated lack of benefit on the basis of the confidence intervals (CIs) for the hazard ratio,17 estimated by means of a stratified partial-likelihood test with the use of an O'Brien–Fleming boundary. The study was continuously monitored for rates of grades 4 and 5 bleeding events, with early stopping if the rate among the first 336 patients enrolled was significantly higher in the paclitaxel–carboplatin–bevacizumab group than in the paclitaxel–carboplatin group, as calculated with the use of Fisher's exact test.
All efficacy analyses were based on a comparison of the assigned treatments. The primary analysis excluded patients deemed to be ineligible on central review of the submitted data. However, an intention-to-treat analysis of all patients showed similar results (P=0.005 for survival). Survival was defined as the time from randomization to death from any cause, and progression-free survival as the time from randomization to documented disease progression (according to RECIST) or death. Event–time distributions were estimated by the Kaplan–Meier method. Cox proportional-hazards models, stratified according to the measurability of disease, disease stage, presence or absence of prior radiation therapy, and amount of prior weight loss, were used to estimate the hazard ratios and to test for significance of the timing of events. All reported P values are two-sided, and CIs are at the 95% level. Adverse events were compared with the use of Fisher's exact test.
Results
After the second planned interim analysis, the independent data monitoring committee recommended the release of the study results in March 2005, since the criteria for significance prespecified in the protocol had been met (Wald statistic, 2.67; O'Brien–Fleming boundary, at 72.2% information, 2.41). The results reported here include follow-up through October 2005 (median, 19 months; minimum time from study entry to the cutoff point for the primary analysis, 18 months).
Baseline Characteristics of the Patients
Between July 19, 2001, and April 27, 2004, including a prespecified suspension between February and August 2002, a total of 878 patients were enrolled, of whom 444 were assigned to treatment with paclitaxel and carboplatin alone and 434 to paclitaxel and carboplatin plus bevacizumab. Twenty-eight patients were excluded from the primary analysis because of eligibility violations or inadequate data (nine patients because of incorrect disease stage, six because of receipt of radiation therapy within three weeks before entry into the study, four because of histologic findings of squamous-cell cancer, and nine for other reasons) (Figure 1Figure 1
Enrollment, Randomization, and Follow-up of Patients in the Study.). Table 1Table 1
Baseline Characteristics of the Patients. shows the baseline characteristics of eligible patients. The two groups were well balanced, except for a difference in distribution according to sex (men accounted for 58% of patients in the paclitaxel–carboplatin group and 50% of those in the paclitaxel–carboplatin–bevacizumab group; P=0.03, with Fisher's exact test).Treatment
The median number of cycles of therapy was five in the paclitaxel–carboplatin group and seven in the paclitaxel–carboplatin–bevacizumab group (including the cycles of bevacizumab monotherapy). Of the 407 patients starting treatment with paclitaxel and carboplatin plus bevacizumab for whom we had adequate information on the duration of treatment, 215 (53%) continued with bevacizumab monotherapy, and of these, 107 (50%) received more than five cycles of monotherapy. Information on treatment at the time of disease progression was available for 528 of the 850 patients included in the primary analysis. Chemotherapy was given to 200 patients in the paclitaxel–carboplatin group (including 87 of 180 women [48%]) at the time of disease progression, as compared with 180 patients in the paclitaxel–carboplatin–bevacizumab group (82 of 207 women [40%]). In addition, more women in the paclitaxel–carboplatin group received second-line chemotherapy: 48% (87 of 180) as compared with 40% (82 of 207) in the paclitaxel–carboplatin–bevacizumab group. However, there was no significant difference in the number of women who subsequently received epidermal growth factor–tyrosine kinase inhibitors (32 of 180 in the paclitaxel–carboplatin group and 34 of 207 in the paclitaxel–carboplatin–bevacizumab group).
Efficacy Analysis
The median overall survival was 12.3 months in the paclitaxel–carboplatin–bevacizumab group, as compared with 10.3 months in the paclitaxel–carboplatin group (hazard ratio for death, 0.79; 95% CI, 0.67 to 0.92; P=0.003) (Figure 2AFigure 2
Kaplan–Meier Estimates of Overall Survival (Panel A) and Progression-free Survival (Panel B).). Survival rates were 51% in the paclitaxel–carboplatin–bevacizumab group, as compared with 44% in the paclitaxel–carboplatin group, at 1 year and 23%, as compared with 15%, respectively, at 2 years. The median progression-free survival was also significantly improved in the paclitaxel–carboplatin–bevacizumab group (6.2 months, as compared with 4.5 in the paclitaxel–carboplatin group), for a hazard ratio for disease progression of 0.66 (95% CI, 0.57 to 0.77; P<0.001) (Figure 2B). Among 773 patients with measurable disease, the addition of bevacizumab to paclitaxel and carboplatin improved the response rate; 59 of 392 patients (15%) in the paclitaxel–carboplatin group had a response, as compared with 133 of 381 patients (35%) in the paclitaxel–carboplatin–bevacizumab group (P<0.001).The effects of bevacizumab on survival and progression-free survival were consistent among the four subgroups, stratified according to whether patients had measurable or nonmeasurable disease, prior radiation therapy or no prior radiation therapy, a weight loss of 5% or more or a loss of less than 5%, and stage IIIb disease (pleural effusion) or stage IV disease, or recurrent disease (Figure 3Figure 3
Hazard Ratios for Death, According to the Subgroup Analysis.).VEGF Levels
Baseline VEGF levels in 166 patients did not differ significantly according to treatment (P=0.13, calculated by the Wilcoxon rank-sum test) or sex (P=0.67) (median VEGF level, 38.7 ng per milliliter in the paclitaxel–carboplatin group and 33.7 ng per milliliter in the paclitaxel–carboplatin–bevacizumab group; 36.7 ng per milliliter in men and 33.7 ng per milliliter in women; range, 12.5 to 445 in all subgroups). VEGF levels before treatment did not correlate with overall survival (P=0.15).
Safety
All patients known to have received the study treatment (440 patients in the paclitaxel–carboplatin group and 427 in the paclitaxel–carboplatin–bevacizumab group) were included in the analysis of toxic effects. Reporting was limited to hematologic events of grade 4 or higher and all nonhematologic adverse events of grade 3 or higher. Table 2Table 2
Adverse Events, According to Treatment. lists rates of adverse events in each treatment group. The treating physician's attribution of the adverse event to the treatment or to another cause was not considered in this analysis. The rates of hypertension, proteinuria, bleeding, neutropenia, febrile neutropenia, thrombocytopenia, hyponatremia, rash, and headache were significantly higher in the paclitaxel–carboplatin–bevacizumab group than in the paclitaxel–carboplatin group (P<0.05). The difference between the groups appeared during the third cycle; during the first three cycles, events occurred in 57 of the 440 patients in the paclitaxel–carboplatin group (13%) and in 76 of the 427 patients in the paclitaxel–carboplatin–bevacizumab group (18%).Table 3Table 3
Causes of Death. lists all causes of death. There were 17 deaths related to toxic effects of the treatment. Two deaths (from gastrointestinal hemorrhage and febrile neutropenia) occurred in patients in the paclitaxel–carboplatin group and 15 occurred in the paclitaxel–carboplatin–bevacizumab group; the difference between the groups was significant (P=0.001). Of the 15 deaths in the paclitaxel–carboplatin–bevacizumab group, 5 were attributed to pulmonary hemorrhage, 5 to complications of febrile neutropenia, 2 each to a cerebrovascular event or gastrointestinal hemorrhage, and 1 to a probable pulmonary embolus. Most of the deaths occurred during the first two cycles of therapy. Three patients in the paclitaxel–carboplatin–bevacizumab group died of cardiac events that were not considered to be related to the treatment: a myocardial infarction 40 days after the last dose of bevacizumab, a sudden death (no autopsy) during the 18th cycle of treatment, and cardiac arrest with bradycardia after the third cycle (no autopsy). Among the 215 patients receiving bevacizumab monotherapy, the most common grade 3 or 4 toxic effects were hypertension (in 12 patients [5.6%]), proteinuria (in 9 patients [4.2%]), fatigue (in 11 patients [5.1%]), and dyspnea (in 12 patients [5.6%]).Discussion
We found that the addition of bevacizumab to a standard, platin-based chemotherapy regimen improved overall survival in patients with advanced non–squamous-cell, non–small-cell lung cancer and a good ECOG performance status. In addition, bevacizumab prolonged progression-free survival and improved the response rate.
The improvement in the response rate was not anticipated a priori, since antiangiogenic drugs were not considered to have a cytotoxic effect.3 Initially, it was thought that the predominant effect of antiangiogenic agents was the prevention of the development of new blood vessels, and that in this way these agents inhibit tumor growth. Jain reported that elevated VEGF levels cause a disorganized and “leaky” vasculature within the tumor; this effect elevates interstitial pressure and thus decreases delivery of chemotherapy to the tumor.18 Subsequently, Willett et al. found that bevacizumab increases drug delivery to the tumor.19 The significant improvement in the response rate in our study and in previous randomized studies of chemotherapy with or without bevacizumab supports the hypothesis that bevacizumab improves drug delivery to the tumor.14,20,21
In the phase 2 study that served as the impetus for our trial, an unexpectedly high rate of life-threatening and fatal pulmonary hemorrhages was associated with bevacizumab treatment, particularly in patients with squamous-cell lung cancer.15 These results led us to exclude patients with predominantly squamous-cell carcinoma, hemoptysis, or both. With these exclusions, the incidence of life-threatening pulmonary hemorrhage was 1.9% (fatal hemorrhage, 1.2%), whereas in the phase 2 study, in which hemoptysis and predominantly squamous-cell carcinoma were not exclusion criteria, the incidence of this complication was 9.1%. Among the five patients who died from pulmonary hemorrhage in our study, one had hemoptysis before entry into the study (before the amendment to exclude patients with hemoptysis of 1/2 tsp or more at baseline), and hemoptysis developed in another patient during the first cycle of therapy. This second patient continued in the study and had a fatal event during the second cycle of treatment. Clearly, in retrospect, this patient should not have continued to receive bevacizumab. Among the 10 other deaths considered to be related to treatment, 5 were due to complications of febrile neutropenia, 2 to cerebrovascular events, and 2 to gastrointestinal hemorrhage; 1 was thought to be due to a pulmonary embolus.
Neutropenia has not been associated with bevacizumab, yet five patients in the paclitaxel–carboplatin–bevacizumab group had grade 5 febrile neutropenia. Other investigators have reported increased rates of neutropenia when bevacizumab was combined with chemotherapy.22 The hypertension, proteinuria, and headache observed in this study are adverse events that had previously been associated with bevacizumab. They were generally manageable and did not require permanent discontinuation of bevacizumab.
The benefits of bevacizumab were consistent among all prespecified stratification groups. Exploratory analyses of the treatment groups according to baseline characteristics showed that bevacizumab was beneficial in all the subgroups assessed, with the possible exception of survival among women. The median overall survival in the paclitaxel–carboplatin group and the paclitaxel–carboplatin–bevacizumab group was 8.7 and 11.7 months, respectively, among men and 13.1 and 13.3 months, respectively, among women. Possible explanations for this finding include imbalances between the two groups with respect to known or unknown baseline prognostic factors, imbalances in the use of second- and third-line therapies, statistical chance, or a true sex-based difference. More women in the paclitaxel–carboplatin group received second-line chemotherapy than in the paclitaxel–carboplatin–bevacizumab group. However, there was no significant difference between the two groups in the number of women who subsequently received epidermal growth factor–tyrosine kinase inhibitors.
Although it has been postulated that baseline VEGF levels correlate with the clinical outcome with bevacizumab treatment, in this trial, the baseline plasma VEGF levels did not correlate with survival. The absence of a correlation was also reported in a trial of first-line therapy with irinotecan, fluorouracil, and leucovorin with or without bevacizumab in patients with colorectal cancer.23
In summary, the addition of bevacizumab to a standard, platin-based, two-agent chemotherapy regimen conferred a significant improvement in overall survival, progression-free survival, and response rate in patients with non–squamous-cell carcinoma and a good performance status. Increased toxic effects, particularly febrile neutropenia and pulmonary hemorrhage, were associated with the addition of bevacizumab. These risks must be considered within the context of the survival benefit conferred by the addition of bevacizumab to standard treatment for non–small-cell lung cancer.
Presented in part in abstract form at the annual meeting of the American Society of Clinical Oncology (ASCO), Orlando, FL, May 13–17, 2005, and in part in updated form at the annual meeting of ASCO, Atlanta, June 2–6, 2006.
Supported in part by grants from the Department of Health and Human Services and the National Institutes of Health (CA23318 to the ECOG statistical center, CA66636 to the ECOG data management center, CA21115 to the ECOG coordinating center and operations office, CA49957 to Dr. Sandler, CA21076 to Dr. Schiller, CA14548 to Dr. Dowlati, CA12046 and CA31946 to Dr. Perry, and CA16116 to Dr. Brahmer).
Dr. Sandler reports receiving grant support from Genentech, OSI, Pfizer, Eli Lilly, Sunesis, Novartis, and Wyeth, lecture fees from Genentech and Bristol-Myers Squibb, and consulting fees from Genentech, OSI, Bristol-Myers Squibb, Eli Lilly, Sanofi-Aventis, Pfizer, Bayer, AstraZeneca, Novartis, Wyeth, Amgen, and Cyclacel; Dr. Gray, receiving grant support from Bayer, Bristol-Myers Squibb, Genentech, Schering-Plough, Berlex, Sanofi-Aventis, Pfizer, Eli Lilly, and Ortho-Biotech; Dr. Perry, holding equity ownership in Genentech; Dr. Brahmer, receiving grant support from Merck, Pfizer, Mederex, and Wyeth, consulting fees from GlaxoSmithKline and Genentech, and lecture fees from Sanofi-Aventis; Dr. Schiller, receiving grant support from Genentech, GlaxoSmithKline, Cell Pathways, Immunex, Eli Lilly, Abbott, Millennium, Sanofi-Aventis, Novartis, Pfizer, Cell Genesys, Amgen, AstraZeneca, Battelle, and Zivena, and consulting fees from Genentech, AstraZeneca, and Pfizer and serving on an advisory board of EMD Pharmaceuticals; Dr. Dowlati, receiving lecture fees from Genentech; Dr. Lilenbaum, receiving grant support from Genentech, consulting fees from Genentech, Sanofi-Aventis, and AstraZeneca and lecture fees from Eli Lilly; and Dr. Johnson, receiving consulting fees from Merck and Genentech. No other potential conflict of interest relevant to this article was reported.
Source Information
From Vanderbilt University, Nashville (A.S., D.H.J.); the Dana–Farber Cancer Institute, Boston (R.G.); the Ellis Fischel Cancer Center, University of Missouri, Columbia (M.C.P.); Johns Hopkins University, Baltimore (J.B.); the University of Wisconsin, Madison (J.H.S.); University Hospitals of Cleveland, Cleveland (A.D.); and Mount Sinai Hospital, Miami (R.L.).
Address reprint requests to Dr. Sandler at the Vanderbilt–Ingram Cancer Center, 2220 Pierce Ave., Nashville, TN 37232, or at alan.sandler@vanderbilt.edu.
- References
References
1
Jemal A ,Murray T ,Ward E , et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30[Erratum, CA Cancer J Clin 2005;55:259.]
CrossRef | Web of Science | Medline2
Schiller JH ,Harrington D ,Belani CP , et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-98
Full Text | Web of Science | Medline3
Hanahan D ,Weinberg RA . The hallmarks of cancer. Cell 2000;100:57-70
CrossRef | Web of Science | Medline4
Folkman J . What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990;82:4-6
CrossRef | Web of Science | Medline5
Ferrara N . The role of vascular endothelial growth factor in pathological angiogenesis. Breast Cancer Res Treat 1995;36:127-137
CrossRef | Web of Science | Medline6
Mattern J ,Koomagi R ,Volm M . Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma. Br J Cancer 1996;73:931-934
CrossRef | Web of Science | Medline7
Brown LF ,Berse B ,Jackman RW , et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 1993;53:4727-4735
Web of Science | Medline8
Brown LF ,Berse B ,Jackman RW , et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Hum Pathol 1995;26:86-91
CrossRef | Web of Science | Medline9
Seto T ,Higashiyama M ,Funai H , et al. Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer. Lung Cancer 2006;53:91-96
CrossRef | Web of Science | Medline10
Ferrara N ,Gerber HP ,LeCouter J . The biology of VEGF and its receptors. Nat Med 2003;9:669-676
CrossRef | Web of Science | Medline11
Kim KJ ,Li B ,Winer J , et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-844
CrossRef | Web of Science | Medline12
Kabbinavar FF ,Wong JT ,Ayala RE ,Wintroub AB ,Kim KJ ,Ferrara N . The effect of antibody to vascular endothelial growth factor and cisplatin on the growth of lung tumors in nude mice. Proc Am Assoc Cancer Res 1995;36:488-48813
Borgstrom P ,Gold DP ,Hillan KJ ,Ferrara N . Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res 1999;19:4203-4214
Web of Science | Medline14
Hurwitz H ,Fehrenbacher L ,Novotny W , et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342
Full Text | Web of Science | Medline15
Johnson DH ,Fehrenbacher L ,Novotny WF , et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22:2184-2191
CrossRef | Web of Science | Medline16
James K ,Eisenhauer E ,Christian M , et al. Measuring response in solid tumors: unidimensional versus bidimensional measurement. J Natl Cancer Inst 1999;91:523-528
CrossRef | Web of Science | Medline17
Jennison C ,Turnbull BW . Interim analyses: the repeated confidence interval approach. J R Stat Soc [B] 1989;51:305-36118
Jain RK . Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987-989
CrossRef | Web of Science | Medline19
Willett CG ,Boucher Y ,di Tomaso E , et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004;10:145-147[Erratum, Nat Med 2004;10:649.]
CrossRef | Web of Science | Medline20
Giantonio BJ ,Catalano PJ ,Meropol NJ , et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200. J Clin Oncol 2005;23:Suppl:16S-16S21
Miller KD ,Wang W ,Gralow J , al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group (E2100). Breast Cancer Res Treat 2005;94:Suppl 1:S6-S6
Web of Science22
Kozloff M ,Cohn A ,Christiansen N , et al. Safety of bevacizumab among patients receiving first-line chemotherapy for metastatic colorectal cancer: preliminary results from a larger registry in the U.S. J Clin Oncol 2005;23:Suppl:16S-16S23
Jubb AM ,Hurwitz HI ,Bai W , et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 2006;24:217-227
CrossRef | Web of Science | Medline
- Citing Articles (1080)
Citing Articles
1
Charu Aggarwal, Corey J. Langer. (2012) Older age, poor performance status and major comorbidities. Current Opinion in Oncology 24:2, 130-136
CrossRef2
Timothy A. Yap, Paul Workman. (2012) Exploiting the Cancer Genome: Strategies for the Discovery and Clinical Development of Targeted Molecular Therapeutics. Annual Review of Pharmacology and Toxicology 52:1, 549-573
CrossRef3
Ana Custodio, Míriam Méndez, Mariano Provencio. (2012) Targeted therapies for advanced non-small-cell lung cancer: Current status and future implications. Cancer Treatment Reviews 38:1, 36-53
CrossRef4
Richard M. Steingart, George L. Bakris, Helen X. Chen, Ming-Hui Chen, Thomas Force, S. Percy Ivy, Carl V. Leier, Glenn Liu, Daniel Lenihan, JoAnn Lindenfeld, Michael L. Maitland, Scot C. Remick, W.H. Wilson Tang. (2012) Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors. American Heart Journal 163:2, 156-163
CrossRef5
Laura Horsley, Kalena Marti, GC Jayson. (2012) Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy. Expert Opinion on Drug Metabolism & Toxicology1-11
CrossRef6
Jin-tao Qu, Mei Wang, Hai-long He, Yu Tang, Xiao-jian Ye. (2012) The prognostic value of elevated vascular endothelial growth factor in patients with osteosarcoma: a meta-analysis and systemic review. Journal of Cancer Research and Clinical Oncology
CrossRef7
M L Sos, R K Thomas. (2012) Genetic insight and therapeutic targets in squamous-cell lung cancer. Oncogene
CrossRef8
Cristina Fernández, Noelle O'Rourke, Mónica Soto, Cristina Fernández. 2012. Topotecan for advanced non-small cell lung cancer in first and second-line settings. .
CrossRef9
Andrew S. Roberts, Michael J. Campa, Elizabeth B. Gottlin, Chen Jiang, Kouros Owzar, Hedy L. Kindler, Alan P. Venook, Richard M. Goldberg, Eileen M. O'Reilly, Edward F. Patz. (2012) Identification of potential prognostic biomarkers in patients with untreated, advanced pancreatic cancer from a phase 3 trial (Cancer and Leukemia Group B 80303). Cancer 118:2, 571-578
CrossRef10
A du Bois, I Vergote, P Wimberger, I Ray-Coquard, P Harter, L B Curtis, I Mitrica. (2012) Open-label feasibility study of pazopanib, carboplatin, and paclitaxel in women with newly diagnosed, untreated, gynaecologic tumours: a phase I/II trial of the AGO study group. British Journal of Cancer
CrossRef11
C Boni, M Tiseo, L Boni, E Baldini, F Recchia, C Barone, F Grossi, D Germano, E Matano, G Marini, R Labianca, F Di Costanzo, A Bagnulo, C Pennucci, C Caroti, M Mencoboni, F Zanelli, T Prochilo, M A Cafferata, A Ardizzoni. (2012) Triplets versus doublets, with or without cisplatin, in the first-line treatment of stage IIIB–IV non-small cell lung cancer (NSCLC) patients: a multicenter randomised factorial trial (FAST). British Journal of Cancer
CrossRef12
Nicolas Girard. (2012) Driver mutations as predictive biomarkers in lung cancer. Current Respiratory Care Reports
CrossRef13
E Dean, M R Middleton, T Pwint, H Swaisland, J Carmichael, P Goodege-Kunwar, M Ranson. (2012) Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours. British Journal of Cancer
CrossRef14
W. Schütte, S. Nagel, G. Haak, M. Steinert. (2012) Fortgeschrittenes nichtkleinzelliges Lungenkarzinom. Der Pneumologe
CrossRef15
M. Knopf, M. Reck. (2012) Erstlinientherapie beim fortgeschrittenen nichtkleinzelligen Lungenkarzinom. Der Pneumologe
CrossRef16
Janessa Laskin, Lucio Crinò, Enriqueta Felip, Fabio Franke, Vera Gorbunova, Harry Groen, Guo-liang Jiang, Martin Reck, Claus-Peter Schneider. (2012) Safety and Efficacy of First-Line Bevacizumab Plus Chemotherapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer. Journal of Thoracic Oncology 7:1, 203-211
CrossRef17
Christian S. Adonizio, Jane Pope, Andrea Frantz, Raymond A. Smego. (2012) Treating Older Adults with Advanced Non-Small Cell Lung Cancer: A Community Cancer Center Experience. Journal of the American Geriatrics Society 60:1, 177-179
CrossRef18
Jared Weiss, Thomas E Stinchcombe. (2012) Treatment of elderly patients with stage IV non-small-cell lung cancer. Expert Review of Anticancer Therapy 12:1, 111-120
CrossRef19
Seiji Niho, Hideo Kunitoh, Hiroshi Nokihara, Takeshi Horai, Yukito Ichinose, Toyoaki Hida, Nobuyuki Yamamoto, Masaaki Kawahara, Tetsu Shinkai, Kazuhiko Nakagawa, Kaoru Matsui, Shunichi Negoro, Akira Yokoyama, Shinzoh Kudoh, Katsuyuki Kiura, Kiyoshi Mori, Hiroaki Okamoto, Hiroshi Sakai, Koji Takeda, Soichiro Yokota, Nagahiro Saijo, Masahiro Fukuoka. (2012) Randomized phase II study of first-line carboplatin-paclitaxel with or without bevacizumab in Japanese patients with advanced non-squamous non-small-cell lung cancer. Lung Cancer
CrossRef20
C. Clément-Duchêne, B. Godbert, Y. Martinet. (2012) Thérapeutiques antiangiogéniques dans le cancer bronchique : indications et toxicités. Revue des Maladies Respiratoires
CrossRef21
Priscilla K. Brastianos, Harry C. Brastianos, Wesley Hsu, Daniel M. Sciubba, Thomas Kosztowski, Betty M. Tyler, Violette Renard Recinos, Peter Burger, Stuart A. Grossman. (2012) The toxicity of intrathecal bevacizumab in a rabbit model of leptomeningeal carcinomatosis. Journal of Neuro-Oncology 106:1, 81-88
CrossRef22
Yanelys Morera, Mónica Bequet-Romero, Marta Ayala, Pedro Puente Pérez, Jorge Castro, Javier Sánchez, José Suárez Alba, Julio Ancízar, Karelia Cosme, Jorge V. Gavilondo. (2012) Antigen dose escalation study of a VEGF-based therapeutic cancer vaccine in non human primates. Vaccine 30:2, 368-377
CrossRef23
Astrid A.M. Van der Veldt, Mark Lubberink, Idris Bahce, Maudy Walraven, Michiel P. de Boer, Henri N.J.M. Greuter, N. Harry Hendrikse, Jonas Eriksson, Albert D. Windhorst, Pieter E. Postmus, Henk M. Verheul, Erik H. Serné, Adriaan A. Lammertsma, Egbert F. Smit. (2012) Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs. Cancer Cell 21:1, 82-91
CrossRef24
Jing Zhao, Yixin Lu, Han-Ming Shen. (2012) Targeting p53 as a therapeutic strategy in sensitizing TRAIL-induced apoptosis in cancer cells. Cancer Letters 314:1, 8-23
CrossRef25
Athanasios G. Pallis, Kostas Syrigos. (2012) Targeted (and chemotherapeutic) agents as maintenance treatment in patients with metastatic non-small-cell lung cancer: Current status and future challenges. Cancer Treatment Reviews
CrossRef26
David Páez, Melissa J. Labonte, Heinz-Josef Lenz. (2012) Pancreatic Cancer: Medical Management (Novel Chemotherapeutics). Gastroenterology Clinics of North America
CrossRef27
Jaishri Blakeley, Stuart A. Grossman. 2012. Chemotherapy with cytotoxic and cytostatic agents in brain cancer. , 229-254.
CrossRef28
Patricia Calleja, Judit Huarte, Maite Agüeros, Luisa Ruiz-Gatón, Socorro Espuelas, Juan M Irache. (2012) Molecular buckets: cyclodextrins for oral cancer therapy. Therapeutic Delivery 3:1, 43-57
CrossRef29
François Goldwasser. (2012) Traitement du cancer colorectal métastatique : une illustration de l’évolution des concepts fondateurs de la cancérologie. La Presse Médicale 41:1, 46-50
CrossRef30
Guanghui Gao, Haiqing Chu, Lan Zhao, Tao Gui, Qinghua Xu, Jianping Shi. (2012) A meta-analysis of paclitaxel-based chemotherapies administered once every week compared with once every 3 weeks first-line treatment of advanced non-small-cell lung cancer. Lung Cancer
CrossRef31
Caroline Hilmi, Mélanie Guyot, Gilles Pagès. (2012) VEGF Spliced Variants: Possible Role of Anti-Angiogenesis Therapy. Journal of Nucleic Acids 2012, 1-7
CrossRef32
Rodrigo Dienstmann, Felipe Ades, Kamal S. Saini, Otto Metzger-Filho. (2012) Benefit-Risk Assessment of Bevacizumab in the Treatment of Breast Cancer. Drug Safety 35:1, 15-25
CrossRef33
Betty C. Tong, David H. Harpole. (2012) Molecular Markers for Incidence, Prognosis, and Response to Therapy. Surgical Oncology Clinics of North America 21:1, 161-175
CrossRef34
Kosuke Akiyama, Noritaka Ohga, Yasuhiro Hida, Taisuke Kawamoto, Yoshihiro Sadamoto, Shuhei Ishikawa, Nako Maishi, Tomoshige Akino, Miyako Kondoh, Aya Matsuda. (2012) Tumor Endothelial Cells Acquire Drug Resistance by MDR1 Up-Regulation via VEGF Signaling in Tumor Microenvironment. American Journal Of Pathology
CrossRef35
Eric Dansin, Saverio Cinieri, Pilar Garrido, Frank Griesinger, Dolores Isla, Manfred Koehler, Martin Kohlhaeufl. (2012) MO19390 (SAiL): Bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC. Lung Cancer
CrossRef36
Andrew Gaya, Vivien Tse. (2012) A preclinical and clinical review of aflibercept for the management of cancer. Cancer Treatment Reviews
CrossRef37
Robert C. Doebele, Xian Lu, Christopher Sumey, DeLee A. Maxson, Andrew J. Weickhardt, Ana B. Oton, Paul A. Bunn, Anna E. Barón, Wilbur A. Franklin, Dara L. Aisner, Marileila Varella-Garcia, D. Ross Camidge. (2012) Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancern/a-n/a
CrossRef38
Robert W. Ross, Matthew D. Galsky, Phil Febbo, Marc Barry, Jerome P. Richie, Wanling Xie, Fiona M. Fennessy, Rupal S. Bhatt, Julia Hayes, Toni K. Choueiri, Clare M. Tempany, Philip W. Kantoff, Mary E. Taplin, William K. Oh. (2012) Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer. Cancern/a-n/a
CrossRef39
Cesare Gridelli, Filippo de Marinis, Massimo Di Maio, Andrea Ardizzoni, Chandra P. Belani, Federico Cappuzzo, Fortunato Ciardiello, Panagiotis Fidias, Luis Paz-Ares, Francesco Perrone, Robert Pirker, Luigi De Petris, Rolf Stahel. (2012) Maintenance treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Lung Cancer
CrossRef40
H.A. Wakelee, S.E. Dahlberg, J.R. Brahmer, J.H. Schiller, M.C. Perry, C.J. Langer, A.B. Sandler, C.P. Belani, D.H. Johnson. (2012) Differential effect of age on survival in advanced NSCLC in women versus men: Analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab. Lung Cancer
CrossRef41
Kosuke Akiyama, Noritaka Ohga, Yasuhiro Hida, Taisuke Kawamoto, Yoshihiro Sadamoto, Shuhei Ishikawa, Nako Maishi, Tomoshige Akino, Miyako Kondoh, Aya Matsuda, Nobuo Inoue, Masanobu Shindoh, Kyoko Hida. (2012) Tumor Endothelial Cells Acquire Drug Resistance by MDR1 Up-Regulation via VEGF Signaling in Tumor Microenvironment. The American Journal of Pathology
CrossRef42
Carlos Rodríguez de Lope, Silvia Tremosini, Alejandro Forner, María Reig, Jordi Bruix. (2012) Management of HCC. Journal of Hepatology 56, S75-S87
CrossRef43
Shane Rogosin, Alan B. Sandler. (2012) Beyond Bevacizumab: Antiangiogenic Agents. Clinical Lung Cancer
CrossRef44
Manmei Li, Shuai Wu, Zhong Liu, Wei Zhang, Jing Xu, Ying Wang, Junshan Liu, Dongmei Zhang, Haiyan Tian, Yaolan Li, Wencai Ye. (2012) Arenobufagin, a bufadienolide compound from toad venom, inhibits VEGF-mediated angiogenesis through suppression of VEGFR-2 signalling pathway. Biochemical Pharmacology
CrossRef45
Roman Thomas, Jürgen Wolf. (2012) Personalized Therapy of Lung Cancer. Onkologie 35:s1, 14-19
CrossRef46
Oana C. Danciu, Shayan Rayani, Edward A. Michals, J. Lee Villano. (2011) Prolonged activity of bevacizumab in adenocarcinoma of the lung with multiple brain metastases. Medical Oncology
CrossRef47
Boyka Markova, Patricia S. Hähnel, Stefan Kasper, Stephan Herbertz, Martin Schuler, Frank Breitenbuecher. (2011) Pharmacologic inhibition of mTOR antagonizes the cytotoxic activity of pemetrexed in non-small cell lung cancer. Journal of Cancer Research and Clinical Oncology
CrossRef48
Salah Almokadem, Chandra P Belani. (2011) Volociximab in cancer. Expert Opinion on Biological Therapy1-7
CrossRef49
M. Pless. (2011) Das fortgeschrittene Lungenkarzinom. Der Pneumologe
CrossRef50
R. Vijayalakshmi, Arvind Krishnamurthy. (2011) Targetable “Driver” Mutations in Non Small Cell Lung Cancer. Indian Journal of Surgical Oncology
CrossRef51
H. Mishima, K. Oba, J. Sakamoto, K. Muro, T. Yoshino, I. Hyodo, Y. Maehara. (2011) FOLFIRI plus Bevacizumab 5 mg/kg Versus 10 mg/kg as Second-line Therapy in Patients with Metastatic Colorectal Cancer Who Have Failed First-line Bevacizumab Plus Oxaliplatin-based Therapy: A Randomized Phase III Study (EAGLE Study). Japanese Journal of Clinical Oncology
CrossRef52
T. Osawa, M. Muramatsu, F. Wang, R. Tsuchida, T. Kodama, T. Minami, M. Shibuya. (2011) Increased expression of histone demethylase JHDM1D under nutrient starvation suppresses tumor growth via down-regulating angiogenesis. Proceedings of the National Academy of Sciences
CrossRef53
Javier Cortés, Mireia Caralt, Suzette Delaloge, Hernan Cortes-Funes, Jean-Yves Pierga, Kathleen I. Pritchard, David T. Bollag, David W. Miles. (2011) Safety of bevacizumab in metastatic breast cancer patients undergoing surgery. European Journal of Cancer
CrossRef54
Joel W. Neal, Matthew A. Gubens, Heather A. Wakelee. (2011) Current Management of Small Cell Lung Cancer. Clinics in Chest Medicine 32:4, 853-863
CrossRef55
Takeshi Hanagiri, Masaru Takenaka, Soich Oka, Yoshiki Shigematsu, Yoshika Nagata, Hidehiko Shimokawa, Hidetaka Uramoto, Fumihiro Tanaka. (2011) Results of a Surgical Resection for Patients With Stage IV Non–Small-Cell Lung Cancer. Clinical Lung Cancer
CrossRef56
Xu-ming Ji, Bing Ouyang, Heng Liu, Guo-wei Liu, Zhi-chun Wu, Hua-yun Yu, Chun-yan Wang, Zhong-xia Wang, Wen-ping Wang. (2011) In Vitro and In Vivo inhibitory effect of the combination of Wenxia Changfu Formula (
) with cisplatin in non-small cell lung cancer. Chinese Journal of Integrative Medicine 17:12, 908-916
CrossRef57
Mengying Yao, Weihong Zhang, Qingxian Zhang, Lihua Xing, Aiguo Xu, Qiuhong Liu, Bing Cui. (2011) Overexpression of MUC1 Enhances Proangiogenic Activity of Non-Small-Cell Lung Cancer Cells Through Activation of Akt and Extracellular Signal-regulated Kinase Pathways. Lung 189:6, 453-460
CrossRef58
S. Marco, P. Tomasini, L. Greillier, F. Barlesi. (2011) Traitements antiangiogéniques en oncologie thoracique : succès, échecs et perspectives. Revue des Maladies Respiratoires 28:10, 1216-1229
CrossRef59
Jong Pil Park, Jin Hee Kim, Moon Ki Park, Jong Won Yun. (2011) Potential agents for cancer and obesity treatment with herbal medicines from the green garden. Biotechnology and Bioprocess Engineering 16:6, 1065-1076
CrossRef60
Scott Gettinger, Thomas Lynch. (2011) A Decade of Advances in Treatment for Advanced Non–Small Cell Lung Cancer. Clinics in Chest Medicine 32:4, 839-851
CrossRef61
Young Hak Kim, Michiaki Mishima. (2011) How Should We Use Bevacizumab in Patients with Non-small Cell Lung Cancer?. Journal of Thoracic Oncology 6:12, 2145-2146
CrossRef62
Patricia LoRusso, Geoffrey I. Shapiro, Herbert Hurwitz, Mary Jo Pilat, Janice Chemidlin, Georgia Kollia, Shariq Syed, Bruce Fischer, Eric Masson. (2011) Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumors. Cancer Chemotherapy and Pharmacology 68:6, 1377-1385
CrossRef63
Pek Keng Koh, Corinne Faivre-Finn, Fiona H. Blackhall, Dirk De Ruysscher. (2011) Targeted agents in non-small cell lung cancer (NSCLC): Clinical developments and rationale for the combination with thoracic radiotherapy. Cancer Treatment Reviews
CrossRef64
Randeep Sangha, Angela M. Davies, Primo N. Lara, Philip C. Mack, Laurel A. Beckett, Paul J. Hesketh, Derick Lau, Tianhong Li, Natasha Perkins, David R. Gandara. (2011) Intercalated Erlotinib-Docetaxel Dosing Schedules Designed to Achieve Pharmacodynamic Separation. Journal of Thoracic Oncology 6:12, 2112-2119
CrossRef65
Emmy Yanagita, Naoko Imagawa, Chiho Ohbayashi, Tomoo Itoh. (2011) Rapid Multiplex Immunohistochemistry Using the 4-antibody Cocktail YANA-4 in Differentiating Primary Adenocarcinoma From Squamous Cell Carcinoma of the Lung. Applied Immunohistochemistry & Molecular Morphology 19:6, 509-513
CrossRef66
A. Hata, N. Katakami, K. Kunimasa, H. Yoshioka, S. Fujita, R. Kaji, R. Tachikawa, K. Tomii, Y. Imai, M. Iwasaku, T. Ishida. (2011) Erlotinib for Pretreated Squamous Cell Carcinoma of the Lung in Japanese Patients. Japanese Journal of Clinical Oncology 41:12, 1366-1372
CrossRef67
L. V. Sequist, R. S. Heist, A. T. Shaw, P. Fidias, R. Rosovsky, J. S. Temel, I. T. Lennes, S. Digumarthy, B. A. Waltman, E. Bast, S. Tammireddy, L. Morrissey, A. Muzikansky, S. B. Goldberg, J. Gainor, C. L. Channick, J. C. Wain, H. Gaissert, D. M. Donahue, A. Muniappan, C. Wright, H. Willers, D. J. Mathisen, N. C. Choi, J. Baselga, T. J. Lynch, L. W. Ellisen, M. Mino-Kenudson, M. Lanuti, D. R. Borger, A. J. Iafrate, J. A. Engelman, D. Dias-Santagata. (2011) Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice. Annals of Oncology 22:12, 2616-2624
CrossRef68
Wei-Xiang Qi, Li-Na Tang, Ai-Na He, Zan Shen, Yang Yao. (2011) The Role of Vandetanib in the Second-Line Treatment for Advanced Non-Small-Cell-Lung Cancer: A Meta-Analysis of Four Randomized Controlled Trials. Lung 189:6, 437-443
CrossRef69
Shun Lu, Yong-feng Yu. (2011) Maintenance therapy for NSCLC: Consensus and controversy. Chinese Journal of Cancer Research 23:4, 254-258
CrossRef70
Naomi Fujioka, Julia Nguyen, Chunsheng Chen, Yunfang Li, Teena Pasrija, Gloria Niehans, Katherine N. Johnson, Vinita Gupta, Robert A. Kratzke, Kalpna Gupta. (2011) Morphine-Induced Epidermal Growth Factor Pathway Activation in Non–Small Cell Lung Cancer. Anesthesia & Analgesia 113:6, 1353-1364
CrossRef71
Patricia LoRusso, Anthony F. Shields, Shirish Gadgeel, Ulka Vaishampayan, Tina Guthrie, Thomas Puchalski, John Xu, Qi Liu. (2011) Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study. Investigational New Drugs 29:6, 1395-1405
CrossRef72
Jill E. Larsen, John D. Minna. (2011) Molecular Biology of Lung Cancer: Clinical Implications. Clinics in Chest Medicine 32:4, 703-740
CrossRef73
David A. Reardon, Annick Desjardins, Katherine B. Peters, James J. Vredenburgh, Sridharan Gururangan, John H. Sampson, Roger E. McLendon, James E. Herndon, April Coan, Stevie Threatt, Allan H. Friedman, Henry S. Friedman. (2011) Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer 117:23, 5351-5358
CrossRef74
Cesare Gridelli, Andrea Ardizzoni, Sandro Barni, Lucio Crinò, Alberto Caprioli, Elena Piazza, Vito Lorusso, Santi Barbera, Nicoletta Zilembo, Vittorio Gebbia, Vincenzo Adamo, Riccardo Pela, Maurizio Marangolo, Raffaella Morena, Gianfranco Filippelli, Calogero Buscarino, Oscar Alabiso, Paolo Maione, Paola Venturino, Filippo De Marinis. (2011) Medical treatment choices for patients affected by advanced NSCLC in routine clinical practice: Results from the Italian observational “SUN” (Survey on the lUng cancer maNagement) study. Lung Cancer 74:3, 462-468
CrossRef75
Kai Wang, Jin Wei. (2011) Multi-targeted therapies in non-small cell lung cancer. Clinical Oncology and Cancer Research 8:4, 220-223
CrossRef76
Christine H. Chung, Paula R. Pohlmann, Mace L. Rothenberg, Brian B. Burkey, Joel Parker, Kevin Palka, Joseph Aulino, Igor Puzanov, Barbara Murphy, Eben L. Rosenthal. (2011) Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma. Head & Neck 33:12, 1804-1808
CrossRef77
Benjamin Besse, David Planchard, Anne-Sophie Veillard, Laurent Taillade, David Khayat, Muriel Ducourtieux, Jean-Pierre Pignon, Jean Lumbroso, Carole Lafontaine, Claire Mathiot, Jean-Charles Soria. (2011) Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer. Lung Cancer
CrossRef78
Nicholas A. Barber, Apar Kishor Ganti. (2011) Pulmonary toxicities from targeted therapies: a review. Targeted Oncology 6:4, 235-243
CrossRef79
Sara Mariucci, Bianca Rovati, Mariangela Manzoni, Matteo Giovanni Della Porta, Giuditta Comolli, Sara Delfanti, Marco Danova. (2011) Lymphocyte subpopulation and dendritic cell phenotyping during antineoplastic therapy in human solid tumors. Clinical and Experimental Medicine 11:4, 199-210
CrossRef80
Mark A. Socinski. (2011) Multitargeted receptor tyrosine kinase inhibition: An antiangiogenic strategy in non-small cell lung cancer. Cancer Treatment Reviews 37:8, 611-617
CrossRef81
Bryan H. Burmeister, Michael Michael, Elizabeth Burmeister, Sharon Cox, Margot Lehman, Andrew Wirth, Keith Horwood, Giuseppe Sasso, Barham Forouzesh, David Ball. (2011) A Randomized Phase II Trial of Two Regimens of Moderate Dose Chemoradiation Therapy for Patients with Non-small Cell Lung Cancer Not Suitable for Curative Therapy. Journal of Thoracic Oncology 6:12, 2076-2082
CrossRef82
Yun-ze Xu, Yu Zhu, Zhou-jun Shen, Jia-yan Sheng, Hong-chao He, Gui Ma, Yi-cheng Qi, Ju-ping Zhao, Yu-xuan Wu, Wen-bin Rui, Qing Wei, Wen-long Zhou, Xin Xie, Guang Ning. (2011) Significance of heparanase-1 and vascular endothelial growth factor in adrenocortical carcinoma angiogenesis: potential for therapy. Endocrine 40:3, 445-451
CrossRef83
Laura Bonanno, Adolfo Favaretto, Massimo Rugge, Miquel Taron, Rafael Rosell. (2011) Role of Genotyping in Non-Small Cell Lung Cancer Treatment. Drugs 71:17, 2231-2246
CrossRef84
Erik Thunnissen, Keith M. Kerr, Felix J.F. Herth, Sylvie Lantuejoul, Mauro Papotti, Robert C. Rintoul, Giulio Rossi, Birgit G. Skov, Birgit Weynand, Lukas Bubendorf, Grünberg Katrien, Leif Johansson, Fernando López-Ríos, Vincent Ninane, Włodzimierz Olszewski, Helmut Popper, Sauleda Jaume, Philipp Schnabel, Luc Thiberville, Florian Laenger. (2011) The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Lung Cancer
CrossRef85
Radj Gervais, John D. Hainsworth, Normand Blais, Benjamin Besse, Janessa Laskin, John T. Hamm, Allan Lipton, Kathy S. Albain, Gregory A. Masters, Ronald B. Natale, Paulina Selaru, Sindy T. Kim, Richard C. Chao, Ray D. Page. (2011) Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancer. Lung Cancer 74:3, 474-480
CrossRef86
Nancy Y Lee, Qiang Zhang, David G Pfister, John Kim, Adam S Garden, James Mechalakos, Kenneth Hu, Quynh T Le, A Dimitrios Colevas, Bonnie S Glisson, Anthony TC Chan, K Kian Ang. (2011) Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial. The Lancet Oncology
CrossRef87
T. Schmidt, P. Carmeliet. (2011) Angiogenesis: A Target in Solid Tumors, Also in Leukemia?. Hematology 2011:1, 1-8
CrossRef88
Takashi Oshima, Munetaka Masuda. (2011) Molecular targeted agents for gastric and gastroesophageal junction cancer. Surgery Today
CrossRef89
N. Emami-Shahri, T. Hagemann. (2011) Resistance--the true face of biological defiance. Rheumatology
CrossRef90
Thomas Resch, Andreas Pircher, Christian M. Kähler, Johann Pratschke, Wolfgang Hilbe. (2011) Endothelial Progenitor Cells: Current Issues on Characterization and Challenging Clinical Applications. Stem Cell Reviews and Reports
CrossRef91
Yasumitsu Moriya, Nijiro Nohata, Takashi Kinoshita, Muradil Mutallip, Tatsuro Okamoto, Shigetoshi Yoshida, Makoto Suzuki, Ichiro Yoshino, Naohiko Seki. (2011) Tumor suppressive microRNA-133a regulates novel molecular networks in lung squamous cell carcinoma. Journal of Human Genetics
CrossRef92
Chao Cao, Jianmiao Wang, Hansvin Bunjhoo, Yongjian Xu, Huijuan Fang. (2011) Risk profile of bevacizumab in patients with non-small cell lung cancer: A meta-analysis of randomized controlled trials. Acta Oncologica1-6
CrossRef93
Veronique Lorgis, Geric Maura, Guillaume Coppa, Kahina Hassani, Luc Taillandier, Bruno Chauffert, Lionel Apetoh, Sylvain Ladoire, François Ghiringhelli. (2011) Relation between bevacizumab dose intensity and high-grade glioma survival: a retrospective study in two large cohorts. Journal of Neuro-Oncology
CrossRef94
Kyung-Jae Park, Hideyuki Kano, Aditya Iyer, Xiaomin Liu, Ajay Niranjan, John C. Flickinger, Frank S. Lieberman, L. Dade Lunsford, Douglas Kondziolka. (2011) Salvage gamma knife stereotactic radiosurgery followed by bevacizumab for recurrent glioblastoma multiforme: a case–control study. Journal of Neuro-Oncology
CrossRef95
M. Reck, F. Barlesi, L. Crino, C. I. Henschke, D. Isla, S. Stiebeler, D. R. Spigel. (2011) Predicting and managing the risk of pulmonary haemorrhage in patients with NSCLC treated with bevacizumab: a consensus report from a panel of experts. Annals of Oncology
CrossRef96
Domenico Galetta, Salvatore Pisconti, Saverio Cinieri, Giovanni Luigi Pappagallo, Vittorio Gebbia, Nicola Borsellino, Evaristo Maiello, Antonio Rinaldi, Michele Montrone, Pietro Rizzo, Nicola Marzano, Nicola Sasso, Antonio Febbraro, Giuseppe Colucci. (2011) Induction Pemetrexed and Cisplatin Followed by Maintenance Pemetrexed Versus Carboplatin Plus Paclitaxel Plus Bevacizumab Followed by Maintenance Bevacizumab: A Quality of Life–Oriented Randomized Phase III Study in Patients With Advanced Non-Squamous Non–Small-Cell Lung Cancer (ERACLE). Clinical Lung Cancer 12:6, 402-406
CrossRef97
Y. Naito, K. Kubota, H. Ohmatsu, K. Goto, S. Niho, K. Yoh, Y. Ohe. (2011) Phase II study of nedaplatin and docetaxel in patients with advanced squamous cell carcinoma of the lung. Annals of Oncology 22:11, 2471-2475
CrossRef98
Laurie L. Carr, James H. Finigan, Jeffrey A. Kern. (2011) Evaluation and Treatment of Patients with Non–Small Cell Lung Cancer. Medical Clinics of North America 95:6, 1041-1054
CrossRef99
M. H. G. Langenberg, P. O. Witteveen, J. Roodhart, M. P. Lolkema, H. M. W. Verheul, M. Mergui-Roelvink, E. Brendel, J. Kratzschmar, B. Loembe, A. Nol-Boekel, O. Christensen, J. H. M. Schellens, E. E. Voest. (2011) Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors. Annals of Oncology 22:11, 2508-2515
CrossRef100
Patrick Micke, Karolina Edlund, Lars Holmberg, Hanna Göransson Kultima, Larry Mansouri, Simon Ekman, Michael Bergqvist, Lena Scheibenflug, Kristina Lamberg, Gunnar Myrdal, Anders Berglund, Annsofie Andersson, Mats Lambe, Fredrik Nyberg, Andrew Thomas, Anders Isaksson, Johan Botling. (2011) Gene Copy Number Aberrations Are Associated with Survival in Histologic Subgroups of Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:11, 1833-1840
CrossRef101
Young Hak Kim, Michiaki Mishima. (2011) Maintenance chemotherapy for non-small-cell lung cancer. Cancer Treatment Reviews 37:7, 505-510
CrossRef102
David F. Heigener, Yi-Long Wu, Nico van Zandwijk, Pekka Mali, Keith Horwood, Martin Reck. (2011) Second-line erlotinib in patients with advanced non-small-cell lung cancer: Subgroup analyses from the TRUST study. Lung Cancer 74:2, 274-279
CrossRef103
Joaquim Bosch-Barrera, Nuria Quer, Joan Brunet. (2011) Costs and Ethical Issues Related to First-Line Treatment of Metastatic Non–Small-Cell Lung Cancer: Considerations From a Public Healthcare System Perspective. Clinical Lung Cancer 12:6, 335-340
CrossRef104
Nathan A. Pennell. (2011) Integration of EGFR Inhibitors and Conventional Chemotherapy in the Treatment of Non–Small-cell Lung Cancer. Clinical Lung Cancer 12:6, 350-359
CrossRef105
Katherine F. Croom, Sohita Dhillon. (2011) Bevacizumab. Drugs 71:16, 2213-2229
CrossRef106
Mark J.C. Nuijten, Rick Aultman, Javier de Castro Carpeño, Alain Vergnenègre, Christos Chouaid, Stefan Walzer, Uwe Siebert. (2011) An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer. Current Medical Research and Opinion 27:11, 2193-2201
CrossRef107
Min S. Park, Shreyaskumar R. Patel, Joseph A. Ludwig, Jonathan C. Trent, Charles A. Conrad, Alexander J. Lazar, Wei-Lien Wang, Piyaporn Boonsirikamchai, Haesun Choi, Xuemei Wang, Robert S. Benjamin, Dejka M. Araujo. (2011) Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer 117:21, 4939-4947
CrossRef108
Shirish M. Gadgeel. (2011) Safety Profile and Tolerability of Antiangiogenic Agents in Non–Small-Cell Lung Cancer. Clinical Lung Cancer
CrossRef109
Huijuan Qiu, Wenzhuo He, Guifang Guo, Xuxian Chen, Fang Wang, Feifei Zhou, Chenxi Yin, Liangping Xia. (2011) The pooled analysis of efficacy and safety profiles of bevacizumab in Chinese cancer patients. The Chinese-German Journal of Clinical Oncology 10:11, 621-625
CrossRef110
Ezra E.W. Cohen, Janakiraman Subramanian, Feng Gao, Livia Szeto, Mark Kozloff, Leonardo Faoro, Theodore Karrison, Ravi Salgia, Ramaswamy Govindan, Everett E. Vokes. (2011) Targeted and Cytotoxic Therapy in Coordinated Sequence (TACTICS): Erlotinib, Bevacizumab, and Standard Chemotherapy for Non–Small-Cell Lung Cancer, A Phase II Trial. Clinical Lung Cancer
CrossRef111
Cesare Gridelli, Jaafar Bennouna, Javier de Castro, Anne-Marie C. Dingemans, Frank Griesinger, Francesco Grossi, Antonio Rossi, Nick Thatcher, Elaine K. Wong, Corey Langer. (2011) Randomized Phase IIIb Trial Evaluating the Continuation of Bevacizumab Beyond Disease Progression in Patients with Advanced Non-Squamous Non–Small-Cell Lung Cancer after First-Line Treatment with Bevacizumab Plus Platinum-Based Chemotherapy: Treatment Rationale and Protocol Dynamics of the AvaALL (MO22097) Trial. Clinical Lung Cancer 12:6, 407-411
CrossRef112
Andrea Salmaggi, Paola Gaviani, Andrea Botturi, Elena Lamperti, Giorgia Simonetti, Daniela Ferrari, Antonio Silvani. (2011) Bevacizumab at recurrence in high-grade glioma. Neurological Sciences 32:S2, 251-253
CrossRef113
Peter Goldstraw, David Ball, James R Jett, Thierry Le Chevalier, Eric Lim, Andrew G Nicholson, Frances A Shepherd. (2011) Non-small-cell lung cancer. The Lancet 378:9804, 1727-1740
CrossRef114
Gaetana Di Fede, Giuseppe Bronte, Sergio Rizzo, Christian Rolfo Cervetto, Gianfranco Cocorullo, Gaspare Gulotta, Viviana Bazan, Antonio Russo. (2011) Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors. Expert Opinion on Biological Therapy 11:11, 1433-1445
CrossRef115
Peter Mazzone, Tarek Mekhail. (2011) Current and emerging medical treatments for non–small cell lung cancer: A primer for pulmonologists. Respiratory Medicine
CrossRef116
Filippo Bellati, Chiara Napoletano, Maria Luisa Gasparri, Ilary Ruscito, Claudia Marchetti, Sandro Pignata, Federica Tomao, Pierluigi Benedetti Panici, Marianna Nuti. (2011) Current knowledge and open issues regarding Bevacizumab in gynaecological neoplasms. Critical Reviews in Oncology/Hematology
CrossRef117
Akshay Sudhindra, Roberto Ochoa, Edgardo S. Santos. (2011) Biomarkers, Prediction, and Prognosis in Non–Small-Cell Lung Cancer: A Platform for Personalized Treatment. Clinical Lung Cancer 12:6, 360-368
CrossRef118
Chanida Vinayanuwattikun, Virote Sriuranpong, Suebpong Tanasanvimon, Poonchavist Chantranuwat, Apiwat Mutirangura. (2011) Epithelial-Specific Methylation Marker. Journal of Thoracic Oncology 6:11, 1818-1825
CrossRef119
Janakiraman Subramanian, Saiama N. Waqar, Ramaswamy Govindan. (2011) Targeted Therapy in Lung Cancer. Journal of Thoracic Oncology 6, S1786-S1788
CrossRef120
Cesare Gridelli. (2011) Personalized medicine in the treatment of advanced nonsmall cell lung cancer. Current Opinion in Oncology1
CrossRef121
Alberto J. Montero, Mauricio Escobar, Gilberto Lopes, Stefan Glück, Charles Vogel. (2011) Bevacizumab in the Treatment of Metastatic Breast Cancer: Friend or Foe?. Current Oncology Reports
CrossRef122
Cabot, Richard C.Harris, Nancy Lee, Shepard, Jo-Anne O., Rosenberg, Eric S., Cort, Alice M., Ebeling, Sally H.Peters, Christine C., Lanuti, Michael, Sequist, Lecia V., Sharma, Amita, Mino-Kenudson, Mari, . (2011) Case 31-2011. New England Journal of Medicine 365:15, 1426-1435
Full Text123
L. Q. M. Chow, N. Blais, D. J. Jonker, S. A. Laurie, S. G. Diab, C. Canil, M. McWilliam, A. Thall, A. Ruiz-Garcia, K. Zhang, L. Tye, R. C. Chao, D. R. Camidge. (2011) A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer. Cancer Chemotherapy and Pharmacology
CrossRef124
George R. Blumenschein. (2011) Developmental antiangiogenic agents for the treatment of Non-Small Cell Lung Cancer (NSCLC). Investigational New Drugs
CrossRef125
David B. Jackson, Anil K. Sood. (2011) Personalized cancer medicine—advances and socio-economic challenges. Nature Reviews Clinical Oncology 8:12, 735-741
CrossRef126
David A. Reardon, Annick Desjardins, Katherine B. Peters, Sridharan Gururangan, John H. Sampson, Roger E. McLendon, James E. Herndon, Anuradha Bulusu, Stevie Threatt, Allan H. Friedman, James J. Vredenburgh, Henry S. Friedman. (2011) Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. Journal of Neuro-Oncology
CrossRef127
J. Clarey, S. C. Kao, S. J. Clarke, J. Vardy. (2011) The eligibility of advanced non-small-cell lung cancer patients for targeted therapy clinical trials. Annals of Oncology
CrossRef128
Antonio Passaro, Enrico Cortesi, Filippo de Marinis. (2011) Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors?. Expert Review of Anticancer Therapy 11:10, 1587-1597
CrossRef129
Michael B Jameson, Michelle Head. (2011) Pharmacokinetic evaluation of vadimezan (ASA404, 5,6-dimethylxanthenone-4-acetic acid, DMXAA). Expert Opinion on Drug Metabolism & Toxicology 7:10, 1315-1326
CrossRef130
Tobias Engel Ayer Botrel, Otávio Clark, Luciana Clark, Luciano Paladini, Enéas Faleiros, Bruna Pegoretti. (2011) Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): Systematic review and meta-analysis. Lung Cancer 74:1, 89-97
CrossRef131
Zhen Fan, Richard Schraeder. (2011) The Changing Pathology of Lung Cancer. Surgical Oncology Clinics of North America 20:4, 637-653
CrossRef132
Scott T. Tagawa, Matthew I. Milowsky, Stephanie Jeske, Madhu Mazumdar, Sophia Kung, Max Sung, Deborah Lehrer, Daniel Matulich, Jodi Selzer, John J. Wright, David M. Nanus. (2011) A Phase I Trial of Sorafenib Plus Gemcitabine and Capecitabine for Patients With Advanced Renal Cell Carcinoma. American Journal of Clinical Oncology 34:5, 443-448
CrossRef133
Yuan-Yuan Zhao, Cong Xue, Wei Jiang, Hong-Yun Zhao, Yan Huang, Kristin Feenstra, James H. Resau, Chao-Nan Qian, Li Zhang. (2011) Predictive Value of Intratumoral Microvascular Density in Patients with Advanced Non-small Cell Lung Cancer Receiving Chemotherapy Plus Bevacizumab. Journal of Thoracic Oncology1
CrossRef134
Hui-li Wong, Richard H de Boer. (2011) Vandetanib for the treatment of non-small-cell lung cancer. Expert Opinion on Pharmacotherapy 12:14, 2271-2278
CrossRef135
Aspasia Soultati, Giannis Mountzios, Chrysoula Avgerinou, George Papaxoinis, Dimitrios Pectasides, Meletios-Athanassios Dimopoulos, Christos Papadimitriou. (2011) Endothelial vascular toxicity from chemotherapeutic agents: Preclinical evidence and clinical implications. Cancer Treatment Reviews
CrossRef136
Alejandro D. Ricart, Edward A. Ashton, Matthew M. Cooney, John Sarantopoulos, Joanna M. Brell, Maria A. Feldman, Kale E. Ruby, Kazuko Matsuda, Mark S. Munsey, Gerardo Medina, Angela Zambito, Anthony W. Tolcher, Scot C. Remick. (2011) A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology 68:4, 959-970
CrossRef137
Güllü Görgün, Kenneth C Anderson. (2011) Intrinsic modulation of lymphocyte function by stromal cell network: advance in therapeutic targeting of cancer. Immunotherapy 3:10, 1253-1264
CrossRef138
Collin Blakely, Thierry Jahan. (2011) Emerging antiangiogenic therapies for non-small-cell lung cancer. Expert Review of Anticancer Therapy 11:10, 1607-1618
CrossRef139
Klazien Matter-Walstra, Markus Joerger, Ursula Kühnel, Thomas Szucs, Bernhard Pestalozzi, Matthias Schwenkglenks. (2011) Cost-Effectiveness of Maintenance Pemetrexed in Patients with Advanced Nonsquamous-Cell Lung Cancer from the Perspective of the Swiss Health Care System. Value in Health
CrossRef140
Frances A. Shepherd, Jean-Yves Douillard, George R. Blumenschein. (2011) Immunotherapy for Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:10, 1763-1773
CrossRef141
Kenjiro Aogi, Norikazu Masuda, Shinji Ohno, Takashi Oda, Hiroji Iwata, Masahiro Kashiwaba, Yasuhiro Fujiwara, Shunji Kamigaki, Yoshinori Ito, Takayuki Ueno, Shigemitsu Takashima. (2011) First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study. Breast Cancer Research and Treatment 129:3, 829-838
CrossRef142
Yoshiki Ishii, Sakae Fujimoto, Kazumi Okazaki, Masaaki Miyoshi, Tomoe Furihata, Isano Hase, Hidenori Takizawa, Yasuko Kikkawa, Issei Yamada, Takeshi Fukuda. (2011) Fractionated administration of carboplatin/paclitaxel reduces neurotoxicity in patients with advanced non-small cell lung cancer. Anti-Cancer Drugs 22:9, 926-932
CrossRef143
Zheng-tao Zhou, Fu-xiang Zhou, Qing Wei, Li-yong Zou, Bin-fang Qin, Xu-shen Peng. (2011) Phase II study of cisplatin/etoposide and endostar for extensive-stage small-cell lung cancer. Cancer Chemotherapy and Pharmacology 68:4, 1027-1032
CrossRef144
Amna Sher, Shenhong Wu. (2011) Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy–A meta-analysis. Acta Oncologica 50:7, 997-1005
CrossRef145
S. Rivera, L. Quéro, S. Wong Hee Kam, C. Maylin, É. Deutsch, C. Hennequin. (2011) Thérapies ciblées et radiothérapie dans les cancers bronchiques non à petites cellules. Cancer/Radiothérapie 15:6-7, 527-535
CrossRef146
Robert S. Kerbel. (2011) Reappraising antiangiogenic therapy for breast cancer. The Breast 20, S56-S60
CrossRef147
Athanasios G. Pallis, Vassilis Georgoulias. (2011) Is there a standard regimen for first-line treatment of advanced/metastatic Non-Small-Cell Lung Cancer? What has meta-analyses contributed to today's standard of care. Lung Cancer
CrossRef148
C-L Cheng, H-A Hou, J-Y Jhuang, C-W Lin, C-Y Chen, J-L Tang, W-C Chou, M-H Tseng, M Yao, S-Y Huang, B-S Ko, S-C Hsu, S-J Wu, W Tsay, Y-C Chen, H-F Tien. (2011) High bone marrow angiopoietin-1 expression is an independent poor prognostic factor for survival in patients with myelodysplastic syndromes. British Journal of Cancer 105:7, 975-982
CrossRef149
Robert Pirker. (2011) Chemotherapy: Advanced NSCLC—should we use doublets in elderly patients?. Nature Reviews Clinical Oncology 8:12, 694-696
CrossRef150
T. Brodowicz, T. Ciuleanu, J. Crawford, M. Filipits, J. R. Fischer, V. Georgoulias, C. Gridelli, F. R. Hirsch, J. Jassem, P. Kosmidis, M. Krzakowski, C. Manegold, J. L. Pujol, R. Stahel, N. Thatcher, J. Vansteenkiste, C. Minichsdorfer, S. Zochbauer-Muller, R. Pirker, C. C. Zielinski, . (2011) Third CECOG consensus on the systemic treatment of non-small-cell lung cancer. Annals of Oncology
CrossRef151
Shan-shan Hu, Li-kun Zhou, Yi Ba, Hong-li Li, Cai-hua Zhu. (2011) A meta-analysis of ginsenoside Rg3 for non-small cell lung cancer. Clinical Oncology and Cancer Research 8:3, 175-180
CrossRef152
Qi Li, Wei Wang, Tadaaki Yamada, Kunio Matsumoto, Katsuya Sakai, Yoshimi Bando, Hisanori Uehara, Yasuhiko Nishioka, Saburo Sone, Shotaro Iwakiri, Kazumi Itoi, Teruhiro Utsugi, Kazuo Yasumoto, Seiji Yano. (2011) Pleural Mesothelioma Instigates Tumor-Associated Fibroblasts To Promote Progression via a Malignant Cytokine Network. The American Journal of Pathology 179:3, 1483-1493
CrossRef153
Danielle M. Patterson, Dongbing Gao, Denae N. Trahan, Brett A. Johnson, Andrew Ludwig, Eveline Barbieri, Zaowen Chen, Jose Diaz-Miron, Lyubomir Vassilev, Jason M. Shohet, Eugene S. Kim. (2011) Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma. Angiogenesis 14:3, 255-266
CrossRef154
Vinochani Pillay, Hui K. Gan, Andrew M. Scott. (2011) Antibodies in oncology. New Biotechnology 28:5, 518-529
CrossRef155
M. Pérol. (2011) Traitement d’induction et de maintenance des CBNPC au stade métastatique. Revue des Maladies Respiratoires Actualités 3:4, 365-371
CrossRef156
Etienne Giroux Leprieur, Armelle Lavole, Anne-Marie Ruppert, Valérie Gounant, Marie Wislez, Jacques Cadranel, Bernard Milleron. (2011) Factors associated with long-term survival of patients with advanced non-small cell lung cancer. Respirologyno-no
CrossRef157
Fabrizio Marcucci, Angelo Corti. (2011) How to improve exposure of tumor cells to drugs — Promoter drugs increase tumor uptake and penetration of effector drugs. Advanced Drug Delivery Reviews
CrossRef158
Paola Claudia Sacco, Paolo Maione, Antonio Rossi, Maria Anna Bareschino, Clorinda Schettino, Cesare Guida, Massimo Elmo, Rita Ambrosio, Valentina Barbato, Rosario Zeppa, Giovanni Palazzolo, Cesare Gridelli. (2011) Combination of radiotherapy and targeted therapies in the treatment of locally advanced non-small cell lung cancer. Targeted Oncology 6:3, 171-180
CrossRef159
Feng Pan, Jing Tian, Xuchao Zhang, Ying Zhang, Yueyin Pan. (2011) Synergistic interaction between sunitinib and docetaxel is sequence dependent in human non–small lung cancer with EGFR TKIs-resistant mutation. Journal of Cancer Research and Clinical Oncology 137:9, 1397-1408
CrossRef160
David P. Carbone, Enriqueta Felip. (2011) Adjuvant Therapy in Non–Small Cell Lung Cancer: Future Treatment Prospects and Paradigms. Clinical Lung Cancer 12:5, 261-271
CrossRef161
Rohit Lal, Deborah Enting, Hartmut Kristeleit. (2011) Systemic treatment of non-small-cell lung cancer. European Journal of Cancer 47, S375-S377
CrossRef162
Bernardo Goulart, Scott Ramsey. (2011) A Trial-Based Assessment of the Cost-Utility of Bevacizumab and Chemotherapy versus Chemotherapy Alone for Advanced Non-Small Cell Lung Cancer. Value in Health 14:6, 836-845
CrossRef163
Roger Henriksson, Thomas Asklund, Hans Skovgaard Poulsen. (2011) Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review. Journal of Neuro-Oncology 104:3, 639-646
CrossRef164
Elisabeth I. Heath, George R. Blumenschein, Roger B. Cohen, Patricia M. LoRusso, Noelle K. LoConte, Sindy T. Kim, Ana Ruiz-Garcia, Richard C. Chao, George Wilding. (2011) Sunitinib in combination with paclitaxel plus carboplatin in patients with advanced solid tumors: phase I study results. Cancer Chemotherapy and Pharmacology 68:3, 703-712
CrossRef165
Mei Zhao, Feng-Hou Gao, Jiong-Yi Wang, Feng Liu, Hai-Hua Yuan, Wen-Ying Zhang, Bin Jiang. (2011) JAK2/STAT3 signaling pathway activation mediates tumor angiogenesis by upregulation of VEGF and bFGF in non-small-cell lung cancer. Lung Cancer 73:3, 366-374
CrossRef166
Titti Martinsson-Niskanen, Rikke Riisbro, Leonard Larsson, Lena Winstedt, Yvonne Stenberg, Steve Pakola, Jean-Marie Stassen, Steven Glazer. (2011) Monoclonal Antibody TB-403: A First-in-Human, Phase I, Double-Blind, Dose Escalation Study Directed Against Placental Growth Factor in Healthy Male Subjects. Clinical Therapeutics 33:9, 1142-1149
CrossRef167
Filip Janku, Ignacio Garrido-Laguna, Lubos B. Petruzelka, David J. Stewart, Razelle Kurzrock. (2011) Novel Therapeutic Targets in Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:9, 1601-1612
CrossRef168
David R. Spigel, John D. Hainsworth, Dianna L. Shipley, Thomas J. Ervin, Peter C. Kohler, Eric T. Lubiner, James D. Peyton, David M. Waterhouse, Howard A. Burris, F. Anthony Greco. (2011) A Randomized Phase II Trial of Pemetrexed/Gemcitabine/Bevacizumab or Pemetrexed/Carboplatin/Bevacizumab in the First-Line Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology1
CrossRef169
Ngayu Thairu, Serafim Kiriakidis, Peter Dawson, Ewa Paleolog. (2011) Angiogenesis as a therapeutic target in arthritis in 2011: learning the lessons of the colorectal cancer experience. Angiogenesis 14:3, 223-234
CrossRef170
Filippo de Marinis, Serena Ricciardi. (2011) Second-line treatment options in advanced non-small cell lung cancer. European Journal of Cancer 47, S258-S271
CrossRef171
Camilla Maria T. Sagerup, Milada Småstuen, Tom B. Johannesen, Åslaug Helland, Odd Terje Brustugun. (2011) Increasing Age and Carcinoma Not Otherwise Specified. Journal of Thoracic Oncology1
CrossRef172
Keith M Kerr. (2011) Personalized medicine for lung cancer: new challenges for pathology. Histopathologyno-no
CrossRef173
C. Eveno, P. Soyer, L. Teixeira, L. Staudacher, M. Pocard. (2011) Anastomotic dehiscence during treatment with bevacizumab 5 years after colo-anal anastomosis with proposition for management without stopping chemotherapy. Clinics and Research in Hepatology and Gastroenterology 35:8-9, 594-596
CrossRef174
Corey J. Langer. (2011) Clinical Evidence on the Undertreatment of Older and Poor Performance Patients Who Have Advanced Non-Small-Cell Lung Cancer: Is There a Role for Targeted Therapy in These Cohorts?. Clinical Lung Cancer 12:5, 272-279
CrossRef175
Cesare Gridelli, Antonio Rossi, Paolo Maione. (2011) 2010 Consensus on Lung Cancer, new clinical recommendations and current status of biomarker assessment — First-line therapy. European Journal of Cancer 47, S248-S257
CrossRef176
G. R. Blumenschein Jr, F. Kabbinavar, H. Menon, T. S. K. Mok, J. Stephenson, J. T. Beck, K. Lakshmaiah, K. Reckamp, Y.- J. Hei, K. Kracht, Y.- N. Sun, R. Sikorski, L. Schwartzberg, . (2011) A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Annals of Oncology 22:9, 2057-2067
CrossRef177
Thomas J. Semrad, Philip C. Mack. (2011) Fibroblast Growth Factor Signaling in Non–Small Cell Lung Cancer. Clinical Lung Cancer
CrossRef178
Ana Custodio, Javier de Castro. (2011) Strategies for maintenance therapy in advanced non-small cell lung cancer: Current status, unanswered questions and future directions. Critical Reviews in Oncology/Hematology
CrossRef179
S. Kruijff, E. Bastiaannet, A. H. Brouwers, W. B. Nagengast, M. J. Speijers, A. J. H. Suurmeijer, G. A. Hospers, H. J. Hoekstra. (2011) Use of S-100B to Evaluate Therapy Effects during Bevacizumab Induction Treatment in AJCC Stage III Melanoma. Annals of Surgical Oncology
CrossRef180
Taroh Satoh, Yasuhide Yamada, Kei Muro, Hidetoshi Hayashi, Yasuhiro Shimada, Daisuke Takahari, Keisei Taku, Takako Eguchi Nakajima, Xiaojin Shi, Kathryn H. Brown, Narikazu Boku. (2011) Phase I study of cediranib in combination with cisplatin plus fluoropyrimidine (S-1 or capecitabine) in Japanese patients with previously untreated advanced gastric cancer. Cancer Chemotherapy and Pharmacology
CrossRef181
Qiang Zhang. (2011) Repeated Confidence Intervals Under Fractional Brownian Motion in Long-Term Clinical Trials. Communications in Statistics - Simulation and Computation 40:8, 1130-1145
CrossRef182
K. D. Miller, A. O'Neill, E. A. Perez, A. D. Seidman, G. W. Sledge. (2011) A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group. Annals of Oncology
CrossRef183
Ignacio Garrido-Laguna, Manuel Hidalgo, Razelle Kurzrock. (2011) The inverted pyramid of biomarker-driven trials. Nature Reviews Clinical Oncology 8:9, 562-566
CrossRef184
F. Tanaka, H. Wada, Y. Fukui, M. Fukushima. (2011) Thymidylate synthase (TS) gene expression in primary lung cancer patients: a large-scale study in Japanese population. Annals of Oncology 22:8, 1791-1797
CrossRef185
Jason L. Smith, Richard F. Riedel. (2011) Emerging Therapeutic Targets for Soft Tissue Sarcoma. Current Oncology Reports 13:4, 350-358
CrossRef186
Peter M. Ellis, Normand Blais, Dennis Soulieres, Diana N. Ionescu, Meenakshi Kashyap, Geoff Liu, Barb Melosky, Tony Reiman, Phillippe Romeo, Frances A. Shepherd, Ming-Sound Tsao, Natasha B. Leighl. (2011) A Systematic Review and Canadian Consensus Recommendations on the Use of Biomarkers in the Treatment of Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:8, 1379-1391
CrossRef187
Apostolos Christopoulos, Sun M Ahn, Jonah D Klein, Seungwon Kim, Jeffrey N. Myers. (2011) Biology of vascular endothelial growth factor and its receptors in head and neck cancer: Beyond angiogenesis. Head & Neck 33:8, 1220-1229
CrossRef188
Shinichi Toyooka, Tetsuya Mitsudomi, Junichi Soh, Keiju Aokage, Masaomi Yamane, Takahiro Oto, Katsuyuki Kiura, Shinichiro Miyoshi. (2011) Molecular oncology of lung cancer. General Thoracic and Cardiovascular Surgery 59:8, 527-537
CrossRef189
Isabelle Ray-Coquard, Axel Le Cesne. (2011) A role for maintenance therapy in managing sarcoma. Cancer Treatment Reviews
CrossRef190
J.- C. Soria, J. Y. Blay, J. P. Spano, X. Pivot, Y. Coscas, D. Khayat. (2011) Added value of molecular targeted agents in oncology. Annals of Oncology 22:8, 1703-1716
CrossRef191
Shirish M. Gadgeel. (2011) The Optimal Chemotherapy for Stage III Non–Small Cell Lung Cancer Patients. Current Oncology Reports 13:4, 272-279
CrossRef192
Yosuke Togashi, Young Hak Kim, Katsuhiro Masago, Koji Tamai, Yuichi Sakamori, Tadashi Mio, Michiaki Mishima. (2011) Pulmonary embolism due to internal jugular vein thrombosis in a patient with non-small cell lung cancer receiving bevacizumab. International Journal of Clinical Oncology 16:4, 444-446
CrossRef193
Paul DeRose, Philip E Thorpe, David E Gerber. (2011) Development of bavituximab, a vascular targeting agent with immune-modulating properties, for lung cancer treatment. Immunotherapy 3:8, 933-944
CrossRef194
Athanasios Kotsakis, Sophia Agelaki, Nikolaos Vardakis, George Stathopoulos, Lambros Vamvakas, Antonia Kalykaki, Nikolaos Kentepozidis, Emmanouel Kontopodis, Georgia Sfakiotaki, Dimitris Mavroudis, Vassilis Georgoulias. (2011) A dose-escalation study of pemetrexed and docetaxel in non-small-cell lung cancer. Cancer Chemotherapy and Pharmacology 68:2, 415-422
CrossRef195
Roberta E. Burden, Julie A. Gormley, Diana Kuehn, Claire Ward, Hang Fai Kwok, Mihaela Gazdoiu, Angela McClurg, Thomas J. Jaquin, James A. Johnston, Christopher J. Scott, Shane A. Olwill. (2011) Inhibition of Cathepsin S by Fsn0503 enhances the efficacy of chemotherapy in colorectal carcinomas. Biochimie
CrossRef196
M. Serke. (2011) Erhaltungstherapie oder „treatment holiday“ nach Erstlinientherapie. Der Onkologe 17:8, 709-714
CrossRef197
J. Köhler, M. Schuler. (2011) Personalisierte medikamentöse Therapie des fortgeschrittenen nichtkleinzelligen Lungenkarzinoms. Der Onkologe 17:8, 702-708
CrossRef198
Domenico Ribatti. (2011) Vascular normalization: a real benefit?. Cancer Chemotherapy and Pharmacology 68:2, 275-278
CrossRef199
David R. Spigel, Johanna C. Bendell, Michael McCleod, Dianna L. Shipley, Edward Arrowsmith, E. Kirk Barnes, Jeffrey R. Infante, Howard A. Burris, F. Anthony Greco, John D. Hainsworth. (2011) Phase II Study of Bevacizumab and Chemoradiation in the Preoperative or Adjuvant Treatment of Patients With Stage II/III Rectal Cancer. Clinical Colorectal Cancer
CrossRef200
Aminah Jatoi. (2011) How Important is Palliative Care?. Current Oncology Reports 13:4, 252-254
CrossRef201
F. Griesinger. (2011) Systemische Therapie des nichtkleinzelligen Lungenkarzinoms. Zeitschrift für Herz-,Thorax- und Gefäßchirurgie 25:4, 224-230
CrossRef202
Eng-Huat Tan, Glenwood D. Goss, Ravi Salgia, Benjamin Besse, David R. Gandara, Nasser H. Hanna, James Chih-Hsin Yang, Raymond Thertulien, Michael Wertheim, Julien Mazieres, Thomas Hensing, Christa Lee, Neeraj Gupta, Rajendra Pradhan, Jiang Qian, Qin Qin, Frank A. Scappaticci, Justin L. Ricker, Dawn M. Carlson, Ross A. Soo. (2011) Phase 2 Trial of Linifanib (ABT-869) in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:8, 1418-1425
CrossRef203
David Planchard. (2011) Bevacizumab in non-small-cell lung cancer: a review. Expert Review of Anticancer Therapy 11:8, 1163-1179
CrossRef204
N. C. Tebbutt, F. Murphy, D. Zannino, K. Wilson, M. M. Cummins, E. Abdi, A. H. Strickland, R. M. Lowenthal, G. Marx, C. Karapetis, J. Shannon, D. Goldstein, S. S. Nayagam, R. Blum, L. Chantrill, R. J. Simes, T. J. Price, . (2011) Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. Annals of Oncology 22:8, 1834-1838
CrossRef205
Domenico Ribatti. (2011) Novel angiogenesis inhibitors: Addressing the issue of redundancy in the angiogenic signaling pathway. Cancer Treatment Reviews 37:5, 344-352
CrossRef206
Alan Sandler, Charles Graham, Maria Baggstrom, Roy Herbst, Christopher Zergebel, Kaku Saito, Dennie Jones. (2011) An Open-Label, Multicenter, Three-Stage, Phase II Study of S-1 in Combination with Cisplatin as First-Line Therapy for Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:8, 1400-1406
CrossRef207
Howard West. (2011) The Evolving Role of Targeted Therapy in Early-Stage and Locally Advanced Non-small Cell Lung Cancer. Current Oncology Reports 13:4, 280-289
CrossRef208
Alice De Sanctis, Laurent Taillade, Stephane Vignot, Silvia Novello, Rosa Conforti, Jean Philippe Spano, Giorgio Vittorio Scagliotti, David Khayat. (2011) Pulmonary toxicity related to systemic treatment of nonsmall cell lung cancer. Cancer 117:14, 3069-3080
CrossRef209
Tom Donnem, Kenneth Lonvik, Katrine Eklo, Thomas Berg, Sveinung W. Sorbye, Khalid Al-Shibli, Samer Al-Saad, Sigve Andersen, Helge Stenvold, Roy M. Bremnes, Lill-Tove Busund. (2011) Independent and tissue-specific prognostic impact of miR-126 in nonsmall cell lung cancer. Cancer 117:14, 3193-3200
CrossRef210
Ryutaro Kikuchi, Makoto Sonobe, Masashi Kobayashi, Masashi Ishikawa, Jiro Kitamura, Ei Nakayama, Toshi Menju, Ryo Miyahara, Cheng-long Huang, Hiroshi Date. (2011) Expression of IGF1R Is Associated with Tumor Differentiation and Survival in Patients with Lung Adenocarcinoma. Annals of Surgical Oncology
CrossRef211
Paul McLoughlin, Michael P. Keane. 2011. Physiological and Pathological Angiogenesis in the Adult Pulmonary Circulation. .
CrossRef212
Håkan Mellstedt, Johan Vansteenkiste, Nick Thatcher. (2011) Vaccines for the treatment of non-small cell lung cancer: Investigational approaches and clinical experience. Lung Cancer 73:1, 11-17
CrossRef213
Jan Nyrop Jakobsen, Jens Benn Sørensen. (2011) Review on clinical trials of targeted treatments in malignant mesothelioma. Cancer Chemotherapy and Pharmacology 68:1, 1-15
CrossRef214
Dolores Isla, Nuria González-Rojas, Diana Nieves, Max Brosa, Henrik W. Finnern. (2011) Treatment patterns, use of resources, and costs of advanced non-small-cell lung cancer patients in Spain: results from a Delphi panel. Clinical and Translational Oncology 13:7, 460-471
CrossRef215
Shu Tian, Haitian Quan, Chengying Xie, Haiyi Guo, Fangfang Lü, Yongping Xu, Jin Li, Liguang Lou. (2011) YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Science 102:7, 1374-1380
CrossRef216
Koji Tsuta, Yuko Tanabe, Akihiko Yoshida, Fumiaki Takahashi, Akiko M. Maeshima, Hisao Asamura, Hitoshi Tsuda. (2011) Utility of 10 Immunohistochemical Markers Including Novel Markers (Desmocollin-3, Glypican 3, S100A2, S100A7, and Sox-2) for Differential Diagnosis of Squamous Cell Carcinoma from Adenocarcinoma of the Lung. Journal of Thoracic Oncology 6:7, 1190-1199
CrossRef217
E. Felip, C. Gridelli, P. Baas, R. Rosell, R. Stahel, . (2011) Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Annals of Oncology 22:7, 1507-1519
CrossRef218
Shirish M. Gadgeel, Percy Ivy, Wei Chen, Joan Mauer, Daryn Smith, Patricia LoRusso. (2011) Analysis of Lung Cancer Patients Enrolled in CTEP (Cancer Therapy Evaluation Program)-Sponsored Phase I Trials. Clinical Lung Cancer 12:4, 218-223
CrossRef219
Kenneth S. Cohen. (2011) Angiogenesis and multiple myeloma: is there a role for angiogenic biomarkers in the context of autologous stem cell transplant?. Leukemia & Lymphoma 52:7, 1173-1175
CrossRef220
Wouter B. Nagengast, Marjolijn N. Lub-de Hooge, Esther M.E. van Straten, Schelto Kruijff, Adrienne H. Brouwers, Wilfred F.A. den Dunnen, Johan R. de Jong, Harry Hollema, Rudi A. Dierckx, Nanno H. Mulder, Elisabeth G.E. de Vries, Harald J. Hoekstra, Geke A.P. Hospers. (2011) VEGF-SPECT with 111In-bevacizumab in stage III/IV melanoma patients. European Journal of Cancer 47:10, 1595-1602
CrossRef221
Tapan K Mukherjee, Karan Paul, Srirupa Mukhopadhyay. (2011) Cell signaling molecules as drug targets in lung cancer: an overview. Current Opinion in Pulmonary Medicine 17:4, 286-291
CrossRef222
Nagahiro Saijo. (2011) Problems involved in the clinical trials for non-small cell lung carcinoma. Cancer Treatment Reviews
CrossRef223
Filippo de Marinis, Antonio Rossi, Massimo Di Maio, Serena Ricciardi, Cesare Gridelli. (2011) Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines. Lung Cancer 73:1, 1-10
CrossRef224
Alex A. Adjei, George R. Blumenschein, Sumithra Mandrekar, Shauna Hillman, Ulrich Gatzemeier, David Heigener. (2011) Long-Term Safety and Tolerability of Sorafenib in Patients with Advanced Non–Small-Cell Lung Cancer: A Case-Based Review. Clinical Lung Cancer 12:4, 212-217
CrossRef225
A. Vergnenègre, C. Chouaïd. (2011) Aspects médico-économiques de la pneumologie. Revue des Maladies Respiratoires Actualités 3:6, 190-201
CrossRef226
Anna Fedorova, Kerry Zobel, Herman S. Gill, Annie Ogasawara, Judith E. Flores, Jeff N. Tinianow, Alexander N. Vanderbilt, Ping Wu, Y. Gloria Meng, Simon-P. Williams, Christian Wiesmann, Jeremy Murray, Jan Marik, Kurt Deshayes. (2011) The Development of Peptide-Based Tools for the Analysis of Angiogenesis. Chemistry & Biology 18:7, 839-845
CrossRef227
Silvia Novello, Carlos Camps, Francesco Grossi, Julien Mazieres, Lauren Abrey, Jean-Marc Vernejoux, Aron Thall, Shem Patyna, Tiziana Usari, Zhixiao Wang, Richard C. Chao, Giorgio Scagliotti. (2011) Phase II Study of Sunitinib in Patients with Non-small Cell Lung Cancer and Irradiated Brain Metastases. Journal of Thoracic Oncology 6:7, 1260-1266
CrossRef228
Iben Kümler, Dorte Lisbet Nielsen. (2011) Trials of bevacizumab in breast cancer – a safety review. Expert Opinion on Drug Safety1-12
CrossRef229
A M Jubb, A Cesario, M Ferguson, M T Congedo, K C Gatter, F Lococo, A Mulè, F Pezzella. (2011) Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases. British Journal of Cancer 104:12, 1877-1881
CrossRef230
Yuh-Min Chen, Jacqueline Whang-Peng, Chien-Ming Chen. (2011) First-line Systemic Therapy for Metastatic Non-small-cell Lung Cancer – A Review. Journal of Experimental & Clinical Medicine 3:3, 116-120
CrossRef231
Antoinette Wozniak. (2011) Challenges in the current antiangiogenic treatment paradigm for patients with non-small cell lung cancer. Critical Reviews in Oncology/Hematology
CrossRef232
Kanwal Pratap Singh Raghav, George R Blumenschein. (2011) Motesanib and advanced NSCLC: experiences and expectations. Expert Opinion on Investigational Drugs 20:6, 859-869
CrossRef233
Baohui Han, Qingyu Xiu, Huimin Wang, Jie Shen, Aiqin Gu, Yi Luo, Chunxue Bai, Shuliang Guo, Wenchao Liu, Zhixiang Zhuang, Yang Zhang, Yizhuo Zhao, Liyan Jiang, Jianying Zhou, Xianqiao Jin. (2011) A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of Paclitaxel-Carboplatin Alone or with Endostar for Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:6, 1104-1109
CrossRef234
William Small, Mary F. Mulcahy, Alfred Rademaker, David J. Bentrem, Al B. Benson, Bing Bing Weitner, Mark S. Talamonti. (2011) Phase II Trial of Full-Dose Gemcitabine and Bevacizumab in Combination With Attenuated Three-Dimensional Conformal Radiotherapy in Patients With Localized Pancreatic Cancer. International Journal of Radiation Oncology*Biology*Physics 80:2, 476-482
CrossRef235
Wilson Gonsalves, Apar Kishor Ganti. (2011) Targeted anti-cancer therapy in the elderly. Critical Reviews in Oncology/Hematology 78:3, 227-242
CrossRef236
Jennifer M. Furst, Dominic A. Solimando, J. Aubrey Waddell. (2011) Cancer Chemotherapy Update - Paclitaxel, Carboplatin, and Bevacizumab. Hospital Pharmacy 46:6, 406-414
CrossRef237
C. Mogler, H.G. Augustin. (2011) Tumorangiogenese und aktuelle therapeutische Möglichkeiten der Inhibition. Der Onkologe 17:6, 513-519
CrossRef238
Robert R. Langley, Isaiah J. Fidler. (2011) The seed and soil hypothesis revisited-The role of tumor-stroma interactions in metastasis to different organs. International Journal of Cancer 128:11, 2527-2535
CrossRef239
Eddie S.Y. Chan, Amit R. Patel, William A. Larchian, Warren D. Heston. (2011) In Vivo Targeted Contrast Enhanced Micro-Ultrasound to Measure Intratumor Perfusion and Vascular Endothelial Growth Factor Receptor 2 Expression in a Mouse Orthotopic Bladder Cancer Model. The Journal of Urology 185:6, 2359-2365
CrossRef240
Gee-Chen CHANG, Myung-Ju AHN, Elaine WRIGHT, Heung Tae KIM, Joo-Hang KIM, Jin Hyoung KANG, Sang-We KIM, Steven SHERMAN, Stefan WALZER. (2011) Comparative effectiveness of bevacizumab plus cisplatin-based chemotherapy versus pemetrexed plus cisplatin treatment in East Asian non-squamous non-small cell lung cancer patients applying real-life outcomes. Asia-Pacific Journal of Clinical Oncology 7, 34-40
CrossRef241
Tony SK MOK, Te-Chun HSIA, Chun-Ming TSAI, Kenneth TSANG, Gee-Chen CHANG, John Wen-Cheng CHANG, Sirisinha THITIYA, Virote SRIURANPONG, Sumitra THONGPRASERT, Daniel TT CHUA, Nicola MOORE, Christian MANEGOLD. (2011) Efficacy of bevacizumab with cisplatin and gemcitabine in Asian patients with advanced or recurrent non-squamous non-small cell lung cancer who have not received prior chemotherapy: A substudy of the Avastin in Lung trial. Asia-Pacific Journal of Clinical Oncology 7, 4-12
CrossRef242
F. A. B. Schutz, Y. Je, G. R. Azzi, P. L. Nguyen, T. K. Choueiri. (2011) Bevacizumab increases the risk of arterial ischemia: a large study in cancer patients with a focus on different subgroup outcomes. Annals of Oncology 22:6, 1404-1412
CrossRef243
Sigve Andersen, Marte Eilertsen, Tom Donnem, Khalid Al-Shibli, Samer Al-Saad, Lill-Tove Busund, Roy M. Bremnes. (2011) Diverging prognostic impacts of hypoxic markers according to NSCLC histology. Lung Cancer 72:3, 294-302
CrossRef244
John Wen-Cheng CHANG, Sumitra THONGPRASERT, Elaine WRIGHT, Kenneth TSANG, Heung Tae KIM, Myung-Ju AHN, Joo-Hang KIM, Jin Hyoung KANG, Sang-We KIM, Stefan WALZER. (2011) An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia. Asia-Pacific Journal of Clinical Oncology 7, 13-21
CrossRef245
Xing Lv, Yan-Qun Xiang, Su-Mei Cao, Chao-Nan Qian, Ning-Wei Li, Ling Guo, Hai-Qiang Mai, Qiu-Yan Chen, Pei-Yu Huang, DongHua Luo, Ka-Jia Cao, Ming-Huang Hong, Xiang Guo. (2011) Prospective validation of the prognostic value of elevated serum vascular endothelial growth factor in patients with nasopharyngeal carcinoma: More distant metastases and shorter overall survival after treatment. Head & Neck 33:6, 780-785
CrossRef246
Xiao Feng Hang, Wen Sheng Xu, Jun Xue Wang, Lei Wang, Hai Guang Xin, Rui Qi Zhang, Wu Ni. (2011) Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials. European Journal of Clinical Pharmacology 67:6, 613-623
CrossRef247
Kostas N. Syrigos, Eleni Karapanagiotou, Paraskevi Boura, Christian Manegold, Kevin Harrington. (2011) Bevacizumab-Induced Hypertension. BioDrugs 25:3, 159-169
CrossRef248
Chun-Ming Tsai, Joseph Siu-kie Au, Gee-Chen Chang, Ashley Chi-kin Cheng, Caicun Zhou, Yi-long Wu. (2011) Safety and Efficacy of First-Line Bevacizumab with Chemotherapy in Asian Patients with Advanced Nonsquamous NSCLC. Journal of Thoracic Oncology 6:6, 1092-1097
CrossRef249
M. Früh. (2011) The search for improved systemic therapy of non-small cell lung cancer—What are today's options?. Lung Cancer 72:3, 265-270
CrossRef250
D. J. Jonker, L. S. Rosen, M. B. Sawyer, F. de Braud, G. Wilding, C. J. Sweeney, G. C. Jayson, G. A. McArthur, G. Rustin, G. Goss, J. Kantor, L. Velasquez, S. Syed, O. Mokliatchouk, D. M. Feltquate, G. Kollia, D. S. A. Nuyten, S. Galbraith. (2011) A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors. Annals of Oncology 22:6, 1413-1419
CrossRef251
Mary A. Foulkes. (2011) After Inclusion, Information and Inference: Reporting on Clinical Trials Results After 15 Years of Monitoring Inclusion of Women. Journal of Women's Health 20:6, 829-836
CrossRef252
Arup Bhattacharya. (2011) Methylselenocysteine – a promising antiangiogenic agent for overcoming drug delivery barriers in solid malignancies for therapeutic synergy with anticancer drugs. Expert Opinion on Drug Delivery 8:6, 749-763
CrossRef253
Zhi-jie Wang, Tong-tong An, Tony Mok, Lu Yang, Hua Bai, Jun Zhao, Jian-chun Duan, Mei-na Wu, Yu-yan Wang, Ping-ping Li, Hong Sun, Ping Yang, Jie Wang. (2011) Immediate versus delayed treatment with EGFR tyrosine kinase inhibitors after first-line therapy in advanced non-small-cell lung cancer. Chinese Journal of Cancer Research 23:2, 112-117
CrossRef254
C.P. Belani, G. Goss, G. Blumenschein. (2011) Recent clinical developments and rationale for combining targeted agents in non-small cell lung cancer (NSCLC). Cancer Treatment Reviews
CrossRef255
T. C. Gauler, B. Besse, A. Mauguen, J. B. Meric, V. Gounant, B. Fischer, T. R. Overbeck, H. Krissel, D. Laurent, M. Tiainen, F. Commo, J. C. Soria, W. E. E. Eberhardt. (2011) Phase II trial of PTK787/ZK 222584 (vatalanib) administered orally once-daily or in two divided daily doses as second-line monotherapy in relapsed or progressing patients with stage IIIB/IV non-small-cell lung cancer (NSCLC). Annals of Oncology
CrossRef256
Olivier Mir, Jérôme Alexandre, Romain Coriat, Stanislas Ropert, Pascaline Boudou-Rouquette, Thach Bui, Jeanne Chapron, Jean-Philippe Durand, Daniel Dusser, François Goldwasser. (2011) Safety of bevacizumab 7.5 mg/kg infusion over 10 minutes in NSCLC patients. Investigational New Drugs
CrossRef257
B. Coudert, T. Ciuleanu, K. Park, Y.-L. Wu, G. Giaccone, W. Brugger, P. Gopalakrishna, F. Cappuzzo, . (2011) Survival benefit with erlotinib maintenance therapy in patients with advanced non-small-cell lung cancer (NSCLC) according to response to first-line chemotherapy. Annals of Oncology
CrossRef258
Rajasubramaniam Shanmugam, Praveen Kusumanchi, Hitesh Appaiah, Liang Cheng, Peter Crooks, Sundar Neelakantan, Tyler Peat, James Klaunig, William Matthews, Harikrishna Nakshatri, Christopher J. Sweeney. (2011) A water soluble parthenolide analog suppresses in vivo tumor growth of two tobacco-associated cancers, lung and bladder cancer, by targeting NF-κB and generating reactive oxygen species. International Journal of Cancer 128:10, 2481-2494
CrossRef259
, Laurence Legros, Bohrane Slama, Jean-Michel Karsenti, Norbert Vey, Shanti Natarajan-Amé, Eric Watel, Bruno Richard, Krimo Bouabdallah, Lionel Mannone, Maxime Benchetrit, Irit Touitou, Sébastien Huault, Jérome Durivault, Damien Ambroseti, Anne-Odile Hueber, Pierre Fenaux, Francois Dreyfus. (2011) Treatment of myelodysplastic syndromes with excess of blasts by bevacizumab is well tolerated and is associated with a decrease of VEGF plasma level. Annals of Hematology
CrossRef260
S Huber, M Oelsner, T Decker, C Meyer zum Büschenfelde, M Wagner, G Lutzny, T Kuhnt, B Schmidt, R A J Oostendorp, C Peschel, I Ringshausen. (2011) Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1. Leukemia 25:5, 838-847
CrossRef261
Giulio Metro, Lucio Crinò. (2011) The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer. Expert Review of Anticancer Therapy 11:5, 673-682
CrossRef262
Takehito Shukuya, Toshiaki Takahashi, Rieko Kaira, Akira Ono, Yukiko Nakamura, Asuka Tsuya, Hirotsugu Kenmotsu, Tateaki Naito, Kyoichi Kaira, Haruyasu Murakami, Masahiro Endo, Kazuhisa Takahashi, Nobuyuki Yamamoto. (2011) Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: A pooled analysis of published reports. Cancer Science 102:5, 1032-1037
CrossRef263
Motomasa Furuse, Shinji Kawabata, Toshihiko Kuroiwa, Shin-Ichi Miyatake. (2011) Repeated treatments with bevacizumab for recurrent radiation necrosis in patients with malignant brain tumors: a report of 2 cases. Journal of Neuro-Oncology 102:3, 471-475
CrossRef264
Andriani Charpidou, Ioannis Gkiozos, Marios Konstantinou, Anastasia Eleftheraki, Panagiotis Demertzis, Kevin Harrington, Aris Polyzos, Kostas N. Syrigos. (2011) Bronchial washing levels of vascular endothelial growth factor receptor-2 (VEGFR2) correlate with overall survival in NSCLC patients. Cancer Letters 304:2, 144-153
CrossRef265
T. Zander, M. Hallek. (2011) Thyrosinkinaseinhibitoren in der Onkologie. Der Internist 52:5, 595-600
CrossRef266
David Berz, Harold Wanebo. (2011) Targeting the growth factors and angiogenesis pathways: Small molecules in solid tumors. Journal of Surgical Oncology 103:6, 574-586
CrossRef267
David F McDermott, Keith T Flaherty. (2011) Combination therapy for renal cell carcinoma: review of the clinical evidence. Clinical Investigation 1:5, 689-697
CrossRef268
Esther M. Bridges, Adrian L. Harris. (2011) The angiogenic process as a therapeutic target in cancer. Biochemical Pharmacology 81:10, 1183-1191
CrossRef269
Christian Hessler, Eik Vettorazzi, Juergen Madert, Carsten Bokemeyer, Jens Panse. (2011) Actual and Predicted Survival Time of Patients With Spinal Metastases of Lung Cancer. Spine 36:12, 983-989
CrossRef270
Niels Reinmuth, Michael Thomas. (2011) An approach to personalized medicine: the BATTLE trial. Clinical Investigation 1:5, 699-705
CrossRef271
Fabio A.B. Schutz, Denis L.F. Jardim, Youjin Je, Toni K. Choueiri. (2011) Haematologic toxicities associated with the addition of bevacizumab in cancer patients. European Journal of Cancer 47:8, 1161-1174
CrossRef272
Roy S Herbst, Rafat Ansari, Frederique Bustin, Patrick Flynn, Lowell Hart, Gregory A Otterson, Gordana Vlahovic, Chang-Heok Soh, Paula O'Connor, John Hainsworth. (2011) Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. The Lancet 377:9780, 1846-1854
CrossRef273
Mark J. McKeage. (2011) Clinical Trials of Vascular Disrupting Agents in Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer 12:3, 143-147
CrossRef274
R. von Moos, B. Seifert, M. Simcock, S. M. Goldinger, S. Gillessen, A. Ochsenbein, O. Michielin, R. Cathomas, M. Schlappi, H. Moch, P. H. Schraml, D. Mjhic-Probst, C. Mamot, N. Schonewolf, R. Dummer, . (2011) First-line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Annals of Oncology
CrossRef275
Antonin Levy, Laurence Albiges-Sauvin, Christophe Massard, Hassan Izzedine, Stéphane Edhery, Ratio Bahleda, Carlos Gomez-Roca, Cyrus Chargari, Isabelle Brocheriou-Spelle, Jean-Charles Soria. (2011) Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trials. Investigational New Drugs
CrossRef276
Susanna V. Ulahannan, Julie R. Brahmer. (2011) Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer. Cancer Investigation 29:4, 325-337
CrossRef277
C. Manegold, N. van Zandwijk, A. Szczesna, P. Zatloukal, J. S. K. Au, M. Blasinska-Morawiec, P. Serwatowski, M. Krzakowski, J. Jassem, E. H. Tan, R. J. Benner, A. Ingrosso, S. J. Meech, D. Readett, N. Thatcher. (2011) A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Annals of Oncology
CrossRef278
She-Juan An, Yi-Sheng Huang, Zhi-Hong Chen, Jian Su, Yan Yang, Jian-Guang Chen, Hong-Hong Yan, Qiu-Xiong Lin, Jin-Ji Yang, Xue-Ning Yang, Qing Zhou, Xu-Chao Zhang, Yi-Long Wu. (2011) Posttreatment plasma VEGF levels may be associated with the overall survival of patients with advanced non-small cell lung cancer treated with bevacizumab plus chemotherapy. Medical Oncology
CrossRef279
E. Szutowicz, K. Konopa, J. Jassem. (2011) Targeted therapies in advanced non-small cell lung cancer: success or failure?. memo - Magazine of European Medical Oncology 4:1, 23-26
CrossRef280
Jonas A de Souza, Blase N Polite, Willard G Manning, A Mark Fendrick, Mark J Ratain. (2011) Value-based insurance design in oncology. The Lancet Oncology 12:4, 321-323
CrossRef281
Ari VanderWalde, Sumanta Kumar Pal, Karen L. Reckamp. (2011) Management of non-small-cell lung cancer in the older adult. Maturitas 68:4, 311-321
CrossRef282
G. Meyer, L. Belmont. (2011) Maladie veineuse thromboembolique et cancer. Revue des Maladies Respiratoires 28:4, 443-452
CrossRef283
Sònia Tugues, Sina Koch, Laura Gualandi, Xiujuan Li, Lena Claesson-Welsh. (2011) Vascular endothelial growth factors and receptors: Anti-angiogenic therapy in the treatment of cancer. Molecular Aspects of Medicine 32:2, 88-111
CrossRef284
Ravi Salgia, Thomas Hensing, Nicholas Campbell, April K. Salama, Michael Maitland, Philip Hoffman, Victoria Villaflor, Everett E. Vokes. (2011) Personalized Treatment of Lung Cancer. Seminars in Oncology 38:2, 274-283
CrossRef285
Peer Joensson, Birgit Hotz, Heinz Johannes Buhr, Hubert G. Hotz. (2011) A novel antiangiogenic approach for adjuvant therapy of pancreatic carcinoma. Langenbeck's Archives of Surgery 396:4, 535-541
CrossRef286
Lauren M. Willis, Azza B. El
Remessy, Payaningal R. Somanath, David L. Deremer, Susan C. Fagan. (2011) Angiotensin receptor blockers and angiogenesis: clinical and experimental evidence. Clinical Science 120:8, 307-319
CrossRef287
Neil S. Horowitz, Richard T. Penson, Dan G. Duda, Emmanuelle di Tomaso, Yves Boucher, Marek Ancukiewicz, Kenneth S. Cohen, Suzanne Berlin, Carolyn N. Krasner, Marsha A. Moses, Rakesh K. Jain. (2011) Safety, Efficacy, and Biomarker Exploration in a Phase II Study of Bevacizumab, Oxaliplatin, and Gemcitabine in Recurrent Müllerian Carcinoma. Clinical Ovarian Cancer
CrossRef288
Tina Cascone, Matthew H. Herynk, Li Xu, Zhiqiang Du, Humam Kadara, Monique B. Nilsson, Carol J. Oborn, Yun-Yong Park, Baruch Erez, Jörg J. Jacoby, Ju-Seog Lee, Heather Y. Lin, Fortunato Ciardiello, Roy S. Herbst, Robert R. Langley, John V. Heymach. (2011) Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor–resistant human lung adenocarcinoma. Journal of Clinical Investigation 121:4, 1313-1328
CrossRef289
L. Bengrine-Lefevre, P. Afchain, B. Chibaudel, H. Gervais, C. Tournigand, A. De Gramont, C. Louvet. (2011) Perforation de la cloison nasale et bevacizumab. La Revue de Médecine Interne 32:4, e43-e45
CrossRef290
Beatrice M. Seddon, Reena Davda. (2011) Uterine sarcomas—Recent progress and future challenges. European Journal of Radiology 78:1, 30-40
CrossRef291
S. I. Rothschild, O. Gautschi. (2011) Maintenance therapy for patients with advanced non-small cell lung cancer: Who to treat and how to treat?. memo - Magazine of European Medical Oncology 4:1, 19-22
CrossRef292
P. A. Kosmidis, G. Fountzilas, A. G. Eleftheraki, H. P. Kalofonos, G. Pentheroudakis, D. Skarlos, M. A. Dimopoulos, D. Bafaloukos, D. Pectasides, E. Samantas, J. Boukovinas, S. Lambaki, N. Katirtzoglou, C. Bakogiannis, K. N. Syrigos. (2011) Paclitaxel and gemcitabine versus paclitaxel and vinorelbine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group (HeCOG). Annals of Oncology 22:4, 827-834
CrossRef293
PETER R. EASTWOOD, KAZUHISA TAKAHASHI, PYNG LEE, TOBY M. MAHER. (2011) Year in review 2010: Interstitial lung diseases, acute lung injury, sleep, physiology, imaging, bronchoscopic intervention and lung cancer. Respirology 16:3, 553-563
CrossRef294
Fernanda Salazar, Miguel Angel Molina, Maria Sanchez-Ronco, Teresa Moran, Jose Luis Ramirez, Jose Miguel Sanchez, Rolf Stahel, Pilar Garrido, Manuel Cobo, Dolores Isla, Jordi Bertran-Alamillo, Bartomeu Massuti, Felipe Cardenal, Christian Manegold, Pilar Lianes, Jose Manuel Trigo, Jose Javier Sanchez, Miquel Taron, Rafael Rosell. (2011) First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients. Lung Cancer 72:1, 84-91
CrossRef295
O. L. Chinot, T. Motte Rouge, N. Moore, A. Zeaiter, A. Das, H. Phillips, Z. Modrusan, T. Cloughesy. (2011) AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme. Advances in Therapy 28:4, 334-340
CrossRef296
Sasan Karimi, Eric Lis, Saba Gilani, Nicholas D'Ambrosio, Andrei Holodny. (2011) Nonenhancing Brain Metastases. Journal of Neuroimaging 21:2, 184-187
CrossRef297
Siamack Sabrkhany, Arjan W. Griffioen, Mirjam G.A. oude Egbrink. (2011) The role of blood platelets in tumor angiogenesis. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1815:2, 189-196
CrossRef298
Igor Puzanov, Patrick Burnett, Keith T. Flaherty. (2011) Biological challenges of BRAF inhibitor therapy. Molecular Oncology 5:2, 116-123
CrossRef299
Arlene Chan, Shailendra Verma, Sibylle Loibl, Jeffrey Crawford, Mi Rim Choi, Lyndah Dreiling, Ted Vandenberg. (2011) Reporting of myelotoxicity associated with emerging regimens for the treatment of selected solid tumors. Critical Reviews in Oncology/Hematology
CrossRef300
Joseph P. Erinjeri, Abigail J. Fong, Nancy E. Kemeny, Karen T. Brown, George I. Getrajdman, Stephen B. Solomon. (2011) Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement. Cancer 117:6, 1296-1301
CrossRef301
Cataldo, Vince D., Gibbons, Don L., Pérez-Soler, Román, Quintás-Cardama, Alfonso, . (2011) Treatment of Non–Small-Cell Lung Cancer with Erlotinib or Gefitinib. New England Journal of Medicine 364:10, 947-955
Full Text302
Jenny Andrews, Paul Yeh, William Pao, Leora Horn. (2011) Molecular Predictors of Response to Chemotherapy in Non-Small Cell Lung Cancer. The Cancer Journal 17:2, 104-113
CrossRef303
A.- M. C. Dingemans, A. J. de Langen, V. van den Boogaart, J. T. Marcus, W. H. Backes, H. T. G. M. Scholtens, H. van Tinteren, O. S. Hoekstra, J. Pruim, B. Brans, F. B. Thunnissen, E. F. Smit, H. J. M. Groen. (2011) First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging. Annals of Oncology 22:3, 559-566
CrossRef304
Linda E. Coate, Natasha B. Leighl. (2011) How Affordable are Targeted Therapies in Non-Small Cell Lung Cancer?. Current Treatment Options in Oncology 12:1, 1-11
CrossRef305
Rita Nizzoli, Marcello Tiseo, Francesco Gelsomino, Marco Bartolotti, Maria Majori, Lilia Ferrari, Massimo De Filippo, Guido Rindi, Enrico Maria Silini, Annamaria Guazzi, Andrea Ardizzoni. (2011) Accuracy of Fine Needle Aspiration Cytology in the Pathological Typing of Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:3, 489-493
CrossRef306
Michael S Gordon. (2011) Antiangiogenic therapies: is VEGF-A inhibition alone enough?. Expert Review of Anticancer Therapy 11:3, 485-496
CrossRef307
Brian M Slomovitz, Michael J Worley, Maurie Markman, Robert L Coleman. (2011) Emerging therapeutics for primary peritoneal cancer. Expert Opinion on Emerging Drugs 16:1, 71-84
CrossRef308
Michael I. Koukourakis, Vassilios Limberis, Ioannis Tentes, Emmanuel Kontomanolis, Alexandros Kortsaris, Efthimios Sivridis, Alexandra Giatromanolaki. (2011) Serum VEGF levels and tissue activation of VEGFR2/KDR receptors in patients with breast and gynecologic cancer. Cytokine 53:3, 370-375
CrossRef309
Daniel Morgensztern, Nathan A. Pennell, Janakiraman Subramanian, Ramaswamy Govindan. (2011) Summary of Presentations from the 46th Annual Meeting of the American Society of Clinical Oncology (2010): Focus on Developmental Therapeutics Related to Lung Cancer. Clinical Lung Cancer 12:2, 94-99
CrossRef310
M. Joerger, K. Matter-Walstra, M. Fruh, U. Kuhnel, T. Szucs, B. Pestalozzi, M. Schwenkglenks. (2011) Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. Annals of Oncology 22:3, 567-574
CrossRef311
Yufan Zhao, Donglin Zeng, Mark A. Socinski, Michael R. Kosorok. (2011) Reinforcement Learning Strategies for Clinical Trials in Nonsmall Cell Lung Cancer. Biometricsno-no
CrossRef312
Janos L. Tanyi, Georgia McCann, Andrea R. Hagemann, George Coukos, Stephen C. Rubin, John B. Liao, Christina S. Chu. (2011) Clinical predictors of bevacizumab-associated gastrointestinal perforation. Gynecologic Oncology 120:3, 464-469
CrossRef313
Derek G. Power, Nancy E. Kemeny. (2011) Nasal septum perforation and bevacizumab. Medical Oncology 28:1, 89-93
CrossRef314
Paul Baas, Jose SA Belderbos, Michel van den Heuvel. (2011) Chemoradiation therapy in nonsmall cell lung cancer. Current Opinion in Oncology 23:2, 140-149
CrossRef315
Ursula A Matulonis. (2011) Bevacizumab and its use in epithelial ovarian cancer. Future Oncology 7:3, 365-379
CrossRef316
George Dranitsaris, Ilse Truter, Martie S. Lubbe, Eitan Amir, William Evans. (2011) Advances in Cancer Therapeutics and Patient Access to New Drugs. PharmacoEconomics 29:3, 213-224
CrossRef317
Armin Gerger, Melissa LaBonte, Heinz-Josef Lenz. (2011) Molecular Predictors of Response to Antiangiogenesis Therapies. The Cancer Journal 17:2, 134-141
CrossRef318
Giannis Mountzios, Kostas N. Syrigos. (2011) A Benefit-Risk Assessment of Erlotinib in Non-Small-Cell Lung Cancer and Pancreatic Cancer. Drug Safety 34:3, 175-186
CrossRef319
Valsamo K. Anagnostou, Dina G. Tiniakos, Marianthi Fotinou, Apostolos Achimastos, Konstantinos N. Syrigos. (2011) Multiplexed analysis of angiogenesis and lymphangiogenesis factors predicts outcome for non-small cell lung cancer patients. Virchows Archiv 458:3, 331-340
CrossRef320
Cesare Gridelli, Paolo Maione, Antonio Rossi, Maria Anna Bareschino, Clorinda Schettino, Paola Claudia Sacco, Rosario Zeppa. (2011) Pemetrexed in advanced non-small cell lung cancer. Expert Opinion on Drug Safety 10:2, 311-317
CrossRef321
John M. L. Ebos, Robert S. Kerbel. (2011) Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nature Reviews Clinical Oncology 8:4, 210-221
CrossRef322
Suresh S. Ramalingam, Taofeek K. Owonikoko, Fadlo R. Khuri. (2011) Lung cancer: New biological insights and recent therapeutic advances. CA: A Cancer Journal for Clinicians 61:2, 91-112
CrossRef323
Edgardo S. Santos, Jorge E. Gomez, Luis E. Raez. (2011) Targeting angiogenesis from multiple pathways simultaneously: BIBF 1120, an investigational novel triple angiokinase inhibitor. Investigational New Drugs
CrossRef324
Michael Millward, Paul Mainwaring, Alain Mita, Kristine Federico, G. K. Lloyd, Natasha Reddinger, Steffan Nawrocki, Monica Mita, Matthew A. Spear. (2011) Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel. Investigational New Drugs
CrossRef325
Clarisse Eveno, Christine le Maignan, Philippe Soyer, Marine Camus, Emmanuel Barranger, Marc Pocard. (2011) Late anastomotic colonic dehiscence due to antiangiogenic treatment, a specific drug-class complication requiring specific treatment: An example of pazopanib complication. Clinics and Research in Hepatology and Gastroenterology 35:2, 135-139
CrossRef326
John P. Crapanzano, Anjali Saqi, Zubair Baloch. (2011) Pitfalls in pulmonary cytopathology. Diagnostic Cytopathology 39:2, 144-154
CrossRef327
Wendy A Cooper, Sandra OʼToole, Michael Boyer, Lisa Horvath, Annabelle Mahar. (2011) Whatʼs new in non-small cell lung cancer for pathologists: the importance of accurate subtyping, EGFR mutations and ALK rearrangements. Pathology 43:2, 103-115
CrossRef328
Joel W Neal, Matthew A Gubens, Heather A Wakelee. (2011) Emerging treatments for small-cell lung cancer: Phase II and III trials. Clinical Investigation 1:2, 255-263
CrossRef329
Igor A. Astsaturov, Neal J. Meropol, R. Katherine Alpaugh, Barbara A. Burtness, Jonathan D. Cheng, Sue McLaughlin, André Rogatko, Zhiheng Xu, James C. Watson, Louis M. Weiner, Steven J. Cohen. (2011) Phase II and Coagulation Cascade Biomarker Study of Bevacizumab With or Without Docetaxel in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma. American Journal of Clinical Oncology 34:1, 70-75
CrossRef330
William Pao, Nicolas Girard. (2011) New driver mutations in non-small-cell lung cancer. The Lancet Oncology 12:2, 175-180
CrossRef331
Robert O. Dillman. (2011) Cancer Immunotherapy. Cancer Biotherapy & Radiopharmaceuticals 26:1, 1-64
CrossRef332
Kristan D. Guenterberg, Valerie P. Grignol, Kiran V. Relekar, Kimberly A. Varker, Helen X. Chen, Kari L. Kendra, Thomas E. Olencki, William E. Carson. (2011) A Pilot Study of Bevacizumab and Interferon-α2b in Ocular Melanoma. American Journal of Clinical Oncology 34:1, 87-91
CrossRef333
Karen E. Bullock, William P. Petros, Islam Younis, Hope E. Uronis, Michael A. Morse, Gerard C. Blobe, S. Yousuf Zafar, Jon P. Gockerman, Joanne J. Lager, Roxanne Truax, Kellen L. Meadows, Leigh A. Howard, Margot M. O’Neill, Gloria Broadwater, Herbert I. Hurwitz, Johanna C. Bendell. (2011) A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). Cancer Chemotherapy and Pharmacology 67:2, 465-474
CrossRef334
N B Leighl, J Bennouna, J Yi, N Moore, J Hambleton, H Hurwitz. (2011) Bleeding events in bevacizumab-treated cancer patients who received full-dose anticoagulation and remained on study. British Journal of Cancer 104:3, 413-418
CrossRef335
William D. Travis, Elisabeth Brambilla, Masayuki Noguchi, Andrew G. Nicholson, Kim R. Geisinger, Yasushi Yatabe, David G. Beer, Charles A. Powell, Gregory J. Riely, Paul E. Van Schil, Kavita Garg, John H. M. Austin, Hisao Asamura, Valerie W. Rusch, Fred R. Hirsch, Giorgio Scagliotti, Tetsuya Mitsudomi, Rudolf M. Huber, Yuichi Ishikawa, James Jett, Montserrat Sanchez-Cespedes, Jean-Paul Sculier, Takashi Takahashi, Masahiro Tsuboi, Johan Vansteenkiste, Ignacio Wistuba, Pan-Chyr Yang, Denise Aberle, Christian Brambilla, Douglas Flieder, Wilbur Franklin, Adi Gazdar, Michael Gould, Philip Hasleton, Douglas Henderson, Bruce Johnson, David Johnson, Keith Kerr, Keiko Kuriyama, Jin Soo Lee, Vincent A. Miller, Iver Petersen, Victor Roggli, Rafael Rosell, Nagahiro Saijo, Erik Thunnissen, Ming Tsao, David Yankelewitz. (2011) International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. Journal of Thoracic Oncology 6:2, 244-285
CrossRef336
David J. Stewart, Carmen Behrens, Jack Roth, Ignacio I. Wistuba. (2011) Exponential decay nonlinear regression analysis of patient survival curves: Preliminary assessment in non-small cell lung cancer. Lung Cancer 71:2, 217-223
CrossRef337
Rudiger J Weiss, Rikard Wedin. (2011) Surgery for skeletal metastases in lung cancer. Acta Orthopaedica 82:1, 96-101
CrossRef338
Janakiraman Subramanian, Luis Corrales, Denis Soulieres, Daniel Morgensztern, Ramaswamy Govindan. (2011) Summary of Presentations from the 46th Annual Meeting of the American Society of Clinical Oncology (2010) Focus on Tumor Biology and Biomarkers Related to Lung Cancer. Journal of Thoracic Oncology 6:2, 399-403
CrossRef339
Erin Bertino, Miguel A. Villalona-Calero, Patrick Ross, Michael Grever, Gregory A. Otterson. (2011) Preoperative Bevacizumab in Combination With Paclitaxel and Carboplatin in Surgically Resectable Non-Small Cell Lung Cancer. The Annals of Thoracic Surgery 91:2, 640
CrossRef340
Xin Zhao, Kai Mei, Xiaohong Cai, Jing Chen, Jingrui Yu, Chengya Zhou, Qiu Li. (2011) A randomized phase II study of recombinant human endostatin plus gemcitabine/cisplatin compared with gemcitabine/cisplatin alone as first-line therapy in advanced non-small-cell lung cancer. Investigational New Drugs
CrossRef341
A. Ocana, I. F. Tannock. (2011) When Are "Positive" Clinical Trials in Oncology Truly Positive?. JNCI Journal of the National Cancer Institute 103:1, 16-20
CrossRef342
Tarik Mahfoud, Rachid Tanz, Mohamed Mesmoudi, Mohamed Réda Khmamouche, Aziz Bazine, Rachid Aassab, Nabil Ismaili, Saber Boutayeb, Mohamed Ichou, Hassan Errihani. (2011) Bevacizumab 5 or 7.5 mg/kg in Metastatic Colorectal Cancer Can Be Infused Safely Over 10 Minutes. Journal of Gastrointestinal Cancer
CrossRef343
Fumio Imamura, Makoto Nishio, Rintaro Noro, Masahiro Tsuboi, Norihiko Ikeda, Akira Inoue, Yoshinobu Ohsaki, Yukio Kimura, Kazumi Nishino, Junji Uchida, Takeshi Horai. (2011) Randomized Phase II Study of Two Schedules of Carboplatin and Gemcitabine for Stage IIIB and IV Advanced Non-Small Cell Lung Cancer (JACCRO LC-01 Study). Chemotherapy 57:4, 357-362
CrossRef344
Thomas E. Stinchcombe, Mark A. Socinski. (2011) Maintenance Therapy in Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:1, 174-182
CrossRef345
M. Pless. (2011) Das fortgeschrittene Lungenkarzinom : Perspektiven in Forschung und Therapie. Der Pneumologe
CrossRef346
David Khayat. (2011) Innovative cancer therapies. Cancern/a-n/a
CrossRef347
Edgardo S Santos. (2011) New discoveries in lung cancer biology: paving the road of personalized medicine. Therapy 8:1, 1-4
CrossRef348
Alaaeldin Shablak, Jackie O’Dwyer, Robert Hawkins, Ruth Board. (2011) Management of a New Isolated Metastasis during Sunitinib Treatment in Renal Cell Carcinoma Patients: A Lesson from Two Cases. Urologia Internationalis 86:2, 245-248
CrossRef349
W. Berger, A. Pircher, M. Sibilia, L. Bubendorf, M. Filipits, M. Fiegl, M. Früh, C. Manegold, H. Popper, W. Hilbe. (2011) Molecular oncology in lung cancer – between biomarkers and clinical application. Relevance of the Ras–Raf–MEK–ERK pathway. memo - Magazine of European Medical Oncology 4:4, 242
CrossRef350
Dal Yong Kim, Dae Ho Lee, Sun-Joo Jang, Sang-We Kim, Cheolwon Suh, Jung Shin Lee. (2011) Phase II Study of S-1 Plus Either Irinotecan or Docetaxel for Non-small Cell Lung Cancer Patients Treated with More Than Three Lines of Treatment. Cancer Research and Treatment 43:4, 212
CrossRef351
Gouji Toyokawa, Ken Masuda, Yataro Daigo, Hyun-Soo Cho, Masanori Yoshimatsu, Masashi Takawa, Shinya Hayami, Kazuhiro Maejima, Makoto Chino, Helen I Field, David E Neal, Eiju Tsuchiya, Bruce AJ Ponder, Yoshihiko Maehara, Yusuke Nakamura, Ryuji Hamamoto. (2011) Minichromosome Maintenance Protein 7 is a potential therapeutic target in human cancer and a novel prognostic marker of non-small cell lung cancer. Molecular Cancer 10:1, 65
CrossRef352
Jesús García-Foncillas, Pilar Garrido, Javier Gómez, José Palacios, Miquel Tarón. (2011) Recomendaciones para la determinación de las mutaciones del gen EGFR en el carcinoma de pulmón no microcítico. Revista Española de Patología 44:1, 17-31
CrossRef353
Eiki Ichihara, Kadoaki Ohashi, Nagio Takigawa, Masahiro Osawa, Atsuko Ogino, Mitsune Tanimoto, Katsuyuki Kiura. (2011) Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo. Okayama Igakkai Zasshi (Journal of Okayama Medical Association) 123:1, 13-18
CrossRef354
Penelope Bradbury, John Hilton, Lesley Seymour. (2011) Early-phase oncology clinical trial design in the era of molecularly targeted therapy: pitfalls and progress. Clinical Investigation 1:1, 33-44
CrossRef355
John D. Hainsworth, Liang Fang, Jane E. Huang, David Karlin, Kenneth Russell, Leonardo Faoro, Christopher Azzoli. (2011) BRIDGE: An Open-Label Phase II Trial Evaluating the Safety of Bevacizumab + Carboplatin/Paclitaxel as First-Line Treatment for Patients with Advanced, Previously Untreated, Squamous Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:1, 109-114
CrossRef356
Shiro Tanaka, Yuichi Sakamori, Miyuki Niimi, Megumi Hazama, Young H Kim, Kazuhiro Yanagihara. (2011) Design paper: A phase II study of Bevacizumab and Erlotinib in patients with non-Squamous non-small cell lung cancer that is refractory or relapsed after 1-2 previous Treatment (BEST). Trials 12:1, 120
CrossRef357
Michael Allen, J Louise Jones. (2011) Jekyll and Hyde: the role of the microenvironment on the progression of cancer. The Journal of Pathology 223:2, 163-177
CrossRef358
Kwok-Chi LAM, Tony S. MOK. (2011) Targeted therapy: An evolving world of lung cancer. Respirology 16:1, 13-21
CrossRef359
Yoichi Nakanishi, Hiroyuki Watanabe. (2011) Future Direction of Chemotherapy for Lung Cancer at Outpatient Clinics. Haigan 51:2, 122-126
CrossRef360
Daniel J Lebovic, Alberto Chiappori, Jhanelle Gray. (2011) Maintenance therapies in advanced non-small-cell lung cancer. Therapy 8:1, 33-41
CrossRef361
Pamela M. Holland. (2011) Targeting Apo2L/TRAIL receptors by soluble Apo2L/TRAIL. Cancer Letters
CrossRef362
Satoshi TAKAHASHI, Takahito YAZAKI, Nobuhiro NITORI, Tadashige KANO, Kazunari YOSHIDA, Takeshi KAWASE. (2011) Neuroendoscope-Assisted Removal of an Organized Chronic Subdural Hematoma in a Patient on Bevacizumab Therapy. Neurologia medico-chirurgica 51:7, 515-518
CrossRef363
C. Rochlitz, T. Ruhstaller, S. Lerch, C. Spirig, J. Huober, T. Suter, M. Buhlmann, M. Fehr, A. Schonenberger, R. von Moos, R. Winterhalder, D. Rauch, A. Muller, M. Mannhart-Harms, R. Herrmann, B. Cliffe, M. Mayer, K. Zaman, . (2011) Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06). Annals of Oncology 22:1, 80-85
CrossRef364
Erika P. Hamilton, Kimberly L. Blackwell. (2011) Safety of Bevacizumab in Patients with Metastatic Breast Cancer. Oncology 80:5-6, 314-325
CrossRef365
Seong Ha Cheon, Kyung Seok Kim, Sehyun Kim, Hyun Sik Jung, Won Cheol Choi, Wan Kyu Eo. (2011) Efficacy and Safety of <i>Rhus verniciflua</i> Stokes Extracts in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer. Forschende Komplementärmedizin / Research in Complementary Medicine 18:2, 2-2
CrossRef366
Lauren E. Cipriano, Dorothy Romanus, Craig C. Earle, Bridget A. Neville, Elkan F. Halpern, G. Scott Gazelle, Pamela M. McMahon. (2011) Lung cancer treatment costs, including patient responsibility, by disease stage and treatment modality, 1992 to 2003. Value in Health 14:1, 41-52
CrossRef367
Nuh N Rahbari, Thomas Schmidt, Christine S Falk, Ulf Hinz, Magdalene Herber, Ulrich Bork, Markus W Büchler, Jürgen Weitz, Moritz Koch. (2011) Expression and prognostic value of circulating angiogenic cytokines in pancreatic cancer. BMC Cancer 11:1, 286
CrossRef368
Toshiharu Sakurai, Masatoshi Kudo. (2011) Signaling Pathways Governing Tumor Angiogenesis. Oncology 81:s1, 24-29
CrossRef369
Silvia Novello, Michele Milella, Marcello Tiseo, Giuseppe Banna, Diego Cortinovis, Massimo Di Maio, Marina Garassino, Paolo Maione, Olga Martelli, Tiziana Vavalà, Emilio Bria. (2011) Maintenance therapy in NSCLC: why? To whom? Which agent?. Journal of Experimental & Clinical Cancer Research 30:1, 50
CrossRef370
Dae Ho Lee, Sang-We Kim, Cheolwon Suh, Yun Hee Han, Jung-Shin Lee. (2011) Phase II study of erlotinib for chemotherapy-naïve patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum doublets. Cancer Chemotherapy and Pharmacology 67:1, 35-39
CrossRef371
Elizabeth M. Blanchard, James Moon, Paul J. Hesketh, Karen Kelly, Antoinette J. Wozniak, John Crowley, David Gandara. (2011) Comparison of Platinum-Based Chemotherapy in Patients Older and Younger than 70 Years. Journal of Thoracic Oncology 6:1, 115-120
CrossRef372
Valsamo K. Anagnostou, Anastasios T. Dimou, Taxiarchis Botsis, Elizabeth J. Killiam, Mark D. Gustavson, Robert J. Homer, Daniel Boffa, Vassiliki Zolota, Dimitrios Dougenis, Lynn Tanoue, Scott N. Gettinger, Frank C. Detterbeck, Konstantinos N. Syrigos, Gerold Bepler, David L. Rimm. (2011) Molecular classification of nonsmall-cell lung cancer using a 4-protein quantitative assay. Cancern/a-n/a
CrossRef373
A. Bearz, M. Berretta, A. Lleshi, U. Tirelli. (2011) Target Therapies in Lung Cancer. Journal of Biomedicine and Biotechnology 2011, 1-5
CrossRef374
Howard Burris, Joe Stephenson, Gregory A. Otterson, Mark Stein, Jesse McGreivy, Yu-Nien Sun, Megan Ingram, Yining Ye, Lee S. Schwartzberg. (2011) Safety and Pharmacokinetics of Motesanib in Combination with Panitumumab and Gemcitabine-Cisplatin in Patients with Advanced Cancer. Journal of Oncology 2011, 1-11
CrossRef375
Davide Tassinari, Sergio Sartori, Maximilian Papi, Fabrizio Drudi, Cinzia Castellani, Federica Carloni, Paola Tombesi, Luigi Lazzari-Agli. (2011) Bevacizumab in the Treatment of Advanced, Non-Squamous Non-Small Cell Lung Cancer: An Evidence-Based Approach. Oncology 80:5-6, 350-358
CrossRef376
M. Fiegl, C. Thöni, M. Hochleitner. (2011) Gender aspects in haematology and oncology: Overview and own observations in lung cancer. memo - Magazine of European Medical Oncology 4:4, 209
CrossRef377
Amedeo Amedei, Marisa Benagiano, Chiara della Bella, Elena Niccolai, Mario M. D'Elios. (2011) Novel Immunotherapeutic Strategies of Gastric Cancer Treatment. Journal of Biomedicine and Biotechnology 2011, 1-17
CrossRef378
Dusan Kotasek, Niall Tebbutt, Jayesh Desai, Stephen Welch, Lillian L Siu, Sheryl McCoy, Yu-Nien Sun, Jessica Johnson, Adeboye H Adewoye, Timothy Price. (2011) Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study. BMC Cancer 11:1, 313
CrossRef379
Daniel C. Paech, Adèle R. Weston, Nick Pavlakis, Anthony Gill, Narayan Rajan, Helen Barraclough, Bronwyn Fitzgerald, Maximiliano Van Kooten. (2011) A Systematic Review of the Interobserver Variability for Histology in the Differentiation between Squamous and Nonsquamous Non-small Cell Lung Cancer. Journal of Thoracic Oncology 6:1, 55-63
CrossRef380
Johnny Kao, Eric C. Ko, Samuel Eisenstein, Andrew G. Sikora, Shibo Fu, Shu-hsia Chen. (2011) Targeting immune suppressing myeloid-derived suppressor cells in oncology. Critical Reviews in Oncology/Hematology 77:1, 12-19
CrossRef381
Julie R. Brahmer, Suzanne E. Dahlberg, Robert J. Gray, Joan H. Schiller, Michael C. Perry, Alan Sandler, David H. Johnson. (2011) Sex Differences in Outcome with Bevacizumab Therapy. Journal of Thoracic Oncology 6:1, 103-108
CrossRef382
George R. Simon, Michael J. Schell, Mubeena Begum, Jongphil Kim, Alberto Chiappori, Eric Haura, Scott Antonia, Gerold Bepler. (2011) Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: Evidence from an individual patient analysis. Cancern/a-n/a
CrossRef383
Grace K. Dy, Shauna L. Hillman, Kendrith M. Rowland, Julian R. Molina, Preston D. Steen, Donald B. Wender, Suresh Nair, Sumithra Mandrekar, Steven E. Schild, Alex A. Adjei. (2010) A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer. Cancer 116:24, 5686-5693
CrossRef384
Tom Donnem, Sigve Andersen, Khalid Al-Shibli, Samer Al-Saad, Lill-Tove Busund, Roy M. Bremnes. (2010) Prognostic impact of Notch ligands and receptors in nonsmall cell lung cancer. Cancer 116:24, 5676-5685
CrossRef385
J. Weiss, M. L. Sos, D. Seidel, M. Peifer, T. Zander, J. M. Heuckmann, R. T. Ullrich, R. Menon, S. Maier, A. Soltermann, H. Moch, P. Wagener, F. Fischer, S. Heynck, M. Koker, J. Schottle, F. Leenders, F. Gabler, I. Dabow, S. Querings, L. C. Heukamp, H. Balke-Want, S. Ansen, D. Rauh, I. Baessmann, J. Altmuller, Z. Wainer, M. Conron, G. Wright, P. Russell, B. Solomon, E. Brambilla, C. Brambilla, P. Lorimier, S. Sollberg, O. T. Brustugun, W. Engel-Riedel, C. Ludwig, I. Petersen, J. Sanger, J. Clement, H. Groen, W. Timens, H. Sietsma, E. Thunnissen, E. Smit, D. Heideman, F. Cappuzzo, C. Ligorio, S. Damiani, M. Hallek, R. Beroukhim, W. Pao, B. Klebl, M. Baumann, R. Buettner, K. Ernestus, E. Stoelben, J. Wolf, P. Nurnberg, S. Perner, R. K. Thomas. (2010) Frequent and Focal FGFR1 Amplification Associates with Therapeutically Tractable FGFR1 Dependency in Squamous Cell Lung Cancer. Science Translational Medicine 2:62, 62ra93-62ra93
CrossRef386
Adrian M Jubb, Adrian L Harris. (2010) Biomarkers to predict the clinical efficacy of bevacizumab in cancer. The Lancet Oncology 11:12, 1172-1183
CrossRef387
Arman Hasani, Natasha B. Leighl. (2010) Targeting Vascular Endothelial Growth Factor in Lung Cancer. Journal of Thoracic Oncology 5, S484-S486
CrossRef388
Kevin C. Braganca, Yelena Y. Janjigian, Christopher G. Azzoli, Mark G. Kris, Maria C. Pietanza, Craig P. Nolan, Antonio M. Omuro, Andrei I. Holodny, Andrew B. Lassman. (2010) Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. Journal of Neuro-Oncology 100:3, 443-447
CrossRef389
Tait Shanafelt, Clive Zent, John Byrd, Charles Erlichman, Betsy Laplant, Asish Ghosh, Timothy Call, Miguel Villalona-Calero, Diane Jelinek, Deborah Bowen, Kristina Laumann, Wenting Wu, Curtis Hanson, Neil Kay. (2010) Phase II trials of single-agent anti-VEGF therapy for patients with chronic lymphocytic leukemia. Leukemia & Lymphoma 51:12, 2222-2229
CrossRef390
Martin Reck. (2010) Examining the safety profile of angiogenesis inhibitors: implications for clinical practice. Targeted Oncology 5:4, 257-267
CrossRef391
Shadia Jalal, Pablo Bedano, Lawrence Einhorn, Sumeet Bhatia, Rafat Ansari, Naftali Bechar, Karuna Koneru, Ramaswamy Govindan, Jingwei Wu, Menggang Yu, Bryan Schneider, Nasser Hanna. (2010) Paclitaxel Plus Bevacizumab in Patients with Chemosensitive Relapsed Small Cell Lung Cancer. Journal of Thoracic Oncology 5:12, 2008-2011
CrossRef392
Ilse Roodink, William P.J. Leenders. (2010) Targeted therapies of cancer: Angiogenesis inhibition seems not enough. Cancer Letters 299:1, 1-10
CrossRef393
A. Chan, D. W. Miles, X. Pivot. (2010) Bevacizumab in combination with taxanes for the first-line treatment of metastatic breast cancer. Annals of Oncology 21:12, 2305-2315
CrossRef394
J. C. Soria, C. Massard, T. Le Chevalier. (2010) Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy?. Annals of Oncology 21:12, 2324-2332
CrossRef395
Joan H. Schiller, Joachim von Pawel, Philipp Schütt, Rafat H. Ansari, Michael Thomas, Mansoor Saleh, Robert D. McCroskey, Wolfgang Pfeifer, Thomas A. Marsland, Goetz H. Kloecker, Martin Sebastian, Robert Pirker, Raffael Kurek, Claire Beadman, Mark A. Socinski. (2010) Pemetrexed with or without Matuzumab as Second-Line Treatment for Patients with Stage IIIB/IV Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:12, 1977-1985
CrossRef396
B. Alt-Epping, F. Nauck. (2010) Tumorspezifische Therapien und ihr Einsatz in der Palliativmedizin. Der Schmerz 24:6, 633-641
CrossRef397
M. Jahn, V. Radchenko, D. V. Filosofov, H. Hauser, M. Eisenhut, Frank Rösch, M. Jennewein. (2010) Separation and purification of no-carrier-added arsenic from bulk amounts of germanium for use in radiopharmaceutical labelling. Radiochimica Acta 98:12, 807-812
CrossRef398
Gopa Iyer, Matthew I Milowsky, Dean F Bajorin. (2010) Novel strategies for treating relapsed/refractory urothelial carcinoma. Expert Review of Anticancer Therapy 10:12, 1917-1932
CrossRef399
Axel Bex, Eric Jonasch, Ziya Kirkali, Arnaud Mejean, Peter Mulders, Stephane Oudard, Jean-Jacques Patard, Thomas Powles, Hendrik van Poppel, Christopher G Wood. (2010) Integrating Surgery with Targeted Therapies for Renal Cell Carcinoma: Current Evidence and Ongoing Trials. European Urology 58:6, 819-828
CrossRef400
Martin Augsten, Christina Hägglöf, Cristina Peña, Arne Östman. (2010) A Digest on the Role of the Tumor Microenvironment in Gastrointestinal Cancers. Cancer Microenvironment 3:1, 167-176
CrossRef401
Beate Köberle, Maja T. Tomicic, Svetlana Usanova, Bernd Kaina. (2010) Cisplatin resistance: Preclinical findings and clinical implications. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1806:2, 172-182
CrossRef402
Myoung Hee Kang, Shi Nae Kim, Noe Kyeong Kim, Young-Iee Park, Young-Woo Kim, Keun Won Ryu, Jun Ho Lee, Jong Seok Lee, Sook Ryun Park. (2010) Clinical Outcomes and Prognostic Factors of Metastatic Gastric Carcinoma Patients Who Experience Gastrointestinal Perforation During Palliative Chemotherapy. Annals of Surgical Oncology 17:12, 3163-3172
CrossRef403
Erin M. Bertino, Gregory A. Otterson. (2010) Benefits and limitations of antiangiogenic agents in patients with non-small cell lung cancer. Lung Cancer 70:3, 233-246
CrossRef404
Shirish M. Gadgeel, Michele L. Cote, Ann G. Schwartz, Larry H. Matherly, Antoinette Wozniak, Gerold Bepler. (2010) Parameters for individualizing systemic therapy in non-small cell lung cancer. Drug Resistance Updates 13:6, 196-204
CrossRef405
Hitomi Nagayama, Kazufumi Matsumoto, Naoyuki Isoo, Hideki Ohno, Naoyuki Takahashi, Takashi Nakaoka, Masaru Shinozaki, Makoto Watanabe, Yusuke Inoue, Fumitaka Nagamura, Naoki Oyaizu, Naohide Yamashita. (2010) Gastrointestinal bleeding during anti-angiogenic peptide vaccination in combination with gemcitabine for advanced pancreatic cancer. Clinical Journal of Gastroenterology 3:6, 307-317
CrossRef406
Joel W Neal. (2010) The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer. Future Oncology 6:12, 1827-1832
CrossRef407
Natasha B. Leighl, Petr Zatloukal, Jörg Mezger, Rodryg Ramlau, Nicola Moore, Martin Reck, Christian Manegold. (2010) Efficacy and Safety of Bevacizumab-Based Therapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer in the Phase III BO17704 Study (AVAiL). Journal of Thoracic Oncology 5:12, 1970-1976
CrossRef408
Jun Wang, Baocheng Wang, Jingwang Bi, Cong Zhang. (2010) Cytoplasmic HuR expression correlates with angiogenesis, lymphangiogenesis, and poor outcome in lung cancer. Medical Oncology
CrossRef409
Elaine T. Lam, Jessie L.- S. Au, Gregory A. Otterson, M. Guillaume Wientjes, Ling Chen, Tong Shen, Yong Wei, Xiaobai Li, Tanios Bekaii-Saab, Anthony J. Murgo, Rhonda R. Jensen, Michael Grever, Miguel A. Villalona-Calero. (2010) Phase I trial of non-cytotoxic suramin as a modulator of docetaxel and gemcitabine therapy in previously treated patients with non-small cell lung cancer. Cancer Chemotherapy and Pharmacology 66:6, 1019-1029
CrossRef410
Cécile Ortholan, Jérôme Durivault, Jean-Michel Hannoun-Levi, Mélanie Guyot, Christine Bourcier, Damien Ambrosetti, Stephen Safe, Gilles Pagès. (2010) Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: A new paradigm for understanding the therapeutic effect of combined treatment. European Journal of Cancer 46:16, 3022-3036
CrossRef411
Benjamin Levy, Alexander Drilon, KarLeung Siu, Michael Grossbard. (2010) Extended-Duration Therapy in Advanced Non–Small-Cell Lung Cancer: Promise and Pitfalls. Clinical Lung Cancer 11:6, 383-390
CrossRef412
Erin M. Casey, Wael Harb, Daniel Bradford, Jose Bufill, Sreenivasa Nattam, Jyoti Patel, William Fisher, Jane E. Latz, Xiaochun Li, Jingwei Wu, Nasser Hanna. (2010) Randomized, Double-Blinded, Multicenter, Phase II Study of Pemetrexed, Carboplatin, and Bevacizumab with Enzastaurin or Placebo in Chemonaïve Patients with Stage IIIB/IV Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:11, 1815-1820
CrossRef413
José Manuel Trigo Pérez, Pilar Garrido López, Enriqueta Felip Font, Dolores Isla Casado. (2010) SEOM clinical guidelines for the treatment of non-small-cell lung cancer: an updated edition. Clinical and Translational Oncology 12:11, 735-741
CrossRef414
E. Stoelben, R.M. Huber, R.-P. Müller, J. Wolf. (2010) Multimodale Therapie des Lungenkarzinoms. Der Internist 51:11, 1348-1357
CrossRef415
L. Trani, J. Myerson, S. Ashley, K. Young, A. Sheri, R. Hubner, M. Puglisi, S. Popat, M.E.R. O’Brien. (2010) Histology classification is not a predictor of clinical outcomes in advanced non-small cell lung cancer (NSCLC) treated with vinorelbine or gemcitabine combinations. Lung Cancer 70:2, 200-204
CrossRef416
Yvonne Kienast, Frank Winkler. (2010) Therapy and prophylaxis of brain metastases. Expert Review of Anticancer Therapy 10:11, 1763-1777
CrossRef417
Christelle Clément-Duchêne, Yelena Krupitskaya, Kristen Ganjoo, Philip Lavori, Alex McMillan, Atul Kumar, Gary Zhao, Sukhmani Padda, Lisa Zhou, Melanie San Pedro-Salcedo, A. Dimitrios Colevas, Heather A. Wakelee. (2010) A Phase II First-Line Study of Gemcitabine, Carboplatin, and Bevacizumab in Advanced Stage Nonsquamous Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:11, 1821-1825
CrossRef418
Martin Reck, Norbert Frickhofen, Susana Cedres, Ulrich Gatzemeier, David Heigener, Heinz-Georg Fuhr, Aron Thall, Silvana Lanzalone, Patricia Stephenson, Ana Ruiz-Garcia, Richard Chao, Enriqueta Felip. (2010) Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: A phase I dose-escalation study. Lung Cancer 70:2, 180-187
CrossRef419
G. P. Stathopoulos, D. Antoniou, J. Dimitroulis, P. Michalopoulou, A. Bastas, K. Marosis, J. Stathopoulos, A. Provata, P. Yiamboudakis, D. Veldekis, N. Lolis, N. Georgatou, M. Toubis, C. Pappas, G. Tsoukalas. (2010) Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial. Annals of Oncology 21:11, 2227-2232
CrossRef420
William Pao, Juliann Chmielecki. (2010) Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nature Reviews Cancer 10:11, 760-774
CrossRef421
Ronan J. Kelly, Colleen Darnell, Olivier Rixe. (2010) Target Inhibition in Antiangiogenic Therapy A Wide Spectrum of Selectivity and Specificity. The Cancer Journal 16:6, 635-642
CrossRef422
A. F. Eichler, K. T. Kahle, D. L. Wang, V. A. Joshi, H. Willers, J. A. Engelman, T. J. Lynch, L. V. Sequist. (2010) EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro-Oncology 12:11, 1193-1199
CrossRef423
Denis Moro-Sibilot, Alain Vergnenegre, Egbert F. Smit, Elisabeth Toy, Barbara Parente, Stephan Schmitz, Kees Kraaij, Carla Visseren-Grul, Victoria Soldatenkova, Jorge Arellano, Claudia Leteneux. (2010) Second-line therapy for NSCLC in clinical practice: baseline results of the European SELECTTION observational study. Current Medical Research and Opinion 26:11, 2661-2672
CrossRef424
R. Goodwin, K. Ding, L. Seymour, A. LeMaitre, A. Arnold, F. A. Shepherd, M. Dediu, T. Ciuleanu, D. Fenton, M. Zukin, D. Walde, F. Laberge, M. Vincent, P. M. Ellis, S. A. Laurie, . (2010) Treatment-emergent hypertension and outcomes in patients with advanced non-small-cell lung cancer receiving chemotherapy with or without the vascular endothelial growth factor receptor inhibitor cediranib: NCIC Clinical Trials Group Study BR24. Annals of Oncology 21:11, 2220-2226
CrossRef425
David Ternant, Nicolas Cézé, Thierry Lecomte, Danielle Degenne, Anne-Claire Duveau, Hervé Watier, Etienne Dorval, Gilles Paintaud. (2010) An Enzyme-Linked Immunosorbent Assay to Study Bevacizumab Pharmacokinetics. Therapeutic Drug Monitoring 32:5, 647-652
CrossRef426
Michael Friedlander, Kenneth C. Hancock, Danny Rischin, Mark J. Messing, Claude A. Stringer, Gemma M. Matthys, Bo Ma, Jeffrey P. Hodge, Joanne J. Lager. (2010) A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecologic Oncology 119:1, 32-37
CrossRef427
Chikako Kiyohara, Yoshiyuki Ohno. (2010) Sex differences in lung cancer susceptibility: A review. Gender Medicine 7:5, 381-401
CrossRef428
Ryan M Tarantola, James C Folk, H Culver Boldt, Vinit B Mahajan. (2010) INTRAVITREAL BEVACIZUMAB DURING PREGNANCY. Retina 30:9, 1405-1411
CrossRef429
Marta Batus, Mary Jo Fidler, Philip D Bonomi. (2010) Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer. Expert Review of Anticancer Therapy 10:10, 1589-1599
CrossRef430
Regina Gironés Sarrió, María Dolores Torregrosa, Pedro López, José Gómez-Codina, Rafael Rosell. (2010) Smoking habits in elderly lung cancer patients: still no changes in epidemiology? A single-center experience. Clinical and Translational Oncology 12:10, 686-691
CrossRef431
Hirotsugu Kenmotsu, Masahiro Yasunaga, Koichi Goto, Tatsuya Nagano, Jun-ichiro Kuroda, Yoshikatsu Koga, Amane Takahashi, Yutaka Nishiwaki, Yasuhiro Matsumura. (2010) The antitumor activity of NK012, an SN-38-incorporating micelle, in combination with bevacizumab against lung cancer xenografts. Cancer 116:19, 4597-4604
CrossRef432
E. De Maio, C. Tibaldi, A. D'Incecco, S. Bursi, C. Barbara, S. Cupini, R. Di Marsico, M. D'Arcangelo, L. Landi, G. Minuti, F. Cappuzzo. (2010) Consequences of targeted treatments for second-line therapy. Annals of Oncology 21:Supplement 7, vii234-vii240
CrossRef433
Lynsay L Waller, Kathryn E Weaver, W Jeffrey Petty, Antonius A Miller. (2010) Effects of continued tobacco use during treatment of lung cancer. Expert Review of Anticancer Therapy 10:10, 1569-1575
CrossRef434
Nicolas Girard. (2010) Thymic Tumors. Journal of Thoracic Oncology 5, S291-S295
CrossRef435
Sang Joon Shin, Hei-Cheul Jeung, Joong Bae Ahn, Sun Young Rha, Jae Kyung Roh, Kyung Soo Park, Dal-Hyun Kim, Chin Kim, Hyun Cheol Chung. (2010) A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer. Investigational New Drugs 28:5, 650-658
CrossRef436
Tony S Mok, Qing Zhou, Linda Leung, Herbert H Loong. (2010) Personalized medicine for non-small-cell lung cancer. Expert Review of Anticancer Therapy 10:10, 1601-1611
CrossRef437
M Roshni Ray, David Jablons, Biao He. (2010) Lung cancer therapeutics that target signaling pathways: an update. Expert Review of Respiratory Medicine 4:5, 631-645
CrossRef438
E. Felip, S. Cedres, E. Checa, P. Martinez. (2010) How to integrate current knowledge in selecting patients for first line in NSCLC?. Annals of Oncology 21:Supplement 7, vii230-vii233
CrossRef439
Liliana Montella, Raffaele Addeo, Michele Caraglia, Salvatore Del Prete. (2010) Latest developments in targeted therapy for hepatocellular carcinoma. Expert Review of Anticancer Therapy 10:10, 1635-1646
CrossRef440
Yasuhito Fujisaka, Yasuhide Yamada, Noboru Yamamoto, Toshio Shimizu, Yutaka Fujiwara, Kazuhiko Yamada, Tomohide Tamura, Hiroyuki Watanabe, Yu-Nien Sun, Michael B. Bass, Mitsuo Seki. (2010) Phase 1 study of the investigational, oral angiogenesis inhibitor motesanib in Japanese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology 66:5, 935-943
CrossRef441
A. F. Gazdar. (2010) Should we continue to use the term non-small-cell lung cancer?. Annals of Oncology 21:Supplement 7, vii225-vii229
CrossRef442
Drew W. Rasco, Jingsheng Yan, Yang Xie, Jonathan E. Dowell, David E. Gerber. (2010) Looking Beyond Surveillance, Epidemiology, and End Results. Journal of Thoracic Oncology 5:10, 1529-1535
CrossRef443
Archontoula Stoffel. (2010) Targeted Therapies for Solid Tumors. BioDrugs 24:5, 303-316
CrossRef444
Robert Goldstein, Lisa Pickering, James Larkin. (2010) Does axitinib (AG-01376) have a future role in metastatic renal cell carcinoma and other malignancies?. Expert Review of Anticancer Therapy 10:10, 1545-1557
CrossRef445
B. F. El-Rayes, M. Zalupski, T. Bekai-Saab, L. K. Heilbrun, N. Hammad, B. Patel, S. Urba, A. F. Shields, U. Vaishampayan, S. Dawson, K. Almhanna, D. Smith, P. A. Philip. (2010) A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. Annals of Oncology 21:10, 1999-2004
CrossRef446
X Ye, Y Li, S Stawicki, S Couto, J Eastham-Anderson, D Kallop, R Weimer, Y Wu, L Pei. (2010) An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies. Oncogene 29:38, 5254-5264
CrossRef447
M. Reck, J. von Pawel, P. Zatloukal, R. Ramlau, V. Gorbounova, V. Hirsh, N. Leighl, J. Mezger, V. Archer, N. Moore, C. Manegold, . (2010) Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Annals of Oncology 21:9, 1804-1809
CrossRef448
TS Kristedja, RJ Morgan, M Cristea. (2010) Targeted agents in ovarian cancer. Women's Health 6:5, 679-694
CrossRef449
Francisco Robert, Alan Sandler, Joan H. Schiller, Glenn Liu, Karen Harper, Lev Verkh, Xin Huang, Jennifer Ilagan, Lesley Tye, Richard Chao, Anne M. Traynor. (2010) Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study. Cancer Chemotherapy and Pharmacology 66:4, 669-680
CrossRef450
Chadrick E. Denlinger, John S. Ikonomidis, Carolyn E. Reed, Francis G. Spinale. (2010) Epithelial to mesenchymal transition: The doorway to metastasis in human lung cancers. The Journal of Thoracic and Cardiovascular Surgery 140:3, 505-513
CrossRef451
Sara Caponi, Enrico Vasile, Laura Ginocchi, Carmelo Tibaldi, Francesca Borghi, Armida D'Incecco, Maurizio Lucchesi, Chiara Caparello, Michele Andreuccetti, Alfredo Falcone. (2010) Second-line Treatment for Non–Small-Cell Lung Cancer: One Size Does Not Fit All. Clinical Lung Cancer 11:5, 320-327
CrossRef452
M. Rodrigues, E. Routier, J.-C. Soria. (2010) Soins spécifiques, soins de support — même combat !. Oncologie 12:9, 555-557
CrossRef453
Rita Graça da Silva, Bernardo Tavora, Stephen D. Robinson, Louise E. Reynolds, Charles Szekeres, John Lamar, Sílvia Batista, Vassiliki Kostourou, Mitchel A. Germain, Andrew R. Reynolds, Dylan T. Jones, Alan R. Watson, Janet L. Jones, Adrian Harris, Ian R. Hart, M. Luisa Iruela-Arispe, C. Michael DiPersio, Jordan A. Kreidberg, Kairbaan M. Hodivala-Dilke. (2010) Endothelial α3β1-Integrin Represses Pathological Angiogenesis and Sustains Endothelial-VEGF. The American Journal of Pathology 177:3, 1534-1548
CrossRef454
Ian Y. Lee, Steven N. Kalkanis, Mark L. Rosenblum. (2010) Malignant Gliomas: Current Concepts. Neurosurgery Quarterly 20:3, 115-121
CrossRef455
Alan Sandler, Jing Yi, Suzanne Dahlberg, Margaret M. Kolb, Lisa Wang, Julie Hambleton, Joan Schiller, David H. Johnson. (2010) Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:9, 1416-1423
CrossRef456
Sergey V. Novitskiy, Ildiko Csiki, Yuhui Huang, David H. Johnson, Eva M. Harth, David P. Carbone, Mikhail M. Dikov. (2010) Anti-Vascular Endothelial Growth Factor Treatment in Combination with Chemotherapy Delays Hematopoietic Recovery Due to Decreased Proliferation of Bone Marrow Hematopoietic Progenitor Cells. Journal of Thoracic Oncology 5:9, 1410-1415
CrossRef457
H. Francis, B. Solomon. (2010) The current status of targeted therapy for non-small cell lung cancer. Internal Medicine Journal 40:9, 611-618
CrossRef458
Haiying Cheng, Xunhai Xu, Daniel B. Costa, Charles A. Powell, Balazs Halmos. (2010) Molecular Testing in Lung Cancer: The Time Is Now. Current Oncology Reports 12:5, 335-348
CrossRef459
Marc C. Chamberlain. (2010) Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas. Cancer 116:17, 3988-3999
CrossRef460
Giuseppe Curigliano, Erica L. Mayer, Harold J. Burstein, Eric P. Winer, Aron Goldhirsch. (2010) Cardiac Toxicity From Systemic Cancer Therapy: A Comprehensive Review. Progress in Cardiovascular Diseases 53:2, 94-104
CrossRef461
Richard M. Zuniga, Roy Torcuator, Rajan Jain, John Anderson, Thomas Doyle, Lonni Schultz, Tom Mikkelsen. (2010) Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma. Journal of Neuro-Oncology 99:2, 237-242
CrossRef462
N. Saijo. (2010) Progress in Cancer Chemotherapy with Special Stress on Molecular-targeted Therapy. Japanese Journal of Clinical Oncology 40:9, 855-862
CrossRef463
Agnieszka Michael, Kate Relph, Hardev Pandha. (2010) Emergence of potential biomarkers of response to anti-angiogenic anti-tumour agents. International Journal of Cancer 127:6, 1251-1258
CrossRef464
Fang Wang, Liangping Xia, Guifang Guo, Huijuan Qiu, Feifei Zhou, Bei Zhang, Li Zhang. (2010) Short-term outcomes of cetuximab combined with standard chemotherapy as non-first line setting for patients with non-small cell lung cancer: a report of 6 cases. The Chinese-German Journal of Clinical Oncology 9:9, 502-506
CrossRef465
Athanasios G. Pallis, Michalis V. Karamouzis, Panagiotis A. Konstantinopoulos, Athanasios G. Papavassiliou. (2010) Molecular networks in respiratory epithelium carcinomas. Cancer Letters 295:1, 1-6
CrossRef466
Ralph G. Zinner, Scott B. Saxman, Guangbin Peng, Matthew J. Monberg, Waldo I. Ortuzar. (2010) Treatment Rationale and Study Design for a Randomized Trial of Pemetrexed/Carboplatin Followed by Maintenance Pemetrexed Versus Paclitaxel/Carboplatin/Bevacizumab Followed by Maintenance Bevacizumab in Patients With Advanced Non–Small-Cell Lung Cancer of Nonsquamous Histology. Clinical Lung Cancer 11:5, 352-357
CrossRef467
S. I. Pascu, R. L. Arrowsmith, S. R. Bayly, S. Brayshaw, Z. Hu. (2010) Towards nanomedicines: design protocols to assemble, visualize and test carbon nanotube probes for multi-modality biomedical imaging. Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences 368:1924, 3683-3712
CrossRef468
T. Fojo, C. Grady. (2010) Response: Re: How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question. JNCI Journal of the National Cancer Institute 102:15, 1207-1210
CrossRef469
Tania Fleitas, Vicenta Martínez-Sales, José Gómez-Codina, María Martín, Gaspar Reynés. (2010) Circulating endothelial and endothelial progenitor cells in non-small-cell lung cancer. Clinical and Translational Oncology 12:8, 521-525
CrossRef470
Giannis Mountzios, Meletios-Athanassios Dimopoulos, Jean-Charles Soria, Despina Sanoudou, Christos A. Papadimitriou. (2010) Histopathologic and genetic alterations as predictors of response to treatment and survival in lung cancer: A review of published data. Critical Reviews in Oncology/Hematology 75:2, 94-109
CrossRef471
F. Barlesi, C. Balleyguier, B. Besse, F. Bonodeau, F. Brenac, O. Corneloup, E. Dansin, G. Ferretti, J. Y. Gaubert, R. Gervais, C. Lacombe, A. Loundou, D. Moro-Sibilot, D. Planchard, A. Scherpereel, Y. Menu. (2010) Inter- and intraobserver consistency in assessing eligibility for bevacizumab (BVZ) in non-small-cell lung cancer (NSCLC) patients with centrally located tumors. Annals of Oncology 21:8, 1682-1686
CrossRef472
Fiona H. Blackhall, Mary OʼBrien, Peter Schmid, Marianne Nicolson, Paul Taylor, Tsveta Milenkova, Sarah J. Kennedy, Nick Thatcher. (2010) A Phase I Study of Vandetanib in Combination with Vinorelbine/Cisplatin or Gemcitabine/Cisplatin as First-Line Treatment for Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:8, 1285-1288
CrossRef473
M Watanabe, J L Boyer, R G Crystal. (2010) AAVrh.10-mediated genetic delivery of bevacizumab to the pleura to provide local anti-VEGF to suppress growth of metastatic lung tumors. Gene Therapy 17:8, 1042-1051
CrossRef474
Pia P. Vihinen, Micaela Hernberg, Meri-Sisko Vuoristo, Kristiina Tyynelä, Marjut Laukka, Johan Lundin, Johanna Ivaska, Seppo Pyrhönen. (2010) A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-α2a as first line treatment in metastatic melanoma. Melanoma Research 20:4, 318-325
CrossRef475
A.G. Pallis, C. Gridelli. (2010) Is age a negative prognostic factor for the treatment of advanced/metastatic non-small-cell lung cancer?. Cancer Treatment Reviews 36:5, 436-441
CrossRef476
Robert Klein, Ron Wielage, Catherine Muehlenbein, Astra M. Liepa, Steve Babineaux, Anthony Lawson, Lee Schwartzberg. (2010) Cost-Effectiveness of Pemetrexed as First-Line Maintenance Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:8, 1263-1272
CrossRef477
Mark Nuijten, David F. Heigener, Helge G. Bischoff, Christos Chouaid, Alain Vergnenègre, Javier de Castro Carpeño, Rick Aultman, Stefan Walzer, Uwe Siebert. (2010) Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancer. Lung Cancer 69, S4-S10
CrossRef478
E. Gabriela Chiorean, Srikar Malireddy, Anne E. Younger, David R. Jones, Mary-Jane Waddell, Melissa I. Sloop, Menggang Yu, Stephen D. Hall, Bryan Schneider, Christopher J. Sweeney. (2010) A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology 66:3, 441-448
CrossRef479
A. Prasse, C. Waller, B. Passlick, J. Müller-Quernheim. (2010) Lungenkrebs aus Sicht der Inneren Medizin und Chirurgie. Der Radiologe 50:8, 662-668
CrossRef480
Sanja Stanisic, Helge G. Bischoff, David F. Heigener, Alain Vergnenègre, Javier de Castro Carpeño, Christos Chouaid, Stefan Walzer, Elvira Mueller, Elvira Schmidt. (2010) Societal cost savings through bevacizumab-based treatment in non-small cell lung cancer (NSCLC). Lung Cancer 69, S24-S30
CrossRef481
Manuela Schmidinger, Joaquim Bellmunt. (2010) Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma. Cancer Treatment Reviews 36:5, 416-424
CrossRef482
Helge G. Bischoff, David F. Heigener, Stefan Walzer, Mark Nuijten. (2010) Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany. Lung Cancer 69, S18-S23
CrossRef483
Lucio Crinò, Eric Dansin, Pilar Garrido, Frank Griesinger, Janessa Laskin, Nick Pavlakis, Daniel Stroiakovski, Nick Thatcher, Chun-Ming Tsai, Yi-long Wu, Caicun Zhou. (2010) Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. The Lancet Oncology 11:8, 733-740
CrossRef484
Giovanni Giuliani, Francesco Grossi, Filippo de Marinis, Stefan Walzer. (2010) Cost-effectiveness analysis of bevacizumab versus pemetrexed for advanced non-squamous NSCLC in Italy. Lung Cancer 69, S11-S17
CrossRef485
Elvira Mueller. (2010) Editorial: Comparative efficacy and cost associated with new agents in the treatment of non-small cell lung cancer (NSCLC). Lung Cancer 69, S1-S3
CrossRef486
Robert Pirker. (2010) Bevacizumab in lung cancer: hurdles in clinical development. The Lancet Oncology 11:8, 703-704
CrossRef487
Alessandra B. Francesconi, Simon Dupre, Marco Matos, David Martin, Brett G. Hughes, David K. Wyld, Jason D. Lickliter. (2010) Carboplatin and etoposide combined with bevacizumab for the treatment of recurrent glioblastoma multiforme. Journal of Clinical Neuroscience 17:8, 970-974
CrossRef488
Mao Mao An, Zui Zou, Hui Shen, Ping Liu, Meng Li Chen, Yong Bing Cao, Yuan Ying Jiang. (2010) Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis. European Journal of Clinical Pharmacology 66:8, 813-821
CrossRef489
K. Tsujino, J. Shiraishi, T. Tsuji, T. Kurata, T. Kawaguchi, A. Kubo, M. Takada. (2010) Is response rate increment obtained by molecular targeted agents related to survival benefit in the phase III trials of advanced cancer?. Annals of Oncology 21:8, 1668-1674
CrossRef490
Y Loriot, P Mordant, N Dorvault, T De la motte Rouge, J Bourhis, J-C Soria, E Deutsch. (2010) BMS-690514, a VEGFR and EGFR tyrosine kinase inhibitor, shows anti-tumoural activity on non-small-cell lung cancer xenografts and induces sequence-dependent synergistic effect with radiation. British Journal of Cancer 103:3, 347-353
CrossRef491
Biana Godin, Rita E. Serda, Jason Sakamoto, Paolo Decuzzi, Mauro Ferrari. 2010. Nanoparticles for Cancer Detection and Therapy. .
CrossRef492
Filip Janku, David J. Stewart, Razelle Kurzrock. (2010) Targeted therapy in non-small-cell lung cancer—is it becoming a reality?. Nature Reviews Clinical Oncology 7:7, 401-414
CrossRef493
I. Floriani, S. Garattini, V. Torri. (2010) Looking for efficiency rather than efficacy in randomized controlled trials in oncology. Annals of Oncology 21:7, 1391-1393
CrossRef494
Cynthia S. Anderson, Walter J. Curran. (2010) Combined Modality Therapy for Stage III Non–Small-Cell Lung Cancer. Seminars in Radiation Oncology 20:3, 186-191
CrossRef495
Robert C. Doebele, Ana B. Oton, Nir Peled, D. Ross Camidge, Paul A. Bunn. (2010) New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer. Lung Cancer 69:1, 1-12
CrossRef496
Min S Park, Vinod Ravi, Dejka M Araujo. (2010) Inhibiting the VEGF–VEGFR pathway in angiosarcoma, epithelioid hemangioendothelioma, and hemangiopericytoma/solitary fibrous tumor. Current Opinion in Oncology 22:4, 351-355
CrossRef497
Maria Alsina, Manuel Ruiz-Echarri, Jaume Capdevila, Eva Muñoz, Josep Tabernero. (2010) Biomarkers for Therapies Directed at Angiogenesis. Current Colorectal Cancer Reports 6:3, 133-143
CrossRef498
Whitfield B Growdon, Michael J Birrer, Richard T Penson. (2010) Ovarian cancer: individualized and personalized care. Expert Review of Obstetrics & Gynecology 5:4, 409-419
CrossRef499
Jennifer L Spratlin, Karen E Mulder, John R Mackey. (2010) Ramucirumab (IMC-1121B): a novel attack on angiogenesis. Future Oncology 6:7, 1085-1094
CrossRef500
Kiran Devisetty, Joseph K. Salama. (2010) Tumor Necrosis and Cavitation after Stereotactic Body Radiation Therapy. Journal of Thoracic Oncology 5:7, 1100-1102
CrossRef501
Sumithra J. Mandrekar, Daniel J. Sargent. (2010) Randomized Phase II Trials. Journal of Thoracic Oncology 5:7, 932-934
CrossRef502
Roy S Herbst, Yan Sun, Wilfried EE Eberhardt, Paul Germonpré, Nagahiro Saijo, Caicun Zhou, Jie Wang, Longyun Li, Fairooz Kabbinavar, Yukito Ichinose, Shukui Qin, Li Zhang, Bonne Biesma, John V Heymach, Peter Langmuir, Sarah J Kennedy, Hiroomi Tada, Bruce E Johnson. (2010) Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. The Lancet Oncology 11:7, 619-626
CrossRef503
Eric M. Thompson, Edit Dosa, Dale F. Kraemer, Edward A. Neuwelt. (2010) Treatment With Bevacizumab Plus Carboplatin for Recurrent Malignant Glioma. Neurosurgery 67:1, 87-93
CrossRef504
C. Lu, J. J. Lee, R. Komaki, R. S. Herbst, L. Feng, W. K. Evans, H. Choy, P. Desjardins, B. T. Esparaz, M. T. Truong, S. Saxman, J. Kelaghan, A. Bleyer, M. J. Fisch. (2010) Chemoradiotherapy With or Without AE-941 in Stage III Non-Small Cell Lung Cancer: A Randomized Phase III Trial. JNCI Journal of the National Cancer Institute 102:12, 859-865
CrossRef505
Mallika Singh, Anthony Lima, Rafael Molina, Patricia Hamilton, Anne C Clermont, Vidusha Devasthali, Jennifer D Thompson, Jason H Cheng, Hani Bou Reslan, Calvin C K Ho, Timothy C Cao, Chingwei V Lee, Michelle A Nannini, Germaine Fuh, Richard A D Carano, Hartmut Koeppen, Ron X Yu, William F Forrest, Gregory D Plowman, Leisa Johnson. (2010) Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nature Biotechnology 28:6, 585-593
CrossRef506
A. Munehiro, K. Yoneda, K. Nakai, T. Demitsu, T. Moriue, J. Moriue, I. Yokoi, N. Fujita, N. Matsuura, S. Ishikawa, H. Yokomise, Y. Kubota. (2010) Bevacizumab-induced hand-foot syndrome: circumscribed type. British Journal of Dermatology 162:6, 1411-1413
CrossRef507
F Toffalorio, E Giovannetti, T De Pas, D Radice, G Pelosi, M Manzotti, D Minocci, L Spaggiari, G Spitaleri, C Noberasco, C Catania, S Boselli, R Danesi, F de Braud. (2010) Expression of gemcitabine- and cisplatin-related genes in non-small-cell lung cancer. The Pharmacogenomics Journal 10:3, 180-190
CrossRef508
Alejandro Forner, Carlos Rodríguez De Lope, María Reig, Jordi Bruix. (2010) Tratamiento del carcinoma hepatocelular avanzado. Gastroenterología y Hepatología 33:6, 461-468
CrossRef509
Gyula Ostoros, Balázs Döme, János Strausz, József Tímár. (2010) Változások a nem-kissejtes tüdőrák diagnosztikus és terápiás stratégiájában. Magyar Onkológia 54:2, 137-143
CrossRef510
G. Rocco, F. Perrone, A. Rossi, C. Gridelli. (2010) Surgical Management of Non-small Cell Lung Cancer with Mediastinal Lymphadenopathy. Clinical Oncology 22:5, 325-333
CrossRef511
Yuichi Takiguchi, Yuji Tada, Akihiko Gemma, Shoji Kudoh, Mitsunori Hino, Kozo Yoshimori, Akinobu Yoshimura, Keiichi Nagao, Hisanobu Niitani. (2010) Phase I/II study of docetaxel and S-1, an oral fluorinated pyrimidine, for untreated advanced non-small cell lung cancer. Lung Cancer 68:3, 409-414
CrossRef512
Giulio Francia, Robert S Kerbel. (2010) Raising the bar for cancer therapy models. Nature Biotechnology 28:6, 561-562
CrossRef513
Lucia Nogova, Matthias Scheffler, Christian Mattonet, Thomas Zander, Jürgen Wolf. (2010) Systemische Therapie des nichtkleinzelligen Bronchialkarzinoms. Onkopipeline 3:2, 113-117
CrossRef514
Bristi Basu, Tim Eisen. (2010) Perspectives in drug development for metastatic renal cell cancer. Targeted Oncology 5:2, 139-156
CrossRef515
Leslie M. Randall, Bradley J. Monk. (2010) Bevacizumab toxicities and their management in ovarian cancer. Gynecologic Oncology 117:3, 497-504
CrossRef516
Federico Cappuzzo, Tudor Ciuleanu, Lilia Stelmakh, Saulius Cicenas, Aleksandra Szczésna, Erzsébet Juhász, Emilio Esteban, Olivier Molinier, Wolfram Brugger, Ivan Melezínek, Gaëlle Klingelschmitt, Barbara Klughammer, Giuseppe Giaccone. (2010) Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study. The Lancet Oncology 11:6, 521-529
CrossRef517
Eva Ciric, Gregor Sersa. (2010) Radiotherapy in combination with vascular-targeted therapies. Radiology and Oncology 44:2, 67-78
CrossRef518
David S. Ettinger. (2010) Emerging profile of cetuximab in non-small cell lung cancer. Lung Cancer 68:3, 332-337
CrossRef519
Cesare Gridelli, Andrea Ardizzoni, Jean-Yves Douillard, Nasser Hanna, Christian Manegold, Francesco Perrone, Robert Pirker, Rafael Rosell, Frances A. Shepherd, Luigi De Petris, Massimo Di Maio, Filippo de Marinis. (2010) Recent issues in first-line treatment of advanced non-small-cell lung cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Lung Cancer 68:3, 319-331
CrossRef520
Giorgio V. Scagliotti, Paul Germonpré, Leon Bosquée, Johan Vansteenkiste, R. Gervais, David Planchard, Martin Reck, Filippo De Marinis, Jin Soo Lee, Keunchil Park, Bonne Biesma, Steven Gans, R. Ramlau, Aleusandra Szczesna, A. Makhson, G. Manikhas, Bruno Morgan, Y. Zhu, Kai C. Chan, Joachim von Pawel. (2010) A randomized phase II study of bortezomib and pemetrexed, in combination or alone, in patients with previously treated advanced non-small-cell lung cancer. Lung Cancer 68:3, 420-426
CrossRef521
Hiroyuki Konno, Masayoshi Yamamoto, Manabu Ohta. (2010) Recent concepts of antiangiogenic therapy. Surgery Today 40:6, 494-500
CrossRef522
M B Nilsson, P E Zage, L Zeng, L Xu, T Cascone, H K Wu, B Saigal, P A Zweidler-McKay, J V Heymach. (2010) Multiple receptor tyrosine kinases regulate HIF-1α and HIF-2α in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors. Oncogene 29:20, 2938-2949
CrossRef523
Rebecca L Stone, Anil K Sood, Robert L Coleman. (2010) Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer. The Lancet Oncology 11:5, 465-475
CrossRef524
Carol Townsley, Amit Oza. (2010) Antiangiogenic therapies in ovarian cancer. Therapy 7:3, 277-284
CrossRef525
Geoffrey Y. Ku, David H. Ilson. (2010) Esophagogastric cancer: Targeted agents. Cancer Treatment Reviews 36:3, 235-248
CrossRef526
Louis M. Weiner, Rishi Surana, Shangzi Wang. (2010) Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nature Reviews Immunology 10:5, 317-327
CrossRef527
Jörg J. Jacoby, Baruch Erez, Maria V. Korshunova, Ryan R. Williams, Kazuhisa Furutani, Osamu Takahashi, Lynn Kirkpatrick, Scott M. Lippman, Garth Powis, Michael S. OʼReilly, Roy S. Herbst. (2010) Treatment with HIF-1α Antagonist PX-478 Inhibits Progression and Spread of Orthotopic Human Small Cell Lung Cancer and Lung Adenocarcinoma in Mice. Journal of Thoracic Oncology1
CrossRef528
G. D'Addario, M. Fruh, M. Reck, P. Baumann, W. Klepetko, E. Felip, . (2010) Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 21:Supplement 5, v116-v119
CrossRef529
Mark A. Socinski. (2010) The Emerging Role of Biomarkers in Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer 11:3, 149-159
CrossRef530
Vishal Ranpura, Bhargava Pulipati, David Chu, Xiaolei Zhu, Shenhong Wu. (2010) Increased Risk of High-Grade Hypertension With Bevacizumab in Cancer Patients: A Meta-Analysis. American Journal of Hypertension 23:5, 460-468
CrossRef531
Jonathan Sleeman, Patricia S. Steeg. (2010) Cancer metastasis as a therapeutic target. European Journal of Cancer 46:7, 1177-1180
CrossRef532
N. Steeghs, T. J. Rabelink, J. op 't Roodt, E. Batman, F. H. M. Cluitmans, N. I. Weijl, E. de Koning, H. Gelderblom. (2010) Reversibility of capillary density after discontinuation of bevacizumab treatment. Annals of Oncology 21:5, 1100-1105
CrossRef533
Tony S. Mok. (2010) A Target or a Demi-Target. Clinical Lung Cancer 11:3, 147-148
CrossRef534
Binu Malhotra, Tracey Evans, Jared Weiss, Beth Eaby, Susan Stonehouse-Lee, Victoria Sherry, Corey J. Langer. (2010) Carboplatin/Pemetrexed/Bevacizumab in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Single-Institution Experience. Clinical Lung Cancer 11:3, 192-197
CrossRef535
Chiharu Tanai, Nobuyuki Yamamoto, Yuichiro Ohe, Toshiaki Takahashi, Hideo Kunitoh, Haruyasu Murakami, Noboru Yamamoto, Yukiko Nakamura, Hiroshi Nokihara, Takehito Shukuya, John R. Baldwin, Minori Koshiji, Tomohide Tamura. (2010) A Phase I Study of Enzastaurin Combined with Pemetrexed in Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology1
CrossRef536
Natasha B. Leighl, Luis E. Raez, Benjamin Besse, Peter J. Rosen, Fabrice Barlesi, E. Massarelli, Nashat Gabrail, Lowell L. Hart, Kathy S. Albain, Lloyd Berkowitz, Ostap Melnyk, Frances A. Shepherd, Lars Sternas, Judie Ackerman, Zhenming Shun, Vincent A. Miller, Roy S. Herbst. (2010) A Multicenter, Phase 2 Study of Vascular Endothelial Growth Factor Trap (Aflibercept) in Platinum- and Erlotinib-Resistant Adenocarcinoma of the Lung. Journal of Thoracic Oncology1
CrossRef537
Mark J. McKeage, Bruce C. Baguley. (2010) Disrupting established tumor blood vessels. Cancer 116:8, 1859-1871
CrossRef538
M. L. Gatza, J. E. Lucas, W. T. Barry, J. W. Kim, Q. Wang, M. D. Crawford, M. B. Datto, M. Kelley, B. Mathey-Prevot, A. Potti, J. R. Nevins. (2010) A pathway-based classification of human breast cancer. Proceedings of the National Academy of Sciences 107:15, 6994-6999
CrossRef539
Bao-yue DING, lei AO, Xue-ying DING, Jing GAO, Wei FAN, Shen GAO. (2010) Active tumor targeting drug delivery system: the current status. Academic Journal of Second Military Medical University 30:3, 321-328
CrossRef540
Vishal Ranpura, Sanjaykumar Hapani, Jeff Chuang, Shenhong Wu. (2010) Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials. Acta Oncologica 49:3, 287-297
CrossRef541
Gerald W. Prager, Eva-Maria Lackner, Maria-Theresa Krauth, Matthias Unseld, Marina Poettler, Sylvia Laffer, Sabine Cerny-Reiterer, Wolfgang Lamm, Gabriela V. Kornek, Bernd R. Binder, Christoph C. Zielinski, Peter Valent. (2010) Targeting of VEGF-dependent transendothelial migration of cancer cells by bevacizumab. Molecular Oncology 4:2, 150-160
CrossRef542
Tianhong Li, Liawaty Ho, Bilal Piperdi, Tarek Elrafei, Fernando J. Camacho, James R. Rigas, Roman Perez-Soler, Rasim Gucalp. (2010) Phase II study of the proteasome inhibitor bortezomib (PS-341, Velcade®) in chemotherapy-naïve patients with advanced stage non-small cell lung cancer (NSCLC). Lung Cancer 68:1, 89-93
CrossRef543
Denise A. Yardley. (2010) Integrating Bevacizumab Into the Treatment of Patients With Early-Stage Breast Cancer: Focus on Cardiac Safety. Clinical Breast Cancer 10:2, 119-129
CrossRef544
Debashish Bose, Funda Meric-Bernstam, Wayne Hofstetter, David A Reardon, Keith T Flaherty, Lee M Ellis. (2010) Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. The Lancet Oncology 11:4, 373-382
CrossRef545
Michel Velez, Astrid Belalcazar, Gelenis Domingo, Marcelo Blaya, Luis E Raez, Edgardo S Santos. (2010) Accelerated second-line or maintenance chemotherapy versus treatment at disease progression in NSCLC. Expert Review of Anticancer Therapy 10:4, 549-557
CrossRef546
Marc C Chamberlain. (2010) Anticancer therapies and CNS relapse: overcoming blood–brain and blood–cerebrospinal fluid barrier impermeability. Expert Review of Neurotherapeutics 10:4, 547-561
CrossRef547
DAI FUKUMURA, DAN G. DUDA, LANCE L. MUNN, RAKESH K. JAIN. (2010) Tumor Microvasculature and Microenvironment: Novel Insights Through Intravital Imaging in Pre-Clinical Models. Microcirculation 17:3, 206-225
CrossRef548
Kun Yang, You-Juan Wang, Xue-Rong Chen, Hai-Ning Chen. (2010) Effectiveness and Safety of Bevacizumab for Unresectable Non-Small-Cell Lung Cancer. Clinical Drug Investigation 30:4, 229-241
CrossRef549
M. Mohr, T. Kessler, U. Krug, P. Hoffknecht, L.H. Schmidt, K. Wiebe, W.E. Berdel, R. Wiewrodt. (2010) Die Primärtherapie des nichtkleinzelligen Lungenkarzinoms. Zeitschrift für Herz-,Thorax- und Gefäßchirurgie 24:2, 97-104
CrossRef550
Siow Ming LEE, Paul BAAS, Heather WAKELEE. (2010) Anti-angiogenesis drugs in lung cancer. Respirology 15:3, 387-392
CrossRef551
A. G. Pallis, C. Gridelli, J. P. van Meerbeeck, L. Greillier, U. Wedding, D. Lacombe, J. Welch, C. P. Belani, M. Aapro. (2010) EORTC Elderly Task Force and Lung Cancer Group and International Society for Geriatric Oncology (SIOG) experts' opinion for the treatment of non-small-cell lung cancer in an elderly population. Annals of Oncology 21:4, 692-706
CrossRef552
F. Elice, F. Rodeghiero. (2010) Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impact. Thrombosis Research 125, S55-S57
CrossRef553
Gloria J. Morris, Frank A. Greco, John D. Hainsworth, Paul F. Engstrom, Salvatore Scialla, W. Edward Jordan, Lisa C. Thomas. (2010) Cancer of Unknown Primary Site. Seminars in Oncology 37:2, 71-79
CrossRef554
Andreas Pircher, I. Heidegger, E. Gunsilius, W. Hilbe. (2010) Biomarkers of angiogenesis and their role in clinical oncology. memo - Magazine of European Medical Oncology 3:1, 27-32
CrossRef555
Peh Sun Loo, Stuart C. Thomas, Marianne C. Nicolson, Margaret N. Fyfe, Keith M. Kerr. (2010) Subtyping of Undifferentiated Non-small Cell Carcinomas in Bronchial Biopsy Specimens. Journal of Thoracic Oncology 5:4, 442-447
CrossRef556
Daniel Renouf, Malcolm Moore. (2010) Evolution of systemic therapy for advanced pancreatic cancer. Expert Review of Anticancer Therapy 10:4, 529-540
CrossRef557
Haritha Samaranayake, Ann-Marie Määttä, Jere Pikkarainen, Seppo Ylä-Herttuala. (2010) Future Prospects and Challenges of Antiangiogenic Cancer Gene Therapy. Human Gene Therapy 21:4, 381-396
CrossRef558
T. Sakakibara, A. Inoue, S. Sugawara, M. Maemondo, T. Ishida, K. Usui, T. Abe, M. Kanbe, H. Watanabe, Y. Saijo, T. Nukiwa. (2010) Randomized phase II trial of weekly paclitaxel combined with carboplatin versus standard paclitaxel combined with carboplatin for elderly patients with advanced non-small-cell lung cancer. Annals of Oncology 21:4, 795-799
CrossRef559
C-H Hsu, T-S Yang, C Hsu, H C Toh, R J Epstein, L-T Hsiao, P-J Chen, Z-Z Lin, T-Y Chao, A-L Cheng. (2010) Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. British Journal of Cancer 102:6, 981-986
CrossRef560
Suresh S Ramalingam, Chandra P Belani. (2010) Antiangiogenic agents in the treatment of nonsmall cell lung cancer: reality and hope. Current Opinion in Oncology 22:2, 79-85
CrossRef561
Luca Toschi, Federico Cappuzzo. (2010) Impact of biomarkers on non-small cell lung cancer treatment. Targeted Oncology 5:1, 5-17
CrossRef562
Adi F. Gazdar. (2010) Epidermal growth factor receptor inhibition in lung cancer: the evolving role of individualized therapy. Cancer and Metastasis Reviews 29:1, 37-48
CrossRef563
Wolfram C.M. Dempke, Tamas Suto, Martin Reck. (2010) Targeted therapies for non-small cell lung cancer. Lung Cancer 67:3, 257-274
CrossRef564
Mark A. Socinski, Frank A. Scappaticci, Meghna Samant, Margaret M. Kolb, Mark F. Kozloff. (2010) Safety and Efficacy of Combining Sunitinib with Bevacizumab + Paclitaxel/Carboplatin in Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:3, 354-360
CrossRef565
Alberto Chiappori, Gerold Bepler, Fabrice Barlesi, Jean-Charles Soria, Martin Reck, Alessandra Bearz, Fernando Barata, Giorgio Scagliotti, Keunchil Park, Asavari Wagle, Astra M. Liepa, Yan Daniel Zhao, Nadia Chouaki, Neill Iscoe, Joachim von Pawel. (2010) Phase II, Double-Blinded, Randomized Study of Enzastaurin Plus Pemetrexed as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:3, 369-375
CrossRef566
Lucian R. Chirieac, Sanja Dacic. (2010) Targeted Therapies in Lung Cancer. Surgical Pathology Clinics 3:1, 71-82
CrossRef567
Philip D. Bonomi. (2010) Implications of key trials in advanced nonsmall cell lung cancer. Cancer 116:5, 1155-1164
CrossRef568
John P. Diaz, William P. Tew, Oliver Zivanovic, Jason Konner, Paul J. Sabbatini, Lisa A. dos Santos, Nadeem R. Abu-Rustum, Dennis S. Chi, Carol Aghajanian, Richard R. Barakat. (2010) Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma. Gynecologic Oncology 116:3, 335-339
CrossRef569
Linda E. Coate, Frances A. Shepherd. (2010) Maintenance Therapy in Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology1
CrossRef570
Youssef Bennis, Benjamin Guillet, Christophe Curti, Pascale Pisano. (2010) Intérêts thérapeutiques des médicaments antiangiogéniques disponibles en cancérologie. Thérapie 65:2, 95-105
CrossRef571
Anil Bagri, Hosein Kouros-Mehr, Kevin G. Leong, Greg D. Plowman. (2010) Use of anti-VEGF adjuvant therapy in cancer: challenges and rationale. Trends in Molecular Medicine 16:3, 122-132
CrossRef572
Cesare Gridelli. (2010) Can a decisional algorithm be used in first-line treatment of advanced nonsmall cell lung cancer?. Current Opinion in Oncology 22:2, 77-78
CrossRef573
Anne Katrin Berger, Thomas Herrmann. (2010) „Targeted therapies“ in der Behandlung solider Tumoren. Onkopipeline 3:1, 48-51
CrossRef574
Michele Basso, Alessandra Cassano, Carlo Barone. (2010) A survey of therapy for advanced renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations 28:2, 121-133
CrossRef575
Swan Swan Leong, Kam Weng Fong, Wan Teck Lim, Chee Keong Toh, Swee Peng Yap, Siew Wan Hee, Eng Huat Tan. (2010) A phase II trial of induction gemcitabine and vinorelbine followed by concurrent vinorelbine and radiotherapy in locally advanced non-small cell lung cancer. Lung Cancer 67:3, 325-329
CrossRef576
Corey Langer, Jean-Charles Soria. (2010) The Role of Anti–Epidermal Growth Factor Receptor and Anti–Vascular Endothelial Growth Factor Therapies in the Treatment of Non–Small-Cell Lung Cancer. Clinical Lung Cancer 11:2, 82-90
CrossRef577
Cesare Gridelli, Antonio Rossi, Filippo de Marinis. (2010) Pattern of care for advanced non-small cell lung cancer in the era of histology-based treatment: A survey of the Italian Association of Thoracic Oncology (AIOT). Lung Cancer 67:3, 339-342
CrossRef578
Martin Reck, Ulrich Gatzemeier. (2010) Targeted therapies: Thalidomide in lung cancer therapy—what have we learned?. Nature Reviews Clinical Oncology 7:3, 134-135
CrossRef579
Kristen Ganjoo, Charlotte Jacobs. (2010) Antiangiogenesis agents in the treatment of soft tissue sarcomas. Cancer 116:5, 1177-1183
CrossRef580
F. Cappuzzo, G. Tallini, G. Finocchiaro, R. S. Wilson, C. Ligorio, L. Giordano, L. Toschi, M. Incarbone, R. Cavina, L. Terracciano, M. Roncalli, M. Alloisio, M. Varella-Garcia, W. A. Franklin, A. Santoro. (2010) Insulin-like growth factor receptor 1 (IGF1R) expression and survival in surgically resected non-small-cell lung cancer (NSCLC) patients. Annals of Oncology 21:3, 562-567
CrossRef581
N C Tebbutt, M M Cummins, T Sourjina, A Strickland, G Van Hazel, V Ganju, D Gibbs, M Stockler, V Gebski, J Zalcberg. (2010) Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. British Journal of Cancer 102:3, 475-481
CrossRef582
J-M Lee, G A Sarosy, C M Annunziata, N Azad, L Minasian, H Kotz, J Squires, N Houston, E C Kohn. (2010) Combination therapy: intermittent sorafenib with bevacizumab yields activity and decreased toxicity. British Journal of Cancer 102:3, 495-499
CrossRef583
Andrea Gombos, Hassan Izzedine, Benjamin Besse, Christophe Massard, Isabelle Brocheriou, Rastislav Bahleda, Jean-Charles Soria. (2010) Proteinuria and proximal tubule lesions induced by an anti-integrin monoclonal antibody treatment: case report. Investigational New Drugs 28:1, 102-105
CrossRef584
Napoleone Ferrara. (2010) Pathways mediating VEGF-independent tumor angiogenesis. Cytokine & Growth Factor Reviews 21:1, 21-26
CrossRef585
Ying-Kiat Zee, James P. B. O'Connor, Geoff J. M. Parker, Alan Jackson, Andrew R. Clamp, M. Ben Taylor, Noel W. Clarke, Gordon C. Jayson. (2010) Imaging angiogenesis of genitourinary tumors. Nature Reviews Urology 7:2, 69-82
CrossRef586
T. N. Kreisl, S. Kotliarova, J. A. Butman, P. S. Albert, L. Kim, L. Musib, D. Thornton, H. A. Fine. (2010) A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas. Neuro-Oncology 12:2, 181-189
CrossRef587
Hua Yang, Kun Yang, Jian-Kun Hu, Hong Tang, Bo Zhang, Zhi-Xin Chen, You-Juan Wang, Jia-Ping Chen. (2010) Eukaryotic expression of extracellular ligand binding domains of murine Tie-2 and its anti-angiogenesis effect in SGC-7901 cell lines. Journal of Gastroenterology and Hepatology 25:2, 345-351
CrossRef588
Taofeek K. Owonikoko, Suresh S. Ramalingam, Beatriz Kanterewicz, Trent E. Balius, Chandra P. Belani, Pamela A. Hershberger. (2010) Vorinostat increases carboplatin and paclitaxel activity in non-small cell lung cancer cells. International Journal of Cancer 126:3, 743-755
CrossRef589
Zachary A. Knight, Henry Lin, Kevan M. Shokat. (2010) Targeting the cancer kinome through polypharmacology. Nature Reviews Cancer 10:2, 130-137
CrossRef590
Elias A. Kotteas, Andriani G. Charpidou, Kostas N. Syrigos. (2010) Targeted therapy for nonsmall cell lung cancer: focusing on angiogenesis, the epidermal growth factor receptor and multikinase inhibitors. Anti-Cancer Drugs 21:2, 151-168
CrossRef591
T. Mitsudomi. (2010) Advances in Target Therapy for Lung Cancer. Japanese Journal of Clinical Oncology 40:2, 101-106
CrossRef592
John Goffin, Christina Lacchetti, Peter M. Ellis, Yee C. Ung, William K. Evans. (2010) First-Line Systemic Chemotherapy in the Treatment of Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:2, 260-274
CrossRef593
Massimo Di Maio, Ciro Gallo, Ermelinda De Maio, Alessandro Morabito, Maria Carmela Piccirillo, Cesare Gridelli, Francesco Perrone. (2010) Methodological aspects of lung cancer clinical trials in the era of targeted agents. Lung Cancer 67:2, 127-135
CrossRef594
E. A. Perez, D. W. Hillman, T. Dentchev, N. A. Le-Lindqwister, L. H. Geeraerts, T. R. Fitch, H. Liu, D. L. Graham, S. P. Kahanic, H. M. Gross, T. A. Patel, F. M. Palmieri, A. C. Dueck. (2010) North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer. Annals of Oncology 21:2, 269-274
CrossRef595
Kaoru Kubota, Hiroshi Sakai, Nobuyuki Yamamoto, Hideo Kunitoh, Kazuhiko Nakagawa, Koji Takeda, Yukito Ichinose, Nagahiro Saijo, Yutaka Ariyoshi, Masahiro Fukuoka. (2010) A Multi-Institution Phase I/II Trial of Triweekly Regimen with S-1 Plus Cisplatin in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology1
CrossRef596
L Vroling, J S W Lind, R R de Haas, H M W Verheul, V W M van Hinsbergh, H J Broxterman, E F Smit. (2010) CD133+ circulating haematopoietic progenitor cells predict for response to sorafenib plus erlotinib in non-small cell lung cancer patients. British Journal of Cancer 102:2, 268-275
CrossRef597
G Mickisch, M Gore, B Escudier, G Procopio, S Walzer, M Nuijten. (2010) Costs of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-α2a compared with sunitinib. British Journal of Cancer 102:1, 80-86
CrossRef598
N Murukesh, C Dive, G C Jayson. (2010) Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. British Journal of Cancer 102:1, 8-18
CrossRef599
Laura R. Triano, Hari Deshpande, Scott N. Gettinger. (2010) Management of Patients with Advanced Non-Small Cell Lung Cancer. Drugs 70:2, 167-179
CrossRef600
Andrew R. Reynolds. (2010) Potential Relevance of Bell-Shaped and U-Shaped Dose-Responses for the Therapeutic Targeting of Angiogenesis in Cancer. Dose-Response 8:3, 253-284
CrossRef601
Ingrid A. Boere, Paul Hamberg, Stefan Sleijfer. (2010) It takes two to tango: Combinations of conventional cytotoxics with compounds targeting the vascular endothelial growth factorâvascular endothelial growth factor receptor pathway in patients with solid malignancies. Cancer Science 101:1, 7-15
CrossRef602
William N. William, Merrill S. Kies, Frank V. Fossella, Diane D. Liu, Gregory Gladish, Warner H. Tse, J. Jack Lee, Waun K. Hong, Scott M. Lippman, Edward S. Kim. (2010) Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer. CancerNA-NA
CrossRef603
Austin Duffy, Shivaani Kummar. (2010) Metastatic Pancreatic Adenocarcinoma: Current Standards, Future Directions. American Journal of Therapeutics 17:1, 79-85
CrossRef604
Shinichi Toyooka, Tetsuya Mitsudomi, Junichi Soh, Hiromasa Yamamoto, Shinichiro Miyoshi. (2010) Molecular Biology of Lung Cancer. Haigan 50:4, 329-341
CrossRef605
Francisco Robert, Karen Harper, Judie Ackerman, Sunil Gupta. (2010) A phase I study of larotaxel (XRP9881) administered in combination with carboplatin in chemotherapy-naïve patients with stage IIIB or stage IV non-small cell lung cancer. Cancer Chemotherapy and Pharmacology 65:2, 227-234
CrossRef606
John McLaughlin, Vadim Markovtsov, Hui Li, Steve Wong, Marina Gelman, Yanhong Zhu, Christian Franci, D. Wayne Lang, Erlina Pali, Joe Lasaga, Caroline Low, Feifei Zhao, Betty Chang, Tarikere L. Gururaja, Weiduan Xu, Muhammad Baluom, David Sweeny, David Carroll, Arvinder Sran, Sambaiah Thota, Manjeet Parmer, Angela Romane, George Clemens, Elliott Grossbard, Kunbin Qu, Yonchu Jenkins, Taisei Kinoshita, Vanessa Taylor, Sacha J. Holland, Ankush Argade, Rajinder Singh, Polly Pine, Donald G. Payan, Yasumichi Hitoshi. (2010) Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen. Journal of Cancer Research and Clinical Oncology 136:1, 99-113
CrossRef607
Grzegorz Korpanty, Laura A. Sullivan, Elizabeth Smyth, Desmond N. Carney, Rolf A. Brekken. (2010) Molecular and Clinical Aspects of Targeting the VEGF Pathway in Tumors. Journal of Oncology 2010, 1-12
CrossRef608
Sumithra J. Mandrekar, Yingwei Qi, Shauna L. Hillman, Katie L. Allen Ziegler, Nicholas F. Reuter, Kendrith M. Rowland, Steven A. Kuross, Randolph S. Marks, Steven E. Schild, Alex A. Adjei. (2010) Endpoints in Phase II Trials for Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 5:1, 3-9
CrossRef609
Lyndsay J. Willmott, John P. Fruehauf. (2010) Targeted Therapy in Ovarian Cancer. Journal of Oncology 2010, 1-9
CrossRef610
Stephen G. SPIRO, Nichole T. TANNER, Gerard A. SILVESTRI, Sam M. JANES, Eric LIM, Johan F. VANSTEENKISTE, Robert PIRKER. (2010) Lung cancer: Progress in diagnosis, staging and therapy. Respirology 15:1, 44-50
CrossRef611
Ronald Natale. 2010. Adjuvant and Neoadjuvant Chemotherapy in Non-Small Cell Lung Cancer. , 247-251.
CrossRef612
Kristina Loukeris, Madeline F. Vazquez, Gabriel Sica, Patrick Wagner, David F. Yankelevitz, Claudia I. Henschke, Matthew D. Cham, Anjali Saqi. (2010) Cytological cell blocks: Predictors of squamous cell carcinoma and adenocarcinoma subtypes. Diagnostic Cytopathologyn/a-n/a
CrossRef613
Bettina Reismüller, Amedeo A. Azizi, Andreas Peyrl, Monika Heinrich, Mariella Gruber-Olipitz, Doris Luckner, Klara Vergesslich Rothschild, Irene Slavc. (2010) Feasibility and tolerability of bevacizumab in children with primary CNS tumors. Pediatric Blood & Cancern/a-n/a
CrossRef614
Yuki Kumihashi, Masaki Hanibuchi, Hideki Tomimoto, Momoyo Azuma, Takanori Kanematsu, Soji Kakiuchi, Hisatsugu Goto, Hiroya Tada, Yasuhiko Nishioka, Saburo Sone. (2010) Assessment of Quality of Life in Non-small-cell Lung Cancer Patients by Patient-reported Outcome (PRO) -A Review of Phase III Trials-. Haigan 50:6, 791-802
CrossRef615
Andrew X Zhu, Jeffrey A Meyerhardt, Lawrence S Blaszkowsky, Avinash R Kambadakone, Alona Muzikansky, Hui Zheng, Jeffrey W Clark, Thomas A Abrams, Jennifer A Chan, Peter C Enzinger, Pankaj Bhargava, Eunice L Kwak, Jill N Allen, Sanjay R Jain, Keith Stuart, Kerry Horgan, Susan Sheehan, Charles S Fuchs, David P Ryan, Dushyant V Sahani. (2010) Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. The Lancet Oncology 11:1, 48-54
CrossRef616
David J. Stewart. 2010. Clinical Management of Lung Cancer. , 437-445.
CrossRef617
P. Starlinger, K. Gebhardt, T. Grünberger, C. Brostjan. (2010) Systemic effects of anti-VEGF therapy – Mini-review. European Surgery 42:1, 12-16
CrossRef618
Michael Medinger, Natalie Fischer, Alexandar Tzankov. (2010) Vascular Endothelial Growth Factor-Related Pathways in Hemato-Lymphoid Malignancies. Journal of Oncology 2010, 1-13
CrossRef619
Renaud Grépin, Gilles Pagès. (2010) Molecular Mechanisms of Resistance to Tumour Anti-Angiogenic Strategies. Journal of Oncology 2010, 1-8
CrossRef620
Luis E. Raez, Svetlana Kobina, Edgardo S. Santos. (2010) Oxaliplatin in First-line Therapy for Advanced Non–Small-Cell Lung Cancer. Clinical Lung Cancer 11:1, 18-24
CrossRef621
Byoung Chul Cho, Joo Hang Kim, Ross A Soo, Chih-Hsin Yang. (2010) The Role of Monoclonal Antibody in Combination with First-Line Chemotherapy in Asian Patients with Advanced Non-Small Cell Lung Cancer. Yonsei Medical Journal 51:1, 1
CrossRef622
Sergio Bracarda, Alexander M.M. Eggermont, Jan Samuelsson. (2010) Redefining the role of interferon in the treatment of malignant diseases. European Journal of Cancer 46:2, 284-297
CrossRef623
Robert A. Burger. (2010) Role of vascular endothelial growth factor inhibitors in the treatment of gynecologic malignancies. Journal of Gynecologic Oncology 21:1, 3
CrossRef624
Natsumi Matsuura, Shinya Ishikawa, Nariyasu Nakashima, Hitoshi Igai, Shintarou Tarumi, Sung-Soo Chang, Noriyuki Misaki, Tetsuhiko Go, Hiroyasu Yokomise. (2010) Experience of Combination Therapy Consisting of Carboplatin, Docetaxel, and Bevacizumab for Previously Treated Advanced Non-small-cell Lung Cancer. Haigan 50:7, 901-905
CrossRef625
Hassane Izzedine, Christophe Massard, Jean Philippe Spano, François Goldwasser, David Khayat, Jean Charles Soria. (2010) VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. European Journal of Cancer 46:2, 439-448
CrossRef626
Nagahiro Saijo, Hirotsugu Kenmotsu. (2010) Recent Development of Molecular-Targeted Drugs in Lung Cancer. Internal Medicine 49:18, 1923-1934
CrossRef627
Corey Langer, Vera Hirsh. (2010) Skeletal morbidity in lung cancer patients with bone metastases: Demonstrating the need for early diagnosis and treatment with bisphosphonates. Lung Cancer 67:1, 4-11
CrossRef628
M. Dietel, P. Schirmacher. (2010) Molekularpathologische Analyse beim metastasierten NSCLC. Der Onkologe 16:1, 63-66
CrossRef629
R. Sikorski, B. Yao. (2009) Parallel Paths to Predictive Biomarkers in Oncology: Uncoupling of Emergent Biomarker Development and Phase III Trial Execution. Science Translational Medicine 1:10, 10ps11-10ps11
CrossRef630
Thoralf Christoffersen, Tormod K. Guren, Karen-Lise Garm Spindler, Olav Dahl, Per Eystein Lønning, Bjørn Tore Gjertsen. (2009) Cancer therapy targeted at cellular signal transduction mechanisms: Strategies, clinical results, and unresolved issues. European Journal of Pharmacology 625:1-3, 6-22
CrossRef631
Barbara Bonnesen, Helle Pappot, Julie Holmstav, Birgit Guldhammer Skov. (2009) Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: Relation to prognosis. Lung Cancer 66:3, 314-318
CrossRef632
Mariëtte HW Kappers, Joep HM van Esch, Stefan Sleijfer, AH Jan Danser, Anton H van den Meiracker. (2009) Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects. Journal of Hypertension 27:12, 2297-2309
CrossRef633
Sara Serrano Solares, Dolores Isla Casado, María Jesús Vidal Losada, María Tobeña Puyal, Ana Isabel Ferrer Pérez, Isabel Pajares. (2009) Dramatic complete response in patient with lung adenocarcinoma. Clinical and Translational Oncology 11:12, 851-853
CrossRef634
Manabu Ohta, Toshiki Kawabata, Masayoshi Yamamoto, Tatsuo Tanaka, Hirotoshi Kikuchi, Yoshihiro Hiramatsu, Kinji Kamiya, Megumi Baba, Hiroyuki Konno. (2009) TSU68, an antiangiogenic receptor tyrosine kinase inhibitor, induces tumor vascular normalization in a human cancer xenograft nude mouse model. Surgery Today 39:12, 1046-1053
CrossRef635
Yongping Crawford, Napoleone Ferrara. (2009) Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies. Trends in Pharmacological Sciences 30:12, 624-630
CrossRef636
Seema Harichand-Herdt, Suresh S. Ramalingam. (2009) Gender-Associated Differences in Lung Cancer: Clinical Characteristics and Treatment Outcomes in Women. Seminars in Oncology 36:6, 572-580
CrossRef637
David R. Spigel, F Anthony Greco, John D. Zubkus, Patrick B. Murphy, Ruben A. Saez, Cindy Farley, Denise A. Yardley, Howard A. Burris, John D. Hainsworth. (2009) Phase II Trial of Irinotecan, Carboplatin, and Bevacizumab in the Treatment of Patients with Extensive-Stage Small-Cell Lung Cancer. Journal of Thoracic Oncology 4:12, 1555-1560
CrossRef638
Akihiro Tamiya, Kentaro Yamazaki, Narikazu Boku, Nozomu Machida, Takashi Kojima, Keisei Taku, Hirofumi Yasui, Akira Fukutomi, Shuichi Hironaka, Yusuke Onozawa. (2009) Safety of bevacizumab treatment in combination with standard chemotherapy for metastatic colorectal cancer: a retrospective review of 65 Japanese patients. International Journal of Clinical Oncology 14:6, 513-517
CrossRef639
Sherry X Yang. (2009) Bevacizumab and breast cancer: current therapeutic progress and future perspectives. Expert Review of Anticancer Therapy 9:12, 1715-1725
CrossRef640
Craig Reynolds, David Barrera, Robert Jotte, Alexander I. Spira, Charles Weissman, Kristi A. Boehm, Sharon Pritchard, Lina Asmar. (2009) Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell Lung Cancer. Journal of Thoracic Oncology 4:12, 1537-1543
CrossRef641
Heather Wakelee, Bill W. Loo ., Kemp H. Kernstine, Joe Bill Putnam ., Martin J. Edelman, Everett E. Vokes, Joan H. Schiller, Paul Baas, Nagahiro Saijo, Alex Adjei, Glenwood Goss, Hak Choy, David R. Gandara. (2009) Cooperative Group Research Efforts in Thoracic Malignancies 2009: A Review From the 10th Annual International Lung Cancer Congress. Clinical Cancer Reviews 3:1, 9-18
CrossRef642
Tanyanika Phillips Towe, Elizabeth O'Toole, Kathryn Engelhardt, Govardhanan Nagaiah, Nathan A. Berger. (2009) Changing Healthcare Practice for Older Adults with Late-Stage Non-Small Cell Lung Cancer: Practical Considerations of Targeted Therapy in Primary Care and Oncology. Journal of the American Geriatrics Society 57, s253-s258
CrossRef643
Jose Ortega, J. Michael Hayes, Scott Antonia. (2009) Hepatic portal venous gas in a patient with metastatic non-small cell lung cancer on bevacizumab therapy: a case report and review of the literature. Cancer Chemotherapy and Pharmacology 65:1, 187-190
CrossRef644
Danielle Shafer, Kathy Albain. (2009) Lung Cancer Outcomes in Women. Seminars in Oncology 36:6, 532-541
CrossRef645
Yufan Zhao, Michael R. Kosorok, Donglin Zeng. (2009) Reinforcement learning design for cancer clinical trials. Statistics in Medicine 28:26, 3294-3315
CrossRef646
David J. Gallagher, Matthew I. Milowsky, Alexia Iasonos, Fernando C. Maluf, Paul Russo, Guido Dalbagni, Machele S. Donat, Mary G. Boyle, Junting Zheng, Jamie Riches, Dean F. Bajorin. (2009) Sequential adjuvant chemotherapy after surgical resection of high-risk urothelial carcinoma. Cancer 115:22, 5193-5201
CrossRef647
S Novello, G V Scagliotti, R Rosell, M A Socinski, J Brahmer, J Atkins, C Pallares, R Burgess, L Tye, P Selaru, E Wang, R Chao, R Govindan. (2009) Phase II study of continuous daily sunitinib dosing in patients with previously treated advanced non-small cell lung cancer. British Journal of Cancer 101:9, 1543-1548
CrossRef648
Bo Liu, Xiao-Chun Peng, Xiao-Li Zheng, Jun Wang, Yong-Wen Qin. (2009) MiR-126 restoration down-regulate VEGF and inhibit the growth of lung cancer cell lines in vitro and in vivo. Lung Cancer 66:2, 169-175
CrossRef649
Yelena Krupitskaya, Heather Wakelee. (2009) Vascular Endothelial Growth Factor Pathway. Journal of Thoracic Oncology 4:Supplement 3, S1071-S1073
CrossRef650
A. R. Jazieh, R. Komrokji, A. Gupta, S. Patil, D. Flora, M. Knapp, M. Issa, N. Abdel Karim. (2009) Phase II Trial of Thalidomide, Irinotecan and Gemcitabine in Chemonaive Patients with Advanced Non-Small Cell Lung Cancer. Cancer Investigation 27:9, 932-936
CrossRef651
Antonio Rossi, Serena Ricciardi, Paolo Maione, Filippo de Marinis, Cesare Gridelli. (2009) Pemetrexed in the treatment of advanced non-squamous lung cancer. Lung Cancer 66:2, 141-149
CrossRef652
Heather Wakelee, Bill W. Loo ., Kemp H. Kernstine, Joe Bill Putnam ., Martin J. Edelman, Everett E. Vokes, Joan H. Schiller, Paul Baas, Nagahiro Saijo, Alex Adjei, Glenwood Goss, Hak Choy, David R. Gandara. (2009) Cooperative Group Research Efforts in Thoracic Malignancies 2009: A Review From the 10th Annual International Lung Cancer Congress. Clinical Lung Cancer 10:6, 395-404
CrossRef653
Lecia V. Sequist, Panos M. Fidias, Jennifer S. Temel, Tatjana Kolevska, Michael S. Rabin, Ralph V. Boccia, Howard A. Burris, Robert J. Belt, Mark S. Huberman, Ostap Melnyk, Glenn M. Mills, Craig W. Englund, David C. Caldwell, James G. Keck, Lisa Meng, Marsha Jones, Gail L. Brown, Martin J. Edelman, Thomas J. Lynch. (2009) Phase 1-2a Multicenter Dose-Ranging Study of Canfosfamide in Combination with Carboplatin and Paclitaxel as First-Line Therapy for Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 4:11, 1389-1396
CrossRef654
Mark A. Socinski. (2009) Fibroblastic Growth Factor Pathway. Journal of Thoracic Oncology 4:Supplement 3, S1066-S1067
CrossRef655
Noboru Yamamoto, Tomohide Tamura, Nobuyuki Yamamoto, Kazuhiko Yamada, Yasuhide Yamada, Hiroshi Nokihara, Yutaka Fujiwara, Toshiaki Takahashi, Haruyasu Murakami, Narikazu Boku, Kentaro Yamazaki, Thomas A. Puchalski, Eisei Shin. (2009) Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN™), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology 64:6, 1165-1172
CrossRef656
Carlos A Castaneda, Henry L Gomez. (2009) Pazopanib: an antiangiogenic drug in perspective. Future Oncology 5:9, 1335-1348
CrossRef657
Ross A Soo, Benjamin O Anderson, Byoung Chul Cho, Chih-Hsin Yang, Meilin Liao, Wan-Teck Lim, Peter Goldstraw, Tony S Mok. (2009) First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009. The Lancet Oncology 10:11, 1102-1110
CrossRef658
Bettina M. Buchholz, Ines Gütgemann, Hans-Peter Fischer, Marcus Gorschlüter, Andreas Türler, Jörg C. Kalff, Andreas Hirner, Jens Standop. (2009) Lymph node dissection in primary intrahepatic malignant mesothelioma: case report and implications for diagnosis and therapy. Langenbeck's Archives of Surgery 394:6, 1123-1130
CrossRef659
Robert Klein, Catherine Muehlenbein, Astra M. Liepa, Steve Babineaux, Ron Wielage, Lee Schwartzberg. (2009) Cost-Effectiveness of Pemetrexed Plus Cisplatin as First-Line Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer. Journal of Thoracic Oncology 4:11, 1404-1414
CrossRef660
Ahmed O. Kaseb, Amr Hanbali, Matthew Cotant, Manal M. Hassan, Ira Wollner, Philip A. Philip. (2009) Vascular endothelial growth factor in the management of hepatocellular carcinoma. Cancer 115:21, 4895-4906
CrossRef661
Sai-Hong Ignatius Ou, Jason A. Zell. (2009) Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies. Journal of Thoracic Oncology 4:10, 1202-1211
CrossRef662
Boone Goodgame, Thomas E. Stinchcombe, George Simon, Antoinette Wozniak, Ramaswamy Govindan. (2009) Recent Advances in Lung Cancer. Journal of Thoracic Oncology 4:10, 1293-1300
CrossRef663
Tudor Ciuleanu, Thomas Brodowicz, Christoph Zielinski, Joo Hang Kim, Maciej Krzakowski, Eckart Laack, Yi-Long Wu, Isabel Bover, Stephen Begbie, Valentina Tzekova, Branka Cucevic, Jose Rodrigues Pereira, Sung Hyun Yang, Jayaprakash Madhavan, Katherine P Sugarman, Patrick Peterson, William J John, Kurt Krejcy, Chandra P Belani. (2009) Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. The Lancet 374:9699, 1432-1440
CrossRef664
Jerry Y. Hsu, Heather A. Wakelee. (2009) Monoclonal Antibodies Targeting Vascular Endothelial Growth Factor. BioDrugs 23:5, 289-304
CrossRef665
Lucyna Kepka, Arkadiusz Sprawka, Francesc Casas, Sherif Abdel-Wahab, Jai Prakash Agarwal, Branislav Jeremic. (2009) Combination of radiotherapy and chemotherapy in locally advanced NSCLC. Expert Review of Anticancer Therapy 9:10, 1389-1403
CrossRef666
Katsuhiro Masago, Shiro Fujita, Yung Haku Kim, Yukimasa Hatachi, Akiko Fukuhara, Hiroki Nagai, Kaoru Irisa, Masataka Ichikawa, Tadashi Mio, Michiaki Mishima. (2009) Effect of vascular endothelial growth factor polymorphisms on survival in advanced-stage non-small-cell lung cancer. Cancer Science 100:10, 1917-1922
CrossRef667
Sharon L. Sanborn, Joseph Gibbons, Smitha Krishnamurthi, Joanna M. Brell, Afshin Dowlati, Joseph A. Bokar, Charles Nock, Nancy Horvath, Jacob Bako, Scot C. Remick, Matthew M. Cooney. (2009) Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors. Investigational New Drugs 27:5, 453-460
CrossRef668
Fausto Petrelli, Mara Ghilardi, Marco Cremonesi, Mary Cabiddu, Sandro Barni. (2009) Is there a role for maintenance therapy in non-small-cell lung cancer? An emerging issue. Expert Review of Anticancer Therapy 9:10, 1455-1465
CrossRef669
R. A. Wilcox, D. A. Wada, S. C. Ziesmer, S. F. Elsawa, N. I. Comfere, A. B. Dietz, A. J. Novak, T. E. Witzig, A. L. Feldman, M. R. Pittelkow, S. M. Ansell. (2009) Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic cells. Blood 114:14, 2936-2944
CrossRef670
Yihai Cao, Weide Zhong, Yan Sun. (2009) Improvement of antiangiogenic cancer therapy by understanding the mechanisms of angiogenic factor interplay and drug resistance. Seminars in Cancer Biology 19:5, 338-343
CrossRef671
Michaela J Higgins, David S Ettinger. (2009) Chemotherapy for lung cancer: the state of the art in 2009. Expert Review of Anticancer Therapy 9:10, 1365-1378
CrossRef672
Hans Petter Eikesdal, Raghu Kalluri. (2009) Drug resistance associated with antiangiogenesis therapy. Seminars in Cancer Biology 19:5, 310-317
CrossRef673
Filippo De Marinis, Wilfried Eberhardt, Peter G. Harper, Bartomeu Massuti Sureda, Kristiaan Nackaerts, Jens Benn Soerensen, Kostas Syrigos, Jean Trédaniel. (2009) Bisphosphonate Use in Patients with Lung Cancer and Bone Metastases. Journal of Thoracic Oncology 4:10, 1280-1288
CrossRef674
Peter J. Van Veldhuizen, Michael Hussey, Primo N. Lara, Philip C. Mack, Regina Gandour-Edwards, Joseph I. Clark, Marianne K. Lange, David E. Crawford. (2009) A Phase II Study of Gemcitabine and Capecitabine in Patients With Advanced Renal Cell Cancer. American Journal of Clinical Oncology 32:5, 453-459
CrossRef675
(2009) Gastrointestinal oncological surgery in patients with metastatic cancer treated with angiogenesis inhibitors: safe or not?. ANZ Journal of Surgery 79:10, 672-673
CrossRef676
Axel Grothey, Evanthia Galanis. (2009) Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nature Reviews Clinical Oncology 6:9, 507-518
CrossRef677
Bo Peng, Jinnong Zhang, Jamile S. Woods, Wei Peng. (2009) Molecular markers and pathogenically targeted therapy in non-small cell lung cancer. Frontiers of Medicine in China 3:3, 245-255
CrossRef678
Joan Carles, Rafael Morales, José Manuel Perez, Cristina Suárez, Jordi Rodón, Claudia Valverde. (2009) Management and interpretation of novel toxicities of molecular targeted therapies: Renal toxicities. European Journal of Cancer 45, 309-317
CrossRef679
Manish R. Sharma, Michael L. Maitland, Mark J. Ratain. (2009) Other Paradigms: Better Treatments Are Identified by Better Trials. The Cancer Journal 15:5, 426-430
CrossRef680
Tait D. Shanafelt, John C. Byrd, Betsy LaPlant, Clive S. Zent, Tim Call, Charla Secreto, Michael R. Grever, Thomas S. Lin, Neil E. Kay. (2009) Pretreatment angiogenic cytokines predict response to chemoimmunotherapy in patients with chronic lymphocytic leukaemia. British Journal of Haematology 146:6, 660-664
CrossRef681
A.G. Pallis, L. Serfass, R. Dziadziuszko, J.P. van Meerbeeck, D. Fennell, D. Lacombe, J. Welch, C. Gridelli. (2009) Targeted therapies in the treatment of advanced/metastatic NSCLC. European Journal of Cancer 45:14, 2473-2487
CrossRef682
Thomas E. Stinchcombe, Lydia Hodgson, James E. Herndon, Michael J. Kelley, M Giulia Cicchetti, Nithya Ramnath, Harvey B. Niell, James N. Atkins, Wallace Akerley, Mark R. Green, Everett E. Vokes. (2009) Treatment Outcomes of Different Prognostic Groups of Patients on Cancer and Leukemia Group B Trial 39801. Journal of Thoracic Oncology 4:9, 1117-1125
CrossRef683
Ping Zhan, Jing Wang, Xiao-jing Lv, Qin Wang, Li-xin Qiu, Xin-qing Lin, Li-ke Yu, Yong Song. (2009) Prognostic Value of Vascular Endothelial Growth Factor Expression in Patients with Lung Cancer. Journal of Thoracic Oncology 4:9, 1094-1103
CrossRef684
Katherine MASSELOS, Stephen BEGBIE, Jennifer Nicole LEES. (2009) Spinal cord infarction in a patient with metastatic non-small cell lung cancer, receiving chemotherapy combined with bevacizumab. Asia-Pacific Journal of Clinical Oncology 5:3, 151-153
CrossRef685
J. -M. Halimi, M. Azizi, G. Bobrie, O. Bouché, G. Deray, G. Guetz, T. Lecomte, B. Levy, J. -J. Mourad, D. Nochy, S. Oudard, P. Rieu, D. Sahali. (2009) Effets vasculaires et rénaux des médicaments anti-angiogéniques: recommandations françaises pour la pratique. Oncologie 11:9-10, 476-489
CrossRef686
Philip H. Gutin, Fabio M. Iwamoto, Kathryn Beal, Nimish A. Mohile, Sasan Karimi, Bob L. Hou, Stella Lymberis, Yoshiya Yamada, Jenghwa Chang, Lauren E. Abrey. (2009) Safety and Efficacy of Bevacizumab With Hypofractionated Stereotactic Irradiation for Recurrent Malignant Gliomas. International Journal of Radiation Oncology*Biology*Physics 75:1, 156-163
CrossRef687
John W Powell, Elisabeth Dexter, Ernest M Scalzetti, Jeffrey A Bogart. (2009) Treatment advances for medically inoperable non-small-cell lung cancer: emphasis on prospective trials. The Lancet Oncology 10:9, 885-894
CrossRef688
J. Boone, R. van Hillegersberg, G. J. A. Offerhaus, P. J. van Diest, I. H. M. Borel Rinkes, F. J. W. ten Kate. (2009) Targets for molecular therapy in esophageal squamous cell carcinoma: an immunohistochemical analysis. Diseases of the Esophagus 22:6, 496-504
CrossRef689
Gregory P. Sfakianos, T. Michael Numnum, Caitlin B. Halverson, Deepa Panjeti, James E. Kendrick, J. Michael Straughn. (2009) The risk of gastrointestinal perforation and/or fistula in patients with recurrent ovarian cancer receiving bevacizumab compared to standard chemotherapy: A retrospective cohort study. Gynecologic Oncology 114:3, 424-426
CrossRef690
Nicolas Girard, Françoise Mornex. (2009) Radiotherapy for locally advanced non-small cell lung cancer. European Journal of Cancer 45, 113-125
CrossRef691
N. T. Okita, Y. Yamada, D. Takahari, Y. Hirashima, J. Matsubara, K. Kato, T. Hamaguchi, K. Shirao, Y. Shimada, H. Taniguchi, T. Shimoda. (2009) Vascular Endothelial Growth Factor Receptor Expression as a Prognostic Marker for Survival in Colorectal Cancer. Japanese Journal of Clinical Oncology 39:9, 595-600
CrossRef692
David F. Heigener. (2009) Tyrosinkinaseinhibitoren beim nichtkleinzelligen Lungenkarzinom. Onkopipeline 2:3, 80-85
CrossRef693
Wangjian Zhong, Richard Hansen, Bing Li, Yihua Cai, Carolina Salvador, Grace D. Moore, Jun Yan. (2009) Effect of Yeast-derived β-glucan in Conjunction With Bevacizumab for the Treatment of Human Lung Adenocarcinoma in Subcutaneous and Orthotopic Xenograft Models. Journal of Immunotherapy 32:7, 703-712
CrossRef694
Randeep Sangha, Primo N. Lara ., Alex A. Adjei, Paul Baas, Hak Choy, Laurie E. Gaspar, Glenwood Goss, Nagahiro Saijo, Joan H. Schiller, Everett E. Vokes, David R. Gandara. (2009) Cooperative Group Research Endeavors in Small-Cell Lung Cancer: Current and Future Directions. Clinical Lung Cancer 10:5, 322-330
CrossRef695
Leigh Ellis, Hans Hammers, Roberto Pili. (2009) Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Letters 280:2, 145-153
CrossRef696
T. Fojo, C. Grady. (2009) How Much Is Life Worth: Cetuximab, Non-Small Cell Lung Cancer, and the $440 Billion Question. JNCI Journal of the National Cancer Institute 101:15, 1044-1048
CrossRef697
William Y. Kim, Samanthi Perera, Bing Zhou, Julian Carretero, Jen Jen Yeh, Samuel A. Heathcote, Autumn L. Jackson, Petros Nikolinakos, Beatriz Ospina, George Naumov, Kathleyn A. Brandstetter, Victor J. Weigman, Sara Zaghlul, D. Neil Hayes, Robert F. Padera, John V. Heymach, Andrew L. Kung, Norman E. Sharpless, William G. Kaelin, Kwok-Kin Wong. (2009) HIF2α cooperates with RAS to promote lung tumorigenesis in mice. Journal of Clinical Investigation 119:8, 2160-2170
CrossRef698
Helen X. Chen, Jessica N. Cleck. (2009) Adverse effects of anticancer agents that target the VEGF pathway. Nature Reviews Clinical Oncology 6:8, 465-477
CrossRef699
Y Wang, C Sung, C Dartois, R Ramchandani, B P Booth, E Rock, J Gobburu. (2009) Elucidation of Relationship Between Tumor Size and Survival in Non-Small-Cell Lung Cancer Patients Can Aid Early Decision Making in Clinical Drug Development. Clinical Pharmacology & Therapeutics 86:2, 167-174
CrossRef700
Riccardo Soffietti, Wallace Akerley, Randy L. Jensen, Joachim Bischoff, Anne Constanze Regierer. (2009) The Role of Intra-cerebrospinal Fluid Treatment and Prophylaxis in Patients With Solid Tumors. Seminars in Oncology 36, S55-S68
CrossRef701
Arkadiusz Z. Dudek, Krzysztof Lesniewski-Kmak, Timothy Larson, Konstantin Dragnev, Rachel Isaksson, Vinita Gupta, Michael A. Maddaus, Robert A. Kratzke. (2009) Phase II Trial of Neoadjuvant Therapy with Carboplatin, Gemcitabine plus Thalidomide for Stages IIB and III Non-small Cell Lung Cancer. Journal of Thoracic Oncology 4:8, 969-975
CrossRef702
Mark J. McKeage, Martin Reck, Michael B. Jameson, Mark A. Rosenthal, David Gibbs, Paul N. Mainwaring, Lutz Freitag, Richard Sullivan, Joachim Von Pawel. (2009) Phase II study of ASA404 (vadimezan, 5,6-dimethylxanthenone-4-acetic acid/DMXAA) 1800mg/m2 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. Lung Cancer 65:2, 192-197
CrossRef703
Johnny Kao, Stuart Packer, Ha Linh Vu, Myron E. Schwartz, Max W. Sung, Richard G. Stock, Yeh-Chi Lo, Delphine Huang, Shu-Hsia Chen, Jamie A. Cesaretti. (2009) Phase 1 study of concurrent sunitinib and image-guided radiotherapy followed by maintenance sunitinib for patients with oligometastases. Cancer 115:15, 3571-3580
CrossRef704
Brian Z Ring, Robert S Seitz, Rodney A Beck, William J Shasteen, Alex Soltermann, Stefanie Arbogast, Francisco Robert, Marshall T Schreeder, Douglas T Ross. (2009) A novel five-antibody immunohistochemical test for subclassification of lung carcinoma. Modern Pathology 22:8, 1032-1043
CrossRef705
César Mendiola, M. Ángeles Vaz. (2009) Is capecitabine a new choice of treatment for lung adenocarcinoma? A case report involving partial response in second line of treatment and hypothesis of the biological basis. Clinical and Translational Oncology 11:8, 554-557
CrossRef706
Asahi Ito, Takashi Ishida, Hiroki Yano, Atsushi Inagaki, Susumu Suzuki, Fumihiko Sato, Hisashi Takino, Fumiko Mori, Masaki Ri, Shigeru Kusumoto, Hirokazu Komatsu, Shinsuke Iida, Hiroshi Inagaki, Ryuzo Ueda. (2009) Defucosylated anti-CCR4 monoclonal antibody exercises potent ADCC-mediated antitumor effect in the novel tumor-bearing humanized NOD/Shi-scid, IL-2Rγnull mouse model. Cancer Immunology, Immunotherapy 58:8, 1195-1206
CrossRef707
Thomas J. Lynch, David Fenton, Vera Hirsh, David Bodkin, Edward L. Middleman, Alberto Chiappori, Balazs Halmos, Reyna Favis, Hua Liu, William L. Trepicchio, Omar Eton, Frances A. Shepherd. (2009) A Randomized Phase 2 Study of Erlotinib Alone and in Combination with Bortezomib in Previously Treated Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 4:8, 1002-1009
CrossRef708
H A Burris. (2009) Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs. Oncogene 28, S4-S13
CrossRef709
J.M.L. Roodhart, M.H.G. Langenberg, L.G.M. Daenen, E.E. Voest. (2009) Translating preclinical findings of (endothelial) progenitor cell mobilization into the clinic; from bedside to bench and back. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1796:1, 41-49
CrossRef710
R.M. Eager, C.C. Cunningham, N. Senzer, D.A. Richards, R.N. Raju, B. Jones, M. Uprichard, J. Nemunaitis. (2009) Phase II Trial of Talabostat and Docetaxel in Advanced Non-small Cell Lung Cancer. Clinical Oncology 21:6, 464-472
CrossRef711
F R Hirsch. (2009) The role of genetic testing in the prediction of response to EGFR inhibitors in NSCLC. Oncogene 28, S1-S3
CrossRef712
Jared Weiss, Corey Langer. (2009) NSCLC in the Elderly—The Legacy of Therapeutic Neglect. Current Treatment Options in Oncology 10:3-4, 180-194
CrossRef713
Yuval Shaked, Emile E. Voest. (2009) Bone marrow derived cells in tumor angiogenesis and growth: are they the good, the bad or the evil?. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1796:1, 1-4
CrossRef714
Andrew S. Chi, Andrew D. Norden, Patrick Y. Wen. (2009) Antiangiogenic strategies for treatment of malignant gliomas. Neurotherapeutics 6:3, 513-526
CrossRef715
Jason A. Zell, Sai-Hong Ignatius Ou. (2009) Survival Prognostication in Non-small Cell Lung Cancer. Journal of Thoracic Oncology 4:7, 785-786
CrossRef716
Martin Mendoza, Chand Khanna. (2009) Revisiting the seed and soil in cancer metastasis. The International Journal of Biochemistry & Cell Biology 41:7, 1452-1462
CrossRef717
Nathan A. Pennell, Tarek Mekhail. (2009) Investigational agents in the management of non-small cell lung cancer. Current Oncology Reports 11:4, 275-284
CrossRef718
Mariano Provencio, Rosario García-Campelo, Dolores Isla, Javier Castro. (2009) Clinical-molecular factors predicting response and survival for tyrosine-kinase inhibitors. Clinical and Translational Oncology 11:7, 428-436
CrossRef719
Julio Sánchez De Cos Escuín. (2009) El cáncer de pulmón en España. Epidemiología, supervivencia y tratamiento actuales. Archivos de Bronconeumología 45:7, 341-348
CrossRef720
Angela M. Davies, Cheryl Ho, Laurel Beckett, Derick Lau, Sidney A. Scudder, Primo N. Lara, Natasha Perkins, David R. Gandara. (2009) Intermittent Erlotinib in Combination with Pemetrexed. Journal of Thoracic Oncology 4:7, 862-868
CrossRef721
Gerald M Higa, Jame Abraham. (2009) Biological mechanisms of bevacizumab-associated adverse events. Expert Review of Anticancer Therapy 9:7, 999-1007
CrossRef722
Atsushi Inagaki, Takashi Ishida, Hiroki Yano, Toshihiko Ishii, Shigeru Kusumoto, Asahi Ito, Masaki Ri, Fumiko Mori, Jianmin Ding, Hirokazu Komatsu, Shinsuke Iida, Ryuzo Ueda. (2009) Expression of the ULBP ligands for NKG2D by B-NHL cells plays an important role in determining their susceptibility to rituximab-induced ADCC. International Journal of Cancer 125:1, 212-221
CrossRef723
M Javle, J Yu, C Garrett, A Pande, B Kuvshinoff, A Litwin, J Phelan, J Gibbs, P Mueller. (2009) Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study. British Journal of Cancer 100:12, 1842-1845
CrossRef724
I Chau, D Cunningham. (2009) Treatment in advanced colorectal cancer: what, when and how?. British Journal of Cancer 100:11, 1704-1719
CrossRef725
Hernán Cortés-Funes. (2009) The role of antiangiogenesis therapy: Bevacizumab and beyond. Clinical and Translational Oncology 11:6, 349-355
CrossRef726
Leslie A. Fecher, Ravi K. Amaravadi, Lynn M. Schuchter, Keith T. Flaherty. (2009) Drug Targeting of Oncogenic Pathways in Melanoma. Hematology/Oncology Clinics of North America 23:3, 599-618
CrossRef727
Paul Van Houtte. (2009) Lung cancer: from staging to treatment – a summary of an international meeting. Expert Review of Respiratory Medicine 3:3, 221-225
CrossRef728
Ronan J. Kelly, Bertrand Billemont, Olivier Rixe. (2009) Renal toxicity of targeted therapies. Targeted Oncology 4:2, 121-133
CrossRef729
Stuart Salmon, Heidi Chen, Shuo Chen, Roy Herbst, Anne Tsao, Hai Tran, Alan Sandler, Dean Billheimer, Yu Shyr, Ju-Whei Lee, Pierre Massion, Julie Brahmer, Joan Schiller, David Carbone, Thao P. Dang. (2009) Classification by Mass Spectrometry Can Accurately and Reliably Predict Outcome in Patients with Non-small Cell Lung Cancer Treated with Erlotinib-Containing Regimen. Journal of Thoracic Oncology 4:6, 689-696
CrossRef730
Emilio Bajetta, Giuseppe Procopio, Sara Pusceddu, Filippo Pietrantonio, Massimo Milione, Marco Maccauro, Elena Verzoni, Valentina Guadalupi, Marco Platania. (2009) From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours. Oncology Reviews 3:2, 79-87
CrossRef731
Kelly L. Snider, Michael L. Maitland. (2009) Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors. Targeted Oncology 4:2, 67-76
CrossRef732
A. d’Onofrio, A. Gandolfi, A. Rocca. (2009) The dynamics of tumour-vasculature interaction suggests low-dose, time-dense anti-angiogenic schedulings. Cell Proliferation 42:3, 317-329
CrossRef733
Wei Wang, Yasuhiko Nishioka, Shuji Ozaki, Ali Jalili, Shinji Abe, Soji Kakiuchi, Masatoshi Kishuku, Kazuo Minakuchi, Toshio Matsumoto, Saburo Sone. (2009) HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody. Cancer Immunology, Immunotherapy 58:6, 967-976
CrossRef734
Antona J. Wagstaff, Susan J. Keam, Paul L. McCormack. (2009) Bevacizumab Plus Platinum-Based Chemotherapy. BioDrugs 23:3, 187-196
CrossRef735
Sanjaykumar Hapani, David Chu, Shenhong Wu. (2009) Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab: a meta-analysis. The Lancet Oncology 10:6, 559-568
CrossRef736
Emilio Esteban, Marta Casillas, Alejo Cassinello. (2009) Pemetrexed in first-line treatment of non-small cell lung cancer. Cancer Treatment Reviews 35:4, 364-373
CrossRef737
David M. Jackman. (2009) Current Options for Systemic Therapy in Mesothelioma. Seminars in Thoracic and Cardiovascular Surgery 21:2, 154-158
CrossRef738
Roberta Ferraldeschi, Paul Lorigan. (2009) Targeting angiogenesis in melanoma. Expert Review of Dermatology 4:3, 237-248
CrossRef739
W. L. Sun, G. Hutarew, J. Gradl, M. Gratzl, E. Heumader, H. Denz, Michael Fiegl. (2009) Bevacizumab-based combination therapy in a patient with pseudomyxoma peritonei. memo - Magazine of European Medical Oncology 2:2, 113-115
CrossRef740
Rakesh K. Jain, Dan G. Duda, Christopher G. Willett, Dushyant V. Sahani, Andrew X. Zhu, Jay S. Loeffler, Tracy T. Batchelor, A. Gregory Sorensen. (2009) Biomarkers of response and resistance to antiangiogenic therapy. Nature Reviews Clinical Oncology 6:6, 327-338
CrossRef741
Masaki Watanabe, Julie L. Boyer, Ronald G. Crystal. (2009) Genetic Delivery of Bevacizumab to Suppress Vascular Endothelial Growth Factor-Induced High-Permeability Pulmonary Edema. Human Gene Therapy 20:6, 598-610
CrossRef742
Giulio Metro, Federico Cappuzzo. (2009) New targeted therapies for non-small-cell lung cancer. Therapy 6:3, 335-350
CrossRef743
, Enriqueta Felip, Pilar Garrido, José Manuel Trigo, Marta López-Brea, Luis Paz-Ares, Mariano Provencio, Dolores Isla. (2009) SEOM guidelines for the management of non-small-cell lung cancer (NSCLC). Clinical and Translational Oncology 11:5, 284-289
CrossRef744
N.J. Dickgreber. (2009) Pemetrexed mit Cisplatin in der Erstlinientherapie des NSCLC. Der Pneumologe 6:3, 176-178
CrossRef745
C. Dreyer, E. Raymond, S. Faivre. (2009) Les thérapies ciblées et leurs indications dans les tumeurs solides. La Revue de Médecine Interne 30:5, 416-424
CrossRef746
Anne Gingery, Emma L Bahe, Jeffrey S Gilbert. (2009) Placental ischemia and breast cancer risk after preeclampsia: tying the knot. Expert Review of Anticancer Therapy 9:5, 671-681
CrossRef747
George Pentheroudakis, F.A. Greco, Nicholas Pavlidis. (2009) Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: A systematic literature review. Cancer Treatment Reviews 35:3, 221-227
CrossRef748
Camillo Porta, Cezary Szczylik. (2009) Tolerability of first-line therapy for metastatic renal cell carcinoma. Cancer Treatment Reviews 35:3, 297-307
CrossRef749
Tsuyoshi Osawa, Masashi Muramatsu, Makoto Watanabe, Masabumi Shibuya. (2009) Hypoxia and low-nutrition double stress induces aggressiveness in a murine model of melanoma. Cancer Science 100:5, 844-851
CrossRef750
H. Izzedine, S. Ederhy, F. Goldwasser, J. C. Soria, G. Milano, A. Cohen, D. Khayat, J. P. Spano. (2009) Management of hypertension in angiogenesis inhibitor-treated patients. Annals of Oncology 20:5, 807-815
CrossRef751
Sai-Hong Ignatius Ou, Coty Ho. (2009) Treatment of Advanced Lung Cancer. Clinical Pulmonary Medicine 16:3, 157-171
CrossRef752
G. D'Addario, E. Felip, . (2009) Non-small-cell lung cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Annals of Oncology 20:Supplement 4, iv68-iv70
CrossRef753
Manuela Schmidinger, Christoph C. Zielinski. (2009) Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy. Cancer Treatment Reviews 35:3, 289-296
CrossRef754
Jens Soltau, Joachim Drevs. (2009) Mode of action and clinical impact of VEGF signaling inhibitors. Expert Review of Anticancer Therapy 9:5, 649-662
CrossRef755
Cemile Dilara Savci-Heijink, Farhad Kosari, Marie-Christine Aubry, Bolette L. Caron, Zhifu Sun, Ping Yang, George Vasmatzis. (2009) The Role of Desmoglein-3 in the Diagnosis of Squamous Cell Carcinoma of the Lung. The American Journal of Pathology 174:5, 1629-1637
CrossRef756
Hatem A. Azim, Inas Elattar, Fausto R. Loberiza, Hamdy Azim, Tony Mok, Apar Kishor Ganti. (2009) Third generation triplet cytotoxic chemotherapy in advanced non-small cell lung cancer: A systematic overview. Lung Cancer 64:2, 194-198
CrossRef757
M. Scheffler, J. Wolf. (2009) Aktuelle Entwicklungen in der Bildgebung beim nichtkleinzelligen Bronchialkarzinom. Der Onkologe 15:5, 496-501
CrossRef758
Jennifer S. Temel, Joseph A. Greer, Sarah Goldberg, Paula Downes Vogel, Michael Sullivan, William F. Pirl, Thomas J. Lynch, David C. Christiani, Matthew R. Smith. (2009) A Structured Exercise Program for Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 4:5, 595-601
CrossRef759
Birgit Guldhammer Skov, Katalin Kiss, Julie Ramsted, Dorte Linnemann. (2009) A technique to improve diagnostic information from fine-needle aspirations. Cancer Cytopathology 117:2, 120-127
CrossRef760
Edward S. Kim, Ann M. Mauer, William N. William, Hai T. Tran, Diane Liu, Jack J. Lee, Paul Windt, Waun K. Hong, Everett E. Vokes, Roy S. Herbst. (2009) A phase 2 study of cetuximab in combination with docetaxel in chemotherapy-refractory/resistant patients with advanced nonsmall cell lung cancer. Cancer 115:8, 1713-1722
CrossRef761
Krishnansu S. Tewari, Bradley J. Monk. (2009) Recent Achievements and Future Developments in Advanced and Recurrent Cervical Cancer: Trials of the Gynecologic Oncology Group. Seminars in Oncology 36:2, 170-180
CrossRef762
Faina Gurevich, Mark A. Perazella. (2009) Renal Effects of Anti-angiogenesis Therapy: Update for the Internist. The American Journal of Medicine 122:4, 322-328
CrossRef763
Andrew R Reynolds, Ian R Hart, Alan R Watson, Jonathan C Welti, Rita G Silva, Stephen D Robinson, Georges Da Violante, Morgane Gourlaouen, Mishal Salih, Matt C Jones, Dylan T Jones, Garry Saunders, Vassiliki Kostourou, Françoise Perron-Sierra, Jim C Norman, Gordon C Tucker, Kairbaan M Hodivala-Dilke. (2009) Stimulation of tumor growth and angiogenesis by low concentrations of RGD-mimetic integrin inhibitors. Nature Medicine 15:4, 392-400
CrossRef764
Richard S Finn, Andrew X Zhu. (2009) Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. Expert Review of Anticancer Therapy 9:4, 503-509
CrossRef765
Renaud Mazeron, Yungan Tao, Antoine Lusinchi, Jean Bourhis. (2009) Current concepts of management in radiotherapy for head and neck squamous-cell cancer. Oral Oncology 45:4-5, 402-408
CrossRef766
Puja Gaur, Debashish Bose, Shaija Samuel, Lee M. Ellis. (2009) Targeting Tumor Angiogenesis. Seminars in Oncology 36, S12-S19
CrossRef767
Elisabeth Schellhaas, Christoph Loddenkemper, Alexander Schmittel, Heinz-J. Buhr, Uwe Pohlen. (2009) Bowel perforation in non-small cell lung cancer after bevacizumab therapy. Investigational New Drugs 27:2, 184-187
CrossRef768
Marcello Tiseo, Marco Bartolotti, Francesco Gelsomino, Andrea Ardizzoni. (2009) First-line treatment in advanced non-small-cell lung cancer: the emerging role of the histologic subtype. Expert Review of Anticancer Therapy 9:4, 425-435
CrossRef769
Ernest S. Han, Paul Lin, Mark Wakabayashi. (2009) Current Status on Biologic Therapies in the Treatment of Epithelial Ovarian Cancer. Current Treatment Options in Oncology 10:1-2, 54-66
CrossRef770
Colin J. Mooney, Govardhanan Nagaiah, Pingfu Fu, Jay K. Wasman, Matthew M. Cooney, Panos S. Savvides, Joseph A. Bokar, Afshin Dowlati, Ding Wang, Sanjiv S. Agarwala, Susan M. Flick, Paul H. Hartman, Jose D. Ortiz, Pierre N. Lavertu, Scot C. Remick. (2009) A Phase II Trial of Fosbretabulin in Advanced Anaplastic Thyroid Carcinoma and Correlation of Baseline Serum-Soluble Intracellular Adhesion Molecule-1 with Outcome. Thyroid 19:3, 233-240
CrossRef771
A.C. Backen, J. Cummings, C. Mitchell, G. Jayson, T.H. Ward, C. Dive. (2009) ‘Fit-for-purpose’ validation of SearchLight multiplex ELISAs of angiogenesis for clinical trial use. Journal of Immunological Methods 342:1-2, 106-114
CrossRef772
Efstathios Kastritis, Andreas Charidimou, Andreas Varkaris, Meletios A. Dimopoulos. (2009) Targeted therapies in multiple myeloma. Targeted Oncology 4:1, 23-36
CrossRef773
Geetika Srivastava, Vishal Rana, Suzy Wallace, Sarah Taylor, Matthew Debnam, Lei Feng, Dima Suki, Daniel Karp, David Stewart, Yun Oh. (2009) Risk of Intracranial Hemorrhage and Cerebrovascular Accidents in Non-small Cell Lung Cancer Brain Metastasis Patients. Journal of Thoracic Oncology 4:3, 333-337
CrossRef774
Said Khayyata, Shine Yun, Theresa Pasha, Bo Jian, Cindy McGrath, Gordon Yu, Prabodh Gupta, Zubair Baloch. (2009) Value of P63 and CK5/6 in distinguishing squamous cell carcinoma from adenocarcinoma in lung fine-needle aspiration specimens. Diagnostic Cytopathology 37:3, 178-183
CrossRef775
Rossana Berardi, Lorena Verdecchia, Marzia Di Pietro Paolo, Riccardo Giampieri, Mario Scartozzi, Chiara Pierantoni, Maristella Bianconi, Paola Mazzanti, Stefano Cascinu. (2009) Women and lung cancer: Clinical and molecular profiling as a determinate for treatment decisions. Critical Reviews in Oncology/Hematology 69:3, 223-236
CrossRef776
Devalingam Mahalingam, Alain Mita, Monica M. Mita, Steffan T. Nawrocki, Francis J. Giles. (2009) Targeted Therapy for Advanced Non-small Cell Lung Cancers: Historical Perspective, Current Practices, and Future Development. Current Problems in Cancer 33:2, 73-111
CrossRef777
Randeep Sangha, Primo N Lara, Philip C Mack, David R Gandara. (2009) Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier. Current Opinion in Oncology 21:2, 116-123
CrossRef778
Shadia I Jalal, Foluso O Ademuyiwa, Nasser H Hanna. (2009) The role of maintenance chemotherapy in advanced nonsmall cell lung cancer. Current Opinion in Oncology 21:2, 110-115
CrossRef779
S Janczar, JS Graham, AJW Paige, H Gabra. (2009) Targeting locoregional peritoneal dissemination in ovarian cancer. Expert Review of Obstetrics & Gynecology 4:2, 133-147
CrossRef780
Valentina Fogal, Kazuki N. Sugahara, Erkki Ruoslahti, Sven Christian. (2009) Cell surface nucleolin antagonist causes endothelial cell apoptosis and normalization of tumor vasculature. Angiogenesis 12:1, 91-100
CrossRef781
Dimiter V Tassev, Nai-Kong V Cheung. (2009) Monoclonal antibody therapies for solid tumors. Expert Opinion on Biological Therapy 9:3, 341-353
CrossRef782
Glenwood Goss, Frances A. Shepherd, Scott Laurie, Isabelle Gauthier, N. Leighl, Eric Chen, Ronald Feld, Jean Powers, Lesley Seymour. (2009) A phase I and pharmacokinetic study of daily oral cediranib, an inhibitor of vascular endothelial growth factor tyrosine kinases, in combination with cisplatin and gemcitabine in patients with advanced non-small cell lung cancer: A study of the National Cancer Institute of Canada Clinical Trials Group. European Journal of Cancer 45:5, 782-788
CrossRef783
Frank Detterbeck. (2009) What is Quality and Does it Matter?. Journal of Thoracic Oncology 4:3, 279-280
CrossRef784
Markos Leggas, Kuei-Ling Kuo, Francisco Robert, Gretchen Cloud, Mollie deShazo, Ruiwen Zhang, Mao Li, Hui Wang, Steve Davidson, John Rinehart. (2009) Intensive anti-inflammatory therapy with dexamethasone in patients with non-small cell lung cancer: effect on chemotherapy toxicity and efficacy. Cancer Chemotherapy and Pharmacology 63:4, 731-743
CrossRef785
Cesare Gridelli. (2009) Histology-based treatment: a new scenario in the management of advanced nonsmall cell lung cancer. Current Opinion in Oncology 21:2, 97-98
CrossRef786
Diane L Reidy, Laura H Tang, Leonard B Saltz. (2009) Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors. Nature Clinical Practice Oncology 6:3, 143-152
CrossRef787
Merce Jorda, Carmen Gomez-Fernandez, Monica Garcia, Fatemeh Mousavi, Gail Walker, Aldo Mejias, Gustavo Fernandez-Castro, Parvin Ganjei-Azar. (2009) P63 differentiates subtypes of nonsmall cell carcinomas of lung in cytologic samples. Cancer Cytopathology 117:1, 46-50
CrossRef788
F. Anthony Greco, Nicholas Pavlidis. (2009) Treatment for Patients With Unknown Primary Carcinoma and Unfavorable Prognostic Factors. Seminars in Oncology 36:1, 65-74
CrossRef789
L P Lefter, S Dima, M Sunamura, T Furukawa, Y Sato, M Abe, M Chivu, I Popescu, A Horii. (2009) Transcriptional silencing of ETS-1 efficiently suppresses angiogenesis of pancreatic cancer. Cancer Gene Therapy 16:2, 137-148
CrossRef790
J. Trédaniel, C. Becht, M. Bekradda, H. De Cremoux, J. Alexandre, F. Chomy, S. Szyldergemajn, Y. Yataghene, S. Culine. (2009) An open phase II trial of gemcitabine, oxaliplatin and vinorelbine combination as first-line therapy in advanced non-small cell lung cancer patients. Lung Cancer 63:2, 259-263
CrossRef791
Tawee Tanvetyanon, Ryan Murtagh, Gerold Bepler. (2009) Rupture of a Cerebral Arteriovenous Malformation in a Patient Treated with Bevacizumab. Journal of Thoracic Oncology 4:2, 268-269
CrossRef792
Thomas E. Stinchcombe, Mark A. Socinski. (2009) Treatment Paradigms for Advanced Stage Non-small Cell Lung Cancer in the Era of Multiple Lines of Therapy. Journal of Thoracic Oncology 4:2, 243-250
CrossRef793
Piotr Rutkowski, Włodzimierz Ruka. (2009) Emergency surgery in the era of molecular treatment of solid tumours. The Lancet Oncology 10:2, 157-163
CrossRef794
Thomas W. Flaig, Fernando J. Kim, Francisco G. Rosa, Kathryn Breaker, Jonathan Schoen, Paul D. Russ. (2009) Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma. Investigational New Drugs 27:1, 83-87
CrossRef795
Hossein Borghaei, Ranee Mehra, George Simon. (2009) Current issues in adjuvant chemotherapy for resected, stage IB non-small-cell lung cancer. Future Oncology 5:1, 19-22
CrossRef796
G C Kumaran, G C Jayson, A R Clamp. (2009) Antiangiogenic drugs in ovarian cancer. British Journal of Cancer 100:1, 1-7
CrossRef797
Kenji Tamura. (2009) EGFR and VEGF-targeted drugs: clinical evidence for their effects from evaluation of biomarkers. Folia Pharmacologica Japonica 133:2, 69-72
CrossRef798
Renaud Grépin, Gilles Pagès. (2009) Le Vascular Endothelial Growth Factor (VEGF) : un modèle de régulation d'expression génique et un marqueur d'agressivité tumorale. Une cible thérapeutique évidente ?. Journal de la Société de Biologie 203:2, 181-192
CrossRef799
Antonio Rossi. (2009) Non-small-cell lung cancer: targeted therapies. Therapy 6:1, 95-98
CrossRef800
Yong Li, Paul J. Cozzi. (2009) Angiogenesis as a strategic target for prostate cancer therapy. Medicinal Research Reviewsn/a-n/a
CrossRef801
Sanghoon Shin, Kwang Joo Kim, Young Joo Lee, Hye Jin Choi, Hyunki Kim, Joo Hang Kim, Byoung Chul Cho. (2009) Complete Response of Recurrent Squamous Cell Carcinoma of the Lung: Dose the Dose Matter?. Journal of Thoracic Oncology 4:1, 141-142
CrossRef802
E Hanna, J Quick, SK Libutti. (2009) The tumour microenvironment: a novel target for cancer therapy. Oral Diseases 15:1, 8-17
CrossRef803
Wei Wang, Yasuhiko Nishioka, Shuji Ozaki, Ali Jalili, Vinod Kumar Verma, Masaki Hanibuchi, Shinji Abe, Kazuo Minakuchi, Toshio Matsumoto, Saburo Sone. (2009) Chimeric and humanized anti-HM1.24 antibodies mediate antibody-dependent cellular cytotoxicity against lung cancer cells. Lung Cancer 63:1, 23-31
CrossRef804
Elia Neninger, Beatriz García Verdecia, Tania Crombet, Carmen Viada, Susana Pereda, Idrissa Leonard, Zaima Mazorra, Gladys Fleites, Marta González, Bárbara Wilkinson, Gisela González, Agustín Lage. (2009) Combining an EGF-based Cancer Vaccine With Chemotherapy in Advanced Nonsmall Cell Lung Cancer. Journal of Immunotherapy 32:1, 92-99
CrossRef805
Cesare Gridelli, Paolo Maione, Antonio Rossi, Marzia Falanga, Marianna Bareschino, Clorinda Schettino, Giuseppe Colantuoni, Ciro Guerriero, Dario Nicolella, Emanuela Rossi, Marianna Luciana Ferrara, Giovanni Palazzolo. (2009) New avenues for second-line treatment of metastatic non-small-cell lung cancer. Expert Review of Anticancer Therapy 9:1, 115-124
CrossRef806
Tony S. K. Mok, Suresh S. Ramalingam. (2009) Maintenance therapy in nonsmall-cell lung cancer : A new treatment paradigm. Cancer 115:22, 5143
CrossRef807
Anil A. Thomas, Brian I. Rini, Steven C. Campbell. (2009) Integration of surgery and systemic therapy in the management of metastatic renal cancer. Current Urology Reports 10:1, 35-41
CrossRef808
Angela M. Davies, Kari Chansky, Primo N. Lara, Paul H. Gumerlock, John Crowley, Kathy S. Albain, Stanley J. Vogel, David R. Gandara. (2009) Bortezomib Plus Gemcitabine/Carboplatin as First-Line Treatment of Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 4:1, 87-92
CrossRef809
Masashi Kusakabe, Tomoko Kutomi, Kousuke Watanabe, Noriko Emoto, Naomi Aki, Hidenori Kage, Emi Hamano, Hiroshi Kitagawa, Takahide Nagase, Atsushi Sano, Yukihiro Yoshida, Takeshi Fukami, Tomohiro Murakawa, Jun Nakajima, Shinichi Takamoto, Satoshi Ota, Masashi Fukayama, Yutaka Yatomi, Nobuya Ohishi, Daiya Takai. (2009) Identification of G0S2 as a gene frequently methylated in squamous lung cancer by combination of in silico and experimental approaches. International Journal of Cancern/a-n/a
CrossRef810
Nir Peled, Ana B Oton, Fred R Hirsch, Paul Bunn. (2009) MAGE A3 antigen-specific cancer immunotherapeutic. Immunotherapy 1:1, 19-25
CrossRef811
Aarati Ranganathan, David Lee, Sabeeha Muneer, Marissa Shrader, David R. Gandara, Primo N. Lara, Roy S. Herbst. (2009) Highlights from: The 2008 Chicago Multidisciplinary Symposium in Thoracic Oncology. Clinical Lung Cancer 10:1, 13-19
CrossRef812
Martin Reck, Lucio Crinò. (2009) Advances in anti-VEGF and anti-EGFR therapy for advanced non-small cell lung cancer. Lung Cancer 63:1, 1-9
CrossRef813
Domingo G. Perez, Vera J. Suman, Tom R. Fitch, Thomas Amatruda, Roscoe F. Morton, Shamim Z. Jilani, Costas L. Constantinou, James R. Egner, Lisa A. Kottschade, Svetomir N. Markovic. (2009) Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma. Cancer 115:1, 119-127
CrossRef814
Shunsuke Okumura, Takaaki Sasaki, Noriaki Sukou, Masao Harada, Satoshi Ohizumi, Fumihiro Motomura, Takushi Saito, Youichi Nishiura, Hiroshi Isobe, Yoshinobu Ohsaki. (2009) Phase I Study of Paclitaxel and Carboplatin Combination Chemotherapy for Elderly Patients Aged 75 Years and Over with Advanced Non-small Cell Lung Cancer. Haigan 49:2, 146-150
CrossRef815
Quynh-Thu Le, David Raben. (2009) Integrating Biologically Targeted Therapy in Head and Neck Squamous Cell Carcinomas. Seminars in Radiation Oncology 19:1, 53-62
CrossRef816
Yongping Crawford, Napoleone Ferrara. (2009) VEGF inhibition: insights from preclinical and clinical studies. Cell and Tissue Research 335:1, 261-269
CrossRef817
Rachel E Sanborn, Angela M Davies. (2009) Erlotinib: applications in therapy and current status of research. Expert Review of Clinical Pharmacology 2:1, 15-36
CrossRef818
M J McKeage, J Von Pawel, M Reck, M B Jameson, M A Rosenthal, R Sullivan, D Gibbs, P N Mainwaring, M Serke, J-J Lafitte, C Chouaid, L Freitag, E Quoix. (2008) Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. British Journal of Cancer 99:12, 2006-2012
CrossRef819
Steven A. Stacker, Marc G. Achen. (2008) From Anti-Angiogenesis to Anti-Lymphangiogenesis: Emerging Trends in Cancer Therapy. Lymphatic Research and Biology 6:3-4, 165-172
CrossRef820
Edgardo S Santos, Aurelio Castrellon, Marcelo Blaya, Luis E Raez. (2008) Controversies in the management of stage IIIA non-small-cell lung cancer. Expert Review of Anticancer Therapy 8:12, 1913-1929
CrossRef821
Ian Buysschaert, Thomas Schmidt, Carmen Roncal, Peter Carmeliet, Diether Lambrechts. (2008) Genetics, epigenetics and pharmaco-(epi)genomics in angiogenesis. Journal of Cellular and Molecular Medicine 12:6b, 2533-2551
CrossRef822
Nilesh Vora, Karen L. Reckamp. (2008) Non-Small Cell Lung Cancer in the Elderly: Defining Treatment Options. Seminars in Oncology 35:6, 590-596
CrossRef823
Yanelys Morera, Mónica Bequet-Romero, Marta Ayala, Humberto Lamdán, Else-Marie Agger, Peter Andersen, Jorge V. Gavilondo. (2008) Anti-tumoral effect of active immunotherapy in C57BL/6 mice using a recombinant human VEGF protein as antigen and three chemically unrelated adjuvants. Angiogenesis 11:4, 381-393
CrossRef824
Sandro Barni, Mary Cabiddu, F Petrelli. (2008) Toxicity of targeted therapies in elderly patients. Expert Review of Anticancer Therapy 8:12, 1965-1976
CrossRef825
Rachel E. Sanborn. (2008) Cisplatin Versus Carboplatin in NSCLC: Is There One “Best” Answer?. Current Treatment Options in Oncology 9:4-6, 326-342
CrossRef826
Taofeek K. Owonikoko, Suresh Ramalingam. (2008) The Role of Targeted Agents in the Treatment of Elderly Patients with Non-Small Cell Lung Cancer (NSCLC). Current Treatment Options in Oncology 9:4-6, 313-325
CrossRef827
P. Blanchard, B. Besse, E. Deutsch. (2008) Bevacizumab et radiothérapie. Revue des Maladies Respiratoires 25:10, 1319-1321
CrossRef828
Cesare Guida, Paolo Maione, Antonio Rossi, Marianna Bareschino, Clorinda Schettino, Domenico Barzaghi, Massimo Elmo, Cesare Gridelli. (2008) Combined chemo-radiotherapy for locally advanced non-small cell lung cancer: Current status and future development. Critical Reviews in Oncology/Hematology 68:3, 222-232
CrossRef829
Bryan J. Schneider, Gregory P. Kalemkerian, Michael J. Kraut, Antoinette J. Wozniak, Francis P. Worden, Daryn W. Smith, Wei Chen, Shirish M. Gadgeel. (2008) Phase II Study of Celecoxib and Docetaxel in Non-small Cell Lung Cancer (NSCLC) Patients with Progression after Platinum-Based Therapy. Journal of Thoracic Oncology 3:12, 1454-1459
CrossRef830
Francis Y. F. Lee, Robert Borzilleri, Craig R. Fairchild, Amrita Kamath, Richard Smykla, Robert Kramer, Gregory Vite. (2008) Preclinical discovery of ixabepilone, a highly active antineoplastic agent. Cancer Chemotherapy and Pharmacology 63:1, 157-166
CrossRef831
George R. Simon. (2008) Individualizing Chemotherapy for Non-small Cell Lung Cancer (NSCLC) in the Adjuvant and Advanced Setting: Current Status and Future Directions. Current Treatment Options in Oncology 9:4-6, 300-312
CrossRef832
Farbod Shojaei, Napoleone Ferrara. (2008) Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies. Drug Resistance Updates 11:6, 219-230
CrossRef833
Marianna Aita, Gianpiero Fasola, Carlotta Defferrari, Annalisa Brianti, Maria Giovanna Dal Bello, Alessandro Follador, Graziella Sinaccio, Paolo Pronzato, Francesco Grossi. (2008) Targeting the VEGF pathway: Antiangiogenic strategies in the treatment of non-small cell lung cancer. Critical Reviews in Oncology/Hematology 68:3, 183-196
CrossRef834
Cesare Gridelli, Antonio Rossi, Paolo Maione, Giovanni Palazzolo, Paola Claudia Sacco, Maria Anna Bareschino, Clorinda Schettino. (2008) Overview of clinical trials for lung cancer in the elderly. Aging Health 4:6, 629-642
CrossRef835
T J Price, L Lipton, J McGreivy, S McCoy, Y-N Sun, M A Rosenthal. (2008) Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours. British Journal of Cancer 99:9, 1387-1394
CrossRef836
Devalingam Mahalingam, Francis Giles. (2008) Challenges in developing targeted therapy for pancreatic adenocarcinoma. Expert Opinion on Therapeutic Targets 12:11, 1389-1401
CrossRef837
Brandon H. Tieu, Rachel E. Sanborn, Charles R. Thomas. (2008) Neoadjuvant Therapy for Resectable Non–Small Cell Lung Cancer with Mediastinal Lymph Node Involvement. Thoracic Surgery Clinics 18:4, 403-415
CrossRef838
Glen J. Weiss, Chris Kingsley. (2008) Pathway Targets to Explore in the Treatment of Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:11, 1342-1352
CrossRef839
Rogerio C. Lilenbaum, Roy S. Herbst. (2008) Advances in the Treatment of Metastatic Non–Small-Cell Lung Cancer With Chemotherapy and Targeted Agents. Clinical Pulmonary Medicine 15:6, 352-358
CrossRef840
Leon A. Adams, Andrew Mitchell, Gerry MacQuillan, Jonathon Tibballs, Rohan vanden Driesen, Luc Delriviere. (2008) Reply: Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia. Liver Transplantation 14:11, 1687-1688
CrossRef841
Francesca Elice, Jack Jacoub, Frederick R. Rickles, Anna Falanga, Francesco Rodeghiero. (2008) Hemostatic complications of angiogenesis inhibitors in cancer patients. American Journal of Hematology 83:11, 862-870
CrossRef842
Ferry ALM Eskens, Stefan Sleijfer. (2008) The use of bevacizumab in colorectal, lung, breast, renal and ovarian cancer: Where does it fit?. European Journal of Cancer 44:16, 2350-2356
CrossRef843
Rachel E. Sanborn, Brian E. Lally. (2008) Adjuvant Therapy for Non–Small Cell Lung Cancer with Mediastinal Nodal Involvement. Thoracic Surgery Clinics 18:4, 423-435
CrossRef844
Hossein Borghaei, Corey J. Langer, Michael Millenson, Karen J. Ruth, Samuel Litwin, Holly Tuttle, Judie Sylvester Seldomridge, Marc Rovito, David Mintzer, Roger Cohen, Joseph Treat. (2008) Phase II Study of Paclitaxel, Carboplatin, and Cetuximab as First Line Treatment, for Patients with Advanced Non-small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology 3:11, 1286-1292
CrossRef845
R. de Boer, Y. Humblet, J. Wolf, L. Nogova, K. Ruffert, T. Milenkova, R. Smith, A. Godwood, J. Vansteenkiste. (2008) An open-label study of vandetanib with pemetrexed in patients with previously treated non-small-cell lung cancer. Annals of Oncology 20:3, 486-491
CrossRef846
J. Ruan, K. Hajjar, S. Rafii, J. P. Leonard. (2008) Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma. Annals of Oncology 20:3, 413-424
CrossRef847
Yingcheng Lin, De Zeng, Hongbiao Wang, Wenzhao Lin, Wen Lin, Chaoqun Hong. (2008) Clinical significance of serum vascular endothelial growth factor in advanced malignant tumors. The Chinese-German Journal of Clinical Oncology 7:10, 611-614
CrossRef848
Paul Wheatley-Price, Frances A. Shepherd. (2008) Targeting Angiogenesis in the Treatment of Lung Cancer. Journal of Thoracic Oncology 3:10, 1173-1184
CrossRef849
A. Heidenreich, D. Thüer, D. Pfister. (2008) Der Stellenwert der Tageted-Therapie beim Peniskarzinom. Der Urologe 47:10, 1320-1327
CrossRef850
Bernard Escudier, Jan Cosaert, Pavel Pisa. (2008) Bevacizumab: direct anti-VEGF therapy in renal cell carcinoma. Expert Review of Anticancer Therapy 8:10, 1545-1557
CrossRef851
Josep M. Llovet, Jordi Bruix. (2008) Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48:4, 1312-1327
CrossRef852
Cesare Gridelli, Antonio Rossi, Paolo Maione. (2008) The potential role of histone deacetylase inhibitors in the treatment of non-small-cell lung cancer. Critical Reviews in Oncology/Hematology 68:1, 29-36
CrossRef853
Grace K. Dy, Alex A. Adjei. (2008) Systemic cancer therapy: Evolution over the last 60 years. Cancer 113:S7, 1857-1887
CrossRef854
Maurie Markman. (2008) The remarkable “paclitaxel story”: How many chapters remain to be written?. Gynecologic Oncology 111:1, 7-8
CrossRef855
Bruce J. Giantonio, Arlene A. Forastiere, Robert L. Comis. (2008) The Role of the Eastern Cooperative Oncology Group in Establishing Standards of Cancer Care: Over 50 Years of Progress Through Clinical Research. Seminars in Oncology 35:5, 494-506
CrossRef856
A.-C. Toffart, E. Pluquet, J.-F. Timsit, S. Diab, D. Moro-Sibilot. (2008) Cancer bronchopulmonaire et réanimation. Revue de Pneumologie Clinique 64:5, 250-256
CrossRef857
Peng H Tan, Amrit S Lota. (2008) Interaction of current cancer treatments and the immune system: implications for breast cancer therapeutics. Expert Opinion on Pharmacotherapy 9:15, 2639-2660
CrossRef858
H. Senellart, J. Bennouna. (2008) Risque thromboembolique et bevacizumab : données de la littérature et recommandations pour l’utilisation des anticoagulants et antiagrégants. Revue des Maladies Respiratoires 25:8, 1027-1030
CrossRef859
Antonius A. Miller, Xiaofei F. Wang, Lin Gu, Philip Hoffman, Jamil Khatri, Frank Dunphy, Martin J. Edelman, Michael Bolger, Everett E. Vokes, Mark R. Green. (2008) Phase II Randomized Study of Dose-Dense Docetaxel and Cisplatin Every 2 Weeks With Pegfilgrastim and Darbepoetin Alfa With and Without the Chemoprotector BNP7787 in Patients With Advanced Non-small Cell Lung Cancer (CALGB 30303). Journal of Thoracic Oncology 3:10, 1159-1165
CrossRef860
Patricia LoRusso, Elisabeth I. Heath, Jesse McGreivy, Yu-Nien Sun, Rebeca Melara, Lucy Yan, Lisa Malburg, Megan Ingram, Jeffrey Wiezorek, Li Chen, Mary Jo Pilat. (2008) Effect of coadministration of ketoconazole, a strong CYP3A4 inhibitor, on pharmacokinetics and tolerability of motesanib diphosphate (AMG 706) in patients with advanced solid tumors. Investigational New Drugs 26:5, 455-462
CrossRef861
Rebecca Suk Heist, Panos Fidias, Mark Huberman, Blair Ardman, Lecia V. Sequist, Jennifer S. Temel, Thomas J. Lynch. (2008) A Phase II Study of Oxaliplatin, Pemetrexed, and Bevacizumab in Previously Treated Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:10, 1153-1158
CrossRef862
Frank Griesinger. (2008) Das fortgeschrittene nichtkleinzellige Lungenkarzinom. best practice onkologie 3:5, 26-36
CrossRef863
Herbst, Roy S., Heymach, John V., Lippman, Scott M., . (2008) Lung Cancer. New England Journal of Medicine 359:13, 1367-1380
Full Text864
Y K Zee, T Eisen. (2008) Survival from lung cancer in England and Wales up to 2001. British Journal of Cancer 99, S43-S46
CrossRef865
Balázs Döme, Melinda Magyar. (2008) A daganatos érhálózat mint terápiás célpont nem kissejtes tüdőrákban. Magyar Onkológia 52:3, 247-259
CrossRef866
Amir T. Fathi, Julie R. Brahmer. (2008) Chemotherapy for Advanced Stage Non-Small Cell Lung Cancer. Seminars in Thoracic and Cardiovascular Surgery 20:3, 210-216
CrossRef867
Zhaohui Zhu, Fang Li. (2008) Serial PET Scans Demonstrate the Success and Limitations of Antiangiogenic Treatment in a Case of Lung Adenocarcinoma. Clinical Nuclear Medicine 33:9, 635-637
CrossRef868
M. Wislez, J. Cadranel. (2008) Place des thérapeutiques biologiques ciblées. Oncologie 10:9, 540-544
CrossRef869
Steven Attia, Anne M. Traynor, KyungMann Kim, Joseph J. Merchant, Tien Hoang, Harish G. Ahuja, Peter A. Beatty, Richard M. Hansen, Gregory A. Masters, Kurt R. Oettel, Gary R. Shapiro, Martha M. Larson, Marilyn L. Larson, Joan H. Schiller. (2008) Phase I/II Study of Vinorelbine and Exisulind as First-Line Treatment of Advanced Non-small Cell Lung Cancer in Patients at Least 70 Years Old. Journal of Thoracic Oncology 3:9, 1018-1025
CrossRef870
Maurie Markman. (2008) Mandating prospectively defined endpoints for ovarian cancer phase 2 trials: A strategy to improve the quality of gynecologic cancer clinical research. Gynecologic Oncology 110:3, 275-277
CrossRef871
Paul J. Hesketh, Kari Chansky, Antoinette J. Wozniak, Fred R. Hirsch, Anna Spreafico, James Moon, Philip C. Mack, Benjamin T. Marchello, Wilbur A. Franklin, John J. Crowley, David R. Gandara. (2008) Southwest Oncology Group Phase II Trial (S0341) of Erlotinib (OSI-774) in Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2. Journal of Thoracic Oncology 3:9, 1026-1031
CrossRef872
Josep Maria del Campo, Aleix Prat, Antonio Gil-Moreno, José Pérez, Marta Parera. (2008) Update on novel therapeutic agents for cervical cancer. Gynecologic Oncology 110:3, S72-S76
CrossRef873
C.-H. Ohlmann, E. Markert, M. Gerharz, D. Pfister, H.-P. Dienes, U. Engelmann, A. Heidenreich. (2008) Molekular getriggerte Therapie des hormonrefraktären Prostatakarzinoms. Der Urologe 47:9, 1218-1223
CrossRef874
Alexandre Bozec, François-Xavier Gros, Frédérique Penault-Llorca, Patricia Formento, Anne Cayre, Clélia Dental, Marie-Christine Etienne-Grimaldi, Jean-Louis Fischel, Gérard Milano. (2008) Vertical VEGF targeting: A combination of ligand blockade with receptor tyrosine kinase inhibition. European Journal of Cancer 44:13, 1922-1930
CrossRef875
Kai-Keen Shiu, David SP Tan, Jorge S Reis-Filho. (2008) Development of therapeutic approaches to ‘triple negative’ phenotype breast cancer. Expert Opinion on Therapeutic Targets 12:9, 1123-1137
CrossRef876
Yuval Shaked, Erik Henke, Jeanine M.L. Roodhart, Patrizia Mancuso, Marlies H.G. Langenberg, Marco Colleoni, Laura G. Daenen, Shan Man, Ping Xu, Urban Emmenegger, Terence Tang, Zhenping Zhu, Larry Witte, Robert M. Strieter, Francesco Bertolini, Emile E. Voest, Robert Benezra, Robert S. Kerbel. (2008) Rapid Chemotherapy-Induced Acute Endothelial Progenitor Cell Mobilization: Implications for Antiangiogenic Drugs as Chemosensitizing Agents. Cancer Cell 14:3, 263-273
CrossRef877
Heather Wakelee, Laveena Chhatwani. (2008) Adjuvant Chemotherapy for Resected Non-Small Cell Lung Cancer. Seminars in Thoracic and Cardiovascular Surgery 20:3, 198-203
CrossRef878
Boone Goodgame, Nirmal Veeramachaneni, Alexander Patterson, Ramaswamy Govindan. (2008) Tracheo-Esophageal Fistula with Bevacizumab after Mediastinal Radiation. Journal of Thoracic Oncology 3:9, 1080-1081
CrossRef879
Aaron P. Brown, Deborah E. Citrin, Kevin A. Camphausen. (2008) Clinical biomarkers of angiogenesis inhibition. Cancer and Metastasis Reviews 27:3, 415-434
CrossRef880
David M. Jackman, Hedy L. Kindler, Beow Y. Yeap, Panos Fidias, Ravi Salgia, Joan Lucca, Linda K. Morse, Patricia A. Ostler, Bruce E. Johnson, Pasi A. Jänne. (2008) Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma. Cancer 113:4, 808-814
CrossRef881
B. Melichar, P. Koralewski, A. Ravaud, A. Pluzanska, S. Bracarda, C. Szczylik, C. Chevreau, M. Filipek, R. Delva, E. Sevin, S. Negrier, J. McKendrick, A. Santoro, P. Pisa, B. Escudier. (2008) First-line bevacizumab combined with reduced dose interferon- 2a is active in patients with metastatic renal cell carcinoma. Annals of Oncology 19:8, 1470-1476
CrossRef882
Farbod Shojaei, Cuiling Zhong, Xiumin Wu, Lanlan Yu, Napoleone Ferrara. (2008) Role of myeloid cells in tumor angiogenesis and growth. Trends in Cell Biology 18:8, 372-378
CrossRef883
Suresh Ramalingam, Michael C. Perry, Renato V. La Rocca, David Rinaldi, Preston S. Gable, William J. Tester, Chandra P. Belani. (2008) Comparison of outcomes for elderly patients treated with weekly paclitaxel in combination with carboplatin versus the standard 3-weekly paclitaxel and carboplatin for advanced nonsmall cell lung cancer. Cancer 113:3, 542-546
CrossRef884
Emmanouel Saloustros, Vassilis Georgoulias. (2008) Docetaxel in the treatment of advanced non-small-cell lung cancer. Expert Review of Anticancer Therapy 8:8, 1207-1222
CrossRef885
Lee M. Ellis, Daniel J. Hicklin. (2008) VEGF-targeted therapy: mechanisms of anti-tumour activity. Nature Reviews Cancer 8:8, 579-591
CrossRef886
Thomas L. Sims, Regan F. Williams, Cathy Y. Ng, Shannon F. Rosati, Yunyu Spence, Andrew M. Davidoff. (2008) Bevacizumab suppresses neuroblastoma progression in the setting of minimal disease. Surgery 144:2, 269-275
CrossRef887
Nithya Ramnath, Jihnhee Yu, Nikhil I. Khushalani, Ronald H. Gottlieb, James K. Schwarz, Renuka V. Iyer, Youcef M. Rustum, Patrick J. Creaven. (2008) Scheduled administration of low dose irinotecan before gemcitabine in the second line therapy of non-small cell lung cancer: a phase II study. Anti-Cancer Drugs 19:7, 749-752
CrossRef888
Michael Boyiadzis, Kenneth A Foon. (2008) Approved monoclonal antibodies for cancer therapy. Expert Opinion on Biological Therapy 8:8, 1151-1158
CrossRef889
Cabot, Richard C.Harris, Nancy Lee, Shepard, Jo-Anne O., Rosenberg, Eric S., Cort, Alice M., Ebeling, Sally H.Peters, Christine C., Sequist, Lecia V., Settleman, Jeffrey E., Ackman, Jeanne B., Iafrate, A. John, . (2008) Case 23-2008. New England Journal of Medicine 359:4, 405-414
Full Text890
Christian Manegold. (2008) Antiangiogenic treatments of advanced non-small cell lung cancer. Targeted Oncology 3:3, 187-196
CrossRef891
R.M. Huber. (2008) Therapie des Lungenkarzinoms. Der Pneumologe 5:4, 259-266
CrossRef892
M. Reck, U. Gatzemeier. (2008) Advanced non-small cell lung cancer therapy: historical and future perspectives. Targeted Oncology 3:3, 135-147
CrossRef893
Axel Grothey, Dirk Arnold, Lee M. Ellis. (2008) Should bevacizumab be continued beyond progression in colorectal cancer?. Current Colorectal Cancer Reports 4:3, 139-143
CrossRef894
Benjamin B. Bridges, Leno Thomas, Petr F. Hausner, L. Austin Doyle, Michelle Bedor, Ruth Smith, Julie Brahmer, Martin J. Edelman. (2008) Phase II trial of gemcitabine/carboplatin followed by paclitaxel in patients with performance status=2,3 or other significant co-morbidity (HIV infection or s/p organ transplantation) in advanced non-small cell lung cancer. Lung Cancer 61:1, 61-66
CrossRef895
Rodryg Ramlau, Elisabeth Quoix, Janusz Rolski, Miklos Pless, Herve Lena, Eric Lévy, Maciej Krzakowski, Dagmar Hess, Eric Tartour, Marie-Pierre Chenard, Jean-Marc Limacher, Nadine Bizouarne, Bruce Acres, Céline Halluard, Thierry Velu. (2008) A Phase II Study of Tg4010 (Mva-Muc1-Il2) in Association with Chemotherapy in Patients with Stage III/IV Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:7, 735-744
CrossRef896
Richard W. Griffiths, Paul Lorigan, Nicholas Thatcher, Fiona H. Blackhall. (2008) Update on targeted therapies for small cell carcinoma of the lung. Targeted Oncology 3:3, 205-215
CrossRef897
H NIMEIRI, A OZA, R MORGAN, G FRIBERG, K KASZA, L FAORO, R SALGIA, W STADLER, E VOKES, G FLEMING. (2008) Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: A trial of the Chicago, PMH, and California Phase II consortia
. Gynecologic Oncology 110:1, 49-55
CrossRef898
Giorgio Vittorio Scagliotti, Giovanni Selvaggi. (2008) Targeted therapies in bronchioloalveolar carcinoma. Targeted Oncology 3:3, 197-204
CrossRef899
E. Briasoulis, G. Fountzilas, A. Bamias, M. A. Dimopoulos, N. Xiros, G. Aravantinos, E. Samantas, H. Kalofonos, T. Makatsoris, N. Mylonakis, P. Papakostas, D. Skarlos, I. Varthalitis, N. Pavlidis. (2008) Multicenter phase-II trial of irinotecan plus oxaliplatin [IROX regimen] in patients with poor-prognosis cancer of unknown primary: a hellenic cooperative oncology group study. Cancer Chemotherapy and Pharmacology 62:2, 277-284
CrossRef900
Michael S. OʼReilly. (2008) The Interaction of Radiation Therapy and Antiangiogenic Therapy. The Cancer Journal 14:4, 207-213
CrossRef901
F. Anthony Greco, Philip Bonomi, Jeffrey Crawford, Karen Kelly, Yun Oh, Wendy Halpern, Larry Lo, Gilles Gallant, Jerry Klein. (2008) Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer 61:1, 82-90
CrossRef902
Dae Ho Lee, Ji‐Youn Han, Heung Tae Kim, Sung Jin Yoon, Hong Ryull Pyo, Kwan Ho Cho, Sang‐Hoon Shin, Heon Yoo, Seung‐Hoon Lee, Jin Soo Lee. (2008) Primary chemotherapy for newly diagnosed nonsmall cell lung cancer patients with synchronous brain metastases compared with whole‐brain radiotherapy administered first. Cancer 113:1, 143-149
CrossRef903
Francesco Grossi, Cesare Gridelli, Marianna Aita, Filippo De Marinis. (2008) Identifying an optimum treatment strategy for patients with advanced non-small cell lung cancer. Critical Reviews in Oncology/Hematology 67:1, 16-26
CrossRef904
Ranjit K. Goudar, Gordana Vlahovic. (2008) Hypoxia, angiogenesis, and lung cancer. Current Oncology Reports 10:4, 277-282
CrossRef905
M. A. Villalona-Calero, G. A. Otterson, M. G. Wientjes, F. Weber, T. Bekaii-Saab, D. Young, A. J. Murgo, R. Jensen, T.-K. Yeh, Y. Wei, Y. Zhang, C. Eng, M. Grever, J. L.-S. Au. (2008) Noncytotoxic suramin as a chemosensitizer in patients with advanced non-small-cell lung cancer: a phase II study. Annals of Oncology 19:11, 1903-1909
CrossRef906
Corey J. Langer. (2008) Targeted therapy in head and neck cancer. Cancer 112:12, 2635-2645
CrossRef907
M H Strijbos, J W Gratama, J Kraan, C H Lamers, MA den Bakker, S Sleijfer. (2008) Circulating endothelial cells in oncology: pitfalls and promises. British Journal of Cancer 98:11, 1731-1735
CrossRef908
Petros Nikolinakos, John V. Heymach. (2008) The Tyrosine Kinase Inhibitor Cediranib for Non-small Cell Lung Cancer and Other Thoracic Malignancies. Journal of Thoracic Oncology 3:Supplement 2, S131-S134
CrossRef909
Rogerio C. Lilenbaum. (2008) New Horizons in Chemotherapy: Platforms for Combinations in First-Line Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:Supplement 2, S171-S174
CrossRef910
Philip A Philip. (2008) Targeting angiogenesis in pancreatic cancer. The Lancet 371:9630, 2062-2064
CrossRef911
Takashi Seto, Takeharu Yamanaka, Makiko Nakano, Mayuko Ota, Riichiroh Maruyama, Tatsuro Okamoto, Hiroshi Wataya, Kazutsugu Uematsu, Nobuhiko Seki, Kenji Eguchi, Hiroshi Semba, Yukito Ichinose. (2008) Tegafur-Uracil Plus Gemcitabine Combination Chemotherapy in Patients with Advanced Non-small Cell Lung Cancer Previously Treated with Platinum. Journal of Thoracic Oncology 3:6, 637-642
CrossRef912
George Blumenschein. (2008) Sorafenib in Lung Cancer: Clinical Developments and Future Directions. Journal of Thoracic Oncology 3:Supplement 2, S124-S127
CrossRef913
Mark A. Socinski. (2008) The Current Status and Evolving Role of Sunitinib in Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:Supplement 2, S119-S123
CrossRef914
Jean-Philippe Spano, Catherine Chodkiewicz, Joan Maurel, Ralph Wong, Harpreet Wasan, Carlo Barone, Richard Létourneau, Emilio Bajetta, Yazdi Pithavala, Paul Bycott, Peter Trask, Katherine Liau, Alejandro D Ricart, Sinil Kim, Olivier Rixe. (2008) Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. The Lancet 371:9630, 2101-2108
CrossRef915
K. N. Syrigos, A. Zalonis, E. Kotteas, Muhammad Wasif Saif. (2008) Targeted therapy for oesophageal cancer: an overview. Cancer and Metastasis Reviews 27:2, 273-288
CrossRef916
R. Bartsch, G. G. Steger. (2008) Adjuvant chemotherapy in breast cancer. memo - Magazine of European Medical Oncology 1:2, 91-98
CrossRef917
Tanguy Y. Seiwert, Ezra E.W. Cohen. (2008) Targeting Angiogenesis in Head and Neck Cancer. Seminars in Oncology 35:3, 274-285
CrossRef918
Katherine Thornton. (2008) Chemotherapeutic Management of Soft Tissue Sarcoma. Surgical Clinics of North America 88:3, 647-660
CrossRef919
Heather Wakelee. (2008) Antibodies to Vascular Endothelial Growth Factor in Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:Supplement 2, S113-S118
CrossRef920
Karen Kelly, Chao Huang. (2008) Biological Agents in Non-small Cell Lung Cancer: A Review of Recent Advances and Clinical Results with a Focus on Epidermal Growth Factor Receptor and Vascular Endothelial Growth Factor. Journal of Thoracic Oncology 3:6, 664-673
CrossRef921
Saskia E. Rademakers, Paul N. Span, Johannes H.A.M. Kaanders, Fred C.G.J. Sweep, Albert J. van der Kogel, Johan Bussink. (2008) Molecular aspects of tumour hypoxia. Molecular Oncology 2:1, 41-53
CrossRef922
Kevin T. Palka, Robbert J. Slebos, Christine H. Chung. (2008) Update on Molecular Diagnostic Tests in Head and Neck Cancer. Seminars in Oncology 35:3, 198-210
CrossRef923
Vittorio Gebbia. (2008) Does an optimal therapeutic sequence exist in advanced non-small cell lung cancer?. Expert Opinion on Pharmacotherapy 9:8, 1321-1337
CrossRef924
M. Filipits, R. Pirker. (2008) Adjuvant therapy in non-small cell lung cancer: Current status and future perspectives. memo - Magazine of European Medical Oncology 1:2, 57-60
CrossRef925
Diego Cortinovis, Paolo Bidoli, Nicoletta Zilembo, Alberto Fusi, Emilio Bajetta. (2008) Oxaliplatin doublets in non-small cell lung cancer: A literature review. Lung Cancer 60:3, 325-331
CrossRef926
Lecia V. Sequist. (2008) First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in EGFR Mutation. Journal of Thoracic Oncology 3:Supplement 2, S143-S145
CrossRef927
Felix Bokstein, Shulim Shpigel, Deborah T. Blumenthal. (2008) Treatment with bevacizumab and irinotecan for recurrent high-grade glial tumors. Cancer 112:10, 2267-2273
CrossRef928
Kerbel, Robert S., . (2008) Tumor Angiogenesis. New England Journal of Medicine 358:19, 2039-2049
Full Text929
Thomas E. Stinchcombe, Mark A. Socinski, Carrie B. Lee, D Neil Hayes, Dominic T. Moore, Richard M. Goldberg, E Claire Dees. (2008) Phase I Trial of Nanoparticle Albumin-Bound Paclitaxel in Combination with Gemcitabine in Patients with Thoracic Malignancies. Journal of Thoracic Oncology 3:5, 521-526
CrossRef930
C. Wilhelm, A. Neubauer. (2008) Molekulare Tumortherapie. Der Internist 49:5, 581-592
CrossRef931
Lynn Feun, Niramol Savaraj. (2008) Topoisomerase I inhibitors for the treatment of brain tumors. Expert Review of Anticancer Therapy 8:5, 707-716
CrossRef932
Axel Grothey, Lee M. Ellis. (2008) Targeting Angiogenesis Driven by Vascular Endothelial Growth Factors Using Antibody-Based Therapies. The Cancer Journal 14:3, 170-177
CrossRef933
Christian Manegold. (2008) Bevacizumab for the treatment of advanced non-small-cell lung cancer. Expert Review of Anticancer Therapy 8:5, 689-699
CrossRef934
Paul Lorigan, Tim Eisen, Axel Hauschild. (2008) Systemic therapy for metastatic malignant melanoma - from deeply disappointing to bright future?. Experimental Dermatology 17:5, 383-394
CrossRef935
Philip C. Mack, David R. Gandara. (2008) 2008 Highlights from: The IASLC-ESMO 1st European Lung Cancer Conference; Geneva, Switzerland; April 2008. Clinical Lung Cancer 9:3, 145-147
CrossRef936
N. V. Zhukov, S. A. Tjulandin. (2008) Targeted therapy in the treatment of solid tumors: Practice contradicts theory. Biochemistry (Moscow) 73:5, 605-618
CrossRef937
Rogerio Lilenbaum, Luis Raez, Jennifer Tseng, Leonard Seigel, Enrique Davila. (2008) Efficacy and Safety of Oxaliplatin and Gemcitabine with Bevacizumab in Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 3:5, 511-515
CrossRef938
Masabumi Shibuya. (2008) Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis. BMB Reports 41:4, 278-286
CrossRef939
Jair Bar, Amir Onn. (2008) Combined anti-proliferative and anti-angiogenic strategies for cancer. Expert Opinion on Pharmacotherapy 9:5, 701-715
CrossRef940
A.K Croker, A.L Allan. (2008) Cancer stem cells: implications for the progression and treatment of metastatic disease. Journal of Cellular and Molecular Medicine 12:2, 374-390
CrossRef941
Rakesh K. Jain. (2008) Lessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer. Nature Reviews Cancer 8:4, 309-316
CrossRef942
Volker Heinemann. (2008) Review of bevacizumab in the treatment of metastatic breast cancer. European Journal of Cancer Supplements 6:8, 13-18
CrossRef943
Edith M. Marom, Carlos H. Martinez, Mylene T. Truong, Xiudong Lei, Bradley S. Sabloff, Reginald F. Munden, Gregory W. Gladish, Roy S. Herbst, Rodolfo C. Morice, David J. Stewart, Carlos A. Jimenez, George R. Blumenschein, Amir Onn. (2008) Tumor Cavitation During Therapy with Antiangiogenesis Agents in Patients with Lung Cancer. Journal of Thoracic Oncology 3:4, 351-357
CrossRef944
Amer H. Zureikat, Mark D. McKee. (2008) Targeted Therapy for Solid Tumors: Current Status. Surgical Oncology Clinics of North America 17:2, 279-301
CrossRef945
Edurne Arriola, Israel Cañadas, Montse Arumí, Federico Rojo, Ana Rovira, Joan Albanell. (2008) Genetic changes in small cell lung carcinoma. Clinical and Translational Oncology 10:4, 189-197
CrossRef946
Katsuyuki Kiura, Kazuhiko Nakagawa, Tetsu Shinkai, Kenji Eguchi, Yuichiro Ohe, Nobuyuki Yamamoto, Masahiro Tsuboi, Soichiro Yokota, Takashi Seto, Haiyi Jiang, Kazuto Nishio, Nagahiro Saijo, Masahiro Fukuoka. (2008) A Randomized, Double-Blind, Phase IIa Dose-Finding Study of Vandetanib (ZD6474) in Japanese Patients With Non-Small Cell Lung Cancer. Journal of Thoracic Oncology 3:4, 386-393
CrossRef947
Whitney A Spannuth, Anil K Sood, Robert L Coleman. (2008) Angiogenesis as a strategic target for ovarian cancer therapy. Nature Clinical Practice Oncology 5:4, 194-204
CrossRef948
David A Reardon, Patrick Y Wen, Annick Desjardins, Tracy T Batchelor, James J Vredenburgh. (2008) Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. Expert Opinion on Biological Therapy 8:4, 541-553
CrossRef949
Enric Carcereny Costa, Núria Viñolas Segarra, Pere Gascón Vilaplana. (2008) Angiogenesis inhibitors in the treatment of non-small-cell lung cancer (NSCLC). Clinical and Translational Oncology 10:4, 198-203
CrossRef950
F. Lordick, J.R. Siewert. (2008) Bevacizumab- (Avastin®-)bedingte chirurgische Komplikationen. Der Chirurg 79:4, 356-360
CrossRef951
Kentaro Okuda, Takashi Hirose, Hiroo Ishida, Sojiro Kusumoto, Tomohide Sugiyama, Kohichi Ando, Takao Shirai, Tsukasa Ohnishi, Naoya Horichi, Tohru Ohmori, Mitsuru Adachi. (2008) Phase I study of the combination of nedaplatin and weekly paclitaxel in patients with advanced non-small cell lung cancer. Cancer Chemotherapy and Pharmacology 61:5, 829-835
CrossRef952
William E. Osai, Chaan S. Ng, Lance C. Pagliaro. (2008) Positive response to bevacizumab in a patient with metastatic, chemotherapy-refractory urothelial carcinoma. Anti-Cancer Drugs 19:4, 427-429
CrossRef953
H. K. CHEW, A. M. DAVIES, T. WUN, D. HARVEY, H. ZHOU, R. H. WHITE. (2008) The incidence of venous thromboembolism among patients with primary lung cancer. Journal of Thrombosis and Haemostasis 6:4, 601-608
CrossRef954
F. Trotta, G. Apolone, S. Garattini, G. Tafuri. (2008) Stopping a trial early in oncology: for patients or for industry?. Annals of Oncology 19:7, 1347-1353
CrossRef955
Claire Louise Cole, Gordon C Jayson. (2008) Oligosaccharides as anti-angiogenic agents. Expert Opinion on Biological Therapy 8:3, 351-362
CrossRef956
Cesare Gridelli. (2008) Targeted therapy developments in the treatment of non-small cell lung cancer: a promising but long and winding road. Current Opinion in Oncology 20:2, 145-147
CrossRef957
Martin Gutierrez, Giuseppe Giaccone. (2008) Antiangiogenic therapy in nonsmall cell lung cancer. Current Opinion in Oncology 20:2, 176-182
CrossRef958
Kristen N. Ganjoo, Annette M. Moore, Attilio Orazi, Joy A. Sen, Cynthia S. Johnson, Caroline S. An. (2008) The importance of angiogenesis markers in the outcome of patients with diffuse large B cell lymphoma: a retrospective study of 97 patients. Journal of Cancer Research and Clinical Oncology 134:3, 381-387
CrossRef959
Masaki Watanabe, Julie L. Boyer, Neil R. Hackett, Jianping Qiu, Ronald G. Crystal. (2008) Gene Delivery of the Murine Equivalent of Bevacizumab (Avastin), an Anti-Vascular Endothelial Growth Factor Monoclonal Antibody, to Suppress Growth of Human Tumors in Immunodeficient Mice. Human Gene Therapy 19:3, 300-310
CrossRef960
A. R. John, S. R. Bramhall, M. C. Eggo. (2008) Antiangiogenic therapy and surgical practice. British Journal of Surgery 95:3, 281-293
CrossRef961
Richard Bell, David Cameron. (2008) Bevacizumab: the first anti-angiogenic agent approved for the treatment of metastatic breast cancer. European Journal of Cancer Supplements 6:6, 1-6
CrossRef962
F. Grossi, A. Brianti, C. Defferrari, P. Pronzato. (2008) Chemotherapy plus bevacizumab in the first-line treatment of non-small cell lung cancer: benefits, risks and limitations. memo - Magazine of European Medical Oncology 1:1, 13-16
CrossRef963
Bobbak Vahid, Paul E. Marik. (2008) Pulmonary Complications of Novel Antineoplastic Agents for Hematologic Malignancies. Clinical Pulmonary Medicine 15:2, 71-80
CrossRef964
Eri Taguchi, Kazuhide Nakamura, Toru Miura, Masabumi Shibuya, Toshiyuki Isoe. (2008) Anti-tumor activity and tumor vessel normalization by the vascular endothelial growth factor receptor tyrosine kinase inhibitor KRN951 in a rat peritoneal disseminated tumor model. Cancer Science 99:3, 623-630
CrossRef965
David Miles. (2008) Management of toxicity in patients receiving therapy with bevacizumab. European Journal of Cancer Supplements 6:6, 29-39
CrossRef966
Eric Holmgren. (2008) Are Phase 2 screening trials in oncology obsolete?. Statistics in Medicine 27:4, 556-567
CrossRef967
A. S.R. Maharaj, T. E. Walshe, M. Saint-Geniez, S. Venkatesha, A. E. Maldonado, N. C. Himes, K. S. Matharu, S. A. Karumanchi, P. A. D'Amore. (2008) VEGF and TGF- are required for the maintenance of the choroid plexus and ependyma. Journal of Experimental Medicine 205:2, 491-501
CrossRef968
Lecia V. Sequist, Thomas J. Lynch. (2008) EGFR Tyrosine Kinase Inhibitors in Lung Cancer: An Evolving Story. Annual Review of Medicine 59:1, 429-442
CrossRef969
Andrea L Harzstark, Charles J Ryan. (2008) Therapies in development for castrate-resistant prostate cancer. Expert Review of Anticancer Therapy 8:2, 259-268
CrossRef970
Andrew Mitchell, Leon A. Adams, Gerry MacQuillan, Jon Tibballs, Rohan vanden Driesen, Luc Delriviere. (2008) Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia. Liver Transplantation 14:2, 210-213
CrossRef971
Zhen-wei Cai, Donna Wei, Robert M. Borzilleri, Ligang Qian, Amrita Kamath, Steven Mortillo, Barri Wautlet, Benjamin J. Henley, Robert Jeyaseelan, John Tokarski, John T. Hunt, Rajeev S. Bhide, Joseph Fargnoli, Louis J. Lombardo. (2008) Synthesis, SAR, and Evaluation of 4-[2,4-Difluoro-5-(cyclopropylcarbamoyl)phenylamino]pyrrolo[2,1-f][1,2,4]triazine-based VEGFR-2 kinase inhibitors. Bioorganic & Medicinal Chemistry Letters 18:4, 1354-1358
CrossRef972
Pawel Zwolak, Arkadiusz Z. Dudek, Vidya D. Bodempudi, Julia Nguyen, Robert P. Hebbel, Nathan J. Gallus, Marna E. Ericson, Michael J. Goblirsch, Denis R. Clohisy. (2008) Local irradiation in combination with bevacizumab enhances radiation control of bone destruction and cancer-induced pain in a model of bone metastases. International Journal of Cancer 122:3, 681-688
CrossRef973
D Yoshikawa, H Ojima, M Iwasaki, N Hiraoka, T Kosuge, S Kasai, S Hirohashi, T Shibata. (2008) Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. British Journal of Cancer 98:2, 418-425
CrossRef974
Angela M. Davies, Christopher Ruel, Primo N. Lara, Derick H. Lau, Paul H. Gumerlock, Richard Bold, Stephen Shibata, Heinz-Josef Lenz, David P. Schenkein, David R. Gandara. (2008) The Proteasome Inhibitor Bortezomib in Combination with Gemcitabine and Carboplatin in Advanced Non-small Cell Lung Cancer: A California Cancer Consortium Phase I Study. Journal of Thoracic Oncology 3:1, 68-74
CrossRef975
Katsuyuki Kiura, Nagio Takigawa, Isao Oze, Masayuki Yasugi, Nobuaki Ochi, Daijiro Harada, Mitsune Tanimoto. (2008) Okayama Igakkai Zasshi (Journal of Okayama Medical Association) 119:3, 285-292
CrossRef976
Fiona J Collinson, Geoff D Hall, Timothy J Perren, Gordon C Jayson. (2008) Development of antiangiogenic agents for ovarian cancer. Expert Review of Anticancer Therapy 8:1, 21-32
CrossRef977
Gwo-Che Huang, Lee-Jen Chen, Hung-Chang Liu, Yu-Jen Chen. (2008) Development of Vitreous Haemorrhage during Treatment with Bevacizumab for Metastatic Rectal Cancer. Clinical Drug Investigation 28:8, 523-526
CrossRef978
N.H. Hanna. (2008) Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer. Yearbook of Medicine 2008, 209-211
CrossRef979
Foluso O Ademuyiwa, Nasser Hanna. (2008) Cetuximab in non-small cell lung cancer. Expert Opinion on Biological Therapy 8:1, 107-113
CrossRef980
Konstantinos Anargyrou, Meletios-Athanassios Dimopoulos, Orhan Sezer, Evangelos Terpos. (2008) Novel anti-myeloma agents and angiogenesis. Leukemia & Lymphoma 49:4, 677-689
CrossRef981
E.L. Mayer. (2008) Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer. Breast Diseases: A Year Book Quarterly 19:3, 272-273
CrossRef982
Francesco Di Costanzo, Francesca Mazzoni, Marinella Micol Mela, Lorenzo Antonuzzo, Daniele Checcacci, Matilde Saggese, Federica Di Costanzo. (2008) Bevacizumab in Non-Small Cell Lung Cancer. Drugs 68:6, 737-746
CrossRef983
Andrea L Harzstark, Charles J Ryan. (2008) Novel therapeutic strategies in development for prostate cancer. Expert Opinion on Investigational Drugs 17:1, 13-22
CrossRef984
S N Metodieva. (2008) Angiogenesis and Non Small Cell Lung Cancer. Balkan Journal of Medical Genetics 11:2, 3-10
CrossRef985
María Sereno, Antonella Brunello, Alberto Chiappori, Jorge Barriuso, Enrique Casado, Cristóbal Belda, Javier Castro, Jaime Feliu, Manuel González-Barón. (2008) Cardiac toxicity: old and new issues in anti-cancer drugs. Clinical and Translational Oncology 10:1, 35-46
CrossRef986
Seung-Ah Yoo, Seung-Ki Kwok, Wan-Uk Kim. (2008) Proinflammatory Role of Vascular Endothelial Growth Factor in the Pathogenesis of Rheumatoid Arthritis: Prospects for Therapeutic Intervention. Mediators of Inflammation 2008, 1-6
CrossRef987
Kye Young Lee. (2008) Targeted Therapy of Lung Cancer. Journal of the Korean Medical Association 51:5, 483
CrossRef988
Jonathan Friedberg, Eric Jacobsen, Donna Neuberg, Jeffrey Kutok, Olivier Munoz, Vassiliki Boussiotis, Hazel Reynolds, David Fisher, Agnieszka Szot, Annick Van Den Abbeele, Arnold Freedman. (2008) Targeting the follicular lymphoma microenvironment through blockade of TNFα with etanercept. Leukemia & Lymphoma 49:5, 902-909
CrossRef989
Richard L. Schilsky, David Geary, Linda Skoog, Apurva A. Desai, Joyce Valickas, Bee-Lian Chen, Eric Masson, Dirk Laurent, Cynthia Pendowski, Everett E. Vokes, Mark J. Ratain. (2008) Phase I and pharmacokinetic study of vatalanib plus capecitabine in patients with advanced cancer. Targeted Oncology 3:1, 3-11
CrossRef990
Miller, Kathy, Wang, Molin, Gralow, Julie, Dickler, Maura, Cobleigh, Melody, Perez, Edith A., Shenkier, Tamara, Cella, David, Davidson, Nancy E., . (2007) Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer. New England Journal of Medicine 357:26, 2666-2676
Full Text991
Barbara A. Weir, Michele S. Woo, Gad Getz, Sven Perner, Li Ding, Rameen Beroukhim, William M. Lin, Michael A. Province, Aldi Kraja, Laura A. Johnson, Kinjal Shah, Mitsuo Sato, Roman K. Thomas, Justine A. Barletta, Ingrid B. Borecki, Stephen Broderick, Andrew C. Chang, Derek Y. Chiang, Lucian R. Chirieac, Jeonghee Cho, Yoshitaka Fujii, Adi F. Gazdar, Thomas Giordano, Heidi Greulich, Megan Hanna, Bruce E. Johnson, Mark G. Kris, Alex Lash, Ling Lin, Neal Lindeman, Elaine R. Mardis, John D. McPherson, John D. Minna, Margaret B. Morgan, Mark Nadel, Mark B. Orringer, John R. Osborne, Brad Ozenberger, Alex H. Ramos, James Robinson, Jack A. Roth, Valerie Rusch, Hidefumi Sasaki, Frances Shepherd, Carrie Sougnez, Margaret R. Spitz, Ming-Sound Tsao, David Twomey, Roel G. W. Verhaak, George M. Weinstock, David A. Wheeler, Wendy Winckler, Akihiko Yoshizawa, Soyoung Yu, Maureen F. Zakowski, Qunyuan Zhang, David G. Beer, Ignacio I. Wistuba, Mark A. Watson, Levi A. Garraway, Marc Ladanyi, William D. Travis, William Pao, Mark A. Rubin, Stacey B. Gabriel, Richard A. Gibbs, Harold E. Varmus, Richard K. Wilson, Eric S. Lander, Matthew Meyerson. (2007) Characterizing the cancer genome in lung adenocarcinoma. Nature 450:7171, 893-898
CrossRef992
Sylke Nagel, Raffaele Califano, Nicholas Thatcher, Fiona Blackhall. (2007) Gemcitabine and carboplatin in combination for the treatment of advanced, metastatic, non-small cell lung cancer. Expert Opinion on Pharmacotherapy 8:18, 3265-3275
CrossRef993
Matthias Kirsch, Rafael Allende, Peter Black, Gabriele Schackert. (2007) Endogenous growth inhibition of angiogenesis in brain tumors. Cancer and Metastasis Reviews 26:3-4, 469-479
CrossRef994
Jan Pander, Hans Gelderblom, Henk-Jan Guchelaar. (2007) Pharmacogenetics of EGFR and VEGF inhibition. Drug Discovery Today 12:23-24, 1054-1060
CrossRef995
Lynn T. Tanoue, Scott Gettinger. (2007) Treatment of Lung Cancer in Older Patients. Clinics in Chest Medicine 28:4, 735-749
CrossRef996
Klaus Podar, Paul G. Richardson, Teru Hideshima, Dharminder Chauhan, Kenneth C. Anderson. (2007) The malignant clone and the bone-marrow environment. Best Practice & Research Clinical Haematology 20:4, 597-612
CrossRef997
Marcello Tiseo, Andrea Ardizzoni. (2007) Cisplatin or carboplatin in the treatment of non-small cell lung cancer: a comprehensive review. Oncology Reviews 1:3, 162-169
CrossRef998
Vicki L. Keedy, Alan B. Sandler. (2007) Inhibition of angiogenesis in the treatment of non-small cell lung cancer. Cancer Science 98:12, 1825-1830
CrossRef999
Bernard Escudier, Anna Pluzanska, Piotr Koralewski, Alain Ravaud, Sergio Bracarda, Cezary Szczylik, Christine Chevreau, Marek Filipek, Bohuslav Melichar, Emilio Bajetta, Vera Gorbunova, Jacques-Olivier Bay, Istvan Bodrogi, Agnieszka Jagiello-Gruszfeld, Nicola Moore. (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. The Lancet 370:9605, 2103-2111
CrossRef1000
Ahmed Ashour Ahmed, Anthony D. Mills, Ashraf E.K. Ibrahim, Jillian Temple, Cherie Blenkiron, Maria Vias, Charlie E. Massie, N. Gopalakrishna Iyer, Adam McGeoch, Robin Crawford, Barbara Nicke, Julian Downward, Charles Swanton, Stephen D. Bell, Helena M. Earl, Ronald A. Laskey, Carlos Caldas, James D. Brenton. (2007) The Extracellular Matrix Protein TGFBI Induces Microtubule Stabilization and Sensitizes Ovarian Cancers to Paclitaxel. Cancer Cell 12:6, 514-527
CrossRef1001
Ying Chun Shen, Chiun Hsu, Ann Lii Cheng. (2007) Molecular targeted therapy for advanced hepatocellular carcinoma. Targeted Oncology 2:4, 199-210
CrossRef1002
August Zabernigg. (2007) Neues in der Behandlung des nicht-kleinzelligen Bronchialkarzinoms im Stadium IIIB (Pleuraerguss) und IV. Wiener Medizinische Wochenschrift 157:21-22, 536-539
CrossRef1003
Georg Pall, Wolfgang Hilbe. (2007) "Targeted Therapies" beim NSCLC – Gegenwart und Zukunft. Wiener Medizinische Wochenschrift 157:21-22, 545-553
CrossRef1004
Mark N. Kirstein, Katie M. Wieman, Brent W. Williams, James E. Fisher, Paul H. Marker, Chap T. Le, Douglas Yee, Robert A. Kratzke. (2007) Short versus continuous gemcitabine treatment of non-small cell lung cancer in an in vitro cell culture bioreactor system. Lung Cancer 58:2, 196-204
CrossRef1005
Antonio Rossi, Paolo Maione, Carmine Ferrara, Filomena Gaizo, Ciro Guerriero, Dario Nicolella, Giovanni Palazzolo, Marzia Falanga, Giuseppe Colantuoni, Cesare Gridelli. (2007) New angiogenic agents and non-small cell lung cancer: current results and future development. Targeted Oncology 2:4, 211-223
CrossRef1006
Norbert Hasenöhrl. (2007) Bevacizumab in der First-Line-Therapie des fortgeschrittenen NSCLC. Wiener Medizinische Wochenschrift 157:21-22, 576-578
CrossRef1007
Ana R. Quesada, Miguel Ángel Medina, Emilio Alba. (2007) Playing only one instrument may be not enough: Limitations and future of the antiangiogenic treatment of cancer. BioEssays 29:11, 1159-1168
CrossRef1008
Ferdinand Ploner. (2007) NSCLC: Update der 2nd line Therapie nach ASCO 2007. Wiener Medizinische Wochenschrift 157:21-22, 540-544
CrossRef1009
Farbod Shojaei, Napoleone Ferrara. (2007) Antiangiogenic Therapy for Cancer: An Update. The Cancer Journal 13:6, 345-348
CrossRef1010
Naomi B. Haas, Robert G. Uzzo. (2007) Tyrosine Kinase Inhibitors and Anti-Angiogenic Therapies in Kidney Cancer. Current Treatment Options in Oncology 8:3, 211-226
CrossRef1011
Fumihiro Tanaka. (2007) UFT (Tegafur and Uracil) as Postoperative Adjuvant Chemotherapy for Solid Tumors (Carcinoma of the Lung, Stomach, Colon/Rectum, and Breast): Clinical Evidence, Mechanism of Action, and Future Direction. Surgery Today 37:11, 923-943
CrossRef1012
Bharat B. Aggarwal, Gautam Sethi, Veera Baladandayuthapani, Sunil Krishnan, Shishir Shishodia. (2007) Targeting cell signaling pathways for drug discovery: An old lock needs a new key. Journal of Cellular Biochemistry 102:3, 580-592
CrossRef1013
O. Tredan, C. M. Galmarini, K. Patel, I. F. Tannock. (2007) Drug Resistance and the Solid Tumor Microenvironment. JNCI Journal of the National Cancer Institute 99:19, 1441-1454
CrossRef1014
E. Bergot, N. Richard, G. Zalcman. (2007) Mécanismes d’action des thérapeutiques ciblées… et mécanismes de résistance. Revue des Maladies Respiratoires 24:8, 180-187
CrossRef1015
É. Lemarié. (2007) Cancer bronchique non à petites cellules de stade IV : la première ligne en 2007. Revue des Maladies Respiratoires 24:8, 101-107
CrossRef1016
Sophie Sun, Joan H. Schiller, Monica Spinola, John D. Minna. (2007) New molecularly targeted therapies for lung cancer. Journal of Clinical Investigation 117:10, 2740-2750
CrossRef1017
Brian I Rini. (2007) Sunitinib. Expert Opinion on Pharmacotherapy 8:14, 2359-2369
CrossRef1018
Eirik Sundlisæter, Aly Dicko, Per Øystein Sakariassen, Karl Sondenaa, Per Øyvind Enger, Rolf Bjerkvig. (2007) Lymphangiogenesis in colorectal cancer—Prognostic and therapeutic aspects. International Journal of Cancer 121:7, 1401-1409
CrossRef1019
Cesare Gridelli. (2007) Elderly lung cancer patients: what treatment strategies?. Expert Review of Anticancer Therapy 7:10, 1331-1334
CrossRef1020
Daniel B. Costa, Susumu Kobayashi, Daniel G. Tenen, Mark S. Huberman. (2007) Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers. Lung Cancer 58:1, 95-103
CrossRef1021
Glen J. Weiss, Everett E. Vokes, Paul A. Bunn, Lyn Magree, Jason Rusk, Don Albert, Karen Kelly. (2007) Docetaxel and Exisulind in Previously Treated Non-small Cell Lung Cancer (NSCLC) Patients: A Multicenter, Phase II Clinical Trial. Journal of Thoracic Oncology 2:10, 933-938
CrossRef1022
Minggui Pan, Monica Santamaria, David B Wollman. (2007) CNS response after erlotinib therapy in a patient with metastatic NSCLC with an EGFR mutation. Nature Clinical Practice Oncology 4:10, 603-607
CrossRef1023
C.-C. Lin, K. P. Papadopoulos. (2007) Novel targeted therapies for advanced esophageal cancer. Diseases of the Esophagus 20:5, 365-371
CrossRef1024
Mark R. Green, Afshin Dowlati, Lalitha Yellamraju, Laura Daniels, Joanne Willey, Michele Andrews, Richard Leff. (2007) Irinotecan-Cisplatin Therapy for Patients with Extensive-Stage Small Cell Lung Cancer: Use Patterns among American Medical Oncologists 2000???2006. Journal of Thoracic Oncology 2:10, 953-956
CrossRef1025
Manrique Alvarez, Eloy Roman, Edgardo S Santos, Luis E Raez. (2007) New targets for non-small-cell lung cancer therapy. Expert Review of Anticancer Therapy 7:10, 1423-1437
CrossRef1026
B. Mennecier. (2007) Place actuelle des anti-angiogéniques dans le traitement des cancers bronchiques primitifs. Revue des Maladies Respiratoires 24:8, 198-205
CrossRef1027
H Kimura, M Suminoe, K Kasahara, T Sone, T Araya, S Tamori, F Koizumi, K Nishio, K Miyamoto, M Fujimura, S Nakao. (2007) Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). British Journal of Cancer 97:6, 778-784
CrossRef1028
Patrick Terheyden, Maja Ann Hofmann, M. Weininger, Eva-B. Bröcker, Jürgen C. Becker. (2007) Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma. Journal of Cancer Research and Clinical Oncology 133:11, 897-901
CrossRef1029
Camillo Porta. (2007) ASCO 2007: “Translating Research into Practice”. Report from the 34th annual meeting of the American Society of Clinical Oncology. Oncology Reviews 1:2, 65-72
CrossRef1030
Willem J van Heeckeren, Sharon L Sanborn, Ajita Narayan, Matthew M Cooney, Keith R McCrae, Alvin H Schmaier, Scot C Remick. (2007) Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis. Current Opinion in Hematology 14:5, 468-480
CrossRef1031
F. Anthony Greco, David R. Spigel, Michel E. Kuzur, Dianna Shipley, James R. Gray, Dana S. Thompson, Howard A. Burris, Denise A. Yardley, Asim Pati, Charles D. Webb, Jitendra G. Gandhi, John D. Hainsworth. (2007) Paclitaxel/Carboplatin/Gemcitabine Versus Gemcitabine/Vinorelbine in Advanced Non–Small-Cell Lung Cancer: A Phase II/III Study of the Minnie Pearl Cancer Research Network. Clinical Lung Cancer 8:8, 483-487
CrossRef1032
Aarati Ranganathan, David Lee, David R. Gandara, Primo N. Lara. (2007) 2007 Highlights from: the 43rd Annual Meeting of the American Society of Clinical Oncology Chicago, IL; June 2007. Clinical Lung Cancer 8:8, 468-475
CrossRef1033
Arindel S.R. Maharaj, Patricia A. D'Amore. (2007) Roles for VEGF in the adult. Microvascular Research 74:2-3, 100-113
CrossRef1034
Maria Q. Baggstrom, Thomas E. Stinchcombe, Daniel B. Fried, Charles Poole, Thomas A. Hensing, Mark A. Socinski. (2007) Third-Generation Chemotherapy Agents in the Treatment of Advanced Non-small Cell Lung Cancer: A Meta-Analysis. Journal of Thoracic Oncology 2:9, 845-853
CrossRef1035
Peter C. Black, Piyush K. Agarwal, Colin P.N. Dinney. (2007) Targeted therapies in bladder cancer—an update. Urologic Oncology: Seminars and Original Investigations 25:5, 433-438
CrossRef1036
Enriqueta Felip, Mariacarmela Santarpia, Rafael Rosell. (2007) Emerging drugs for non-small-cell lung cancer. Expert Opinion on Emerging Drugs 12:3, 449-460
CrossRef1037
Naomi B. Haas, Robert G. Uzzo. (2007) Targeted therapies for kidney cancer in urologic practice. Urologic Oncology: Seminars and Original Investigations 25:5, 420-432
CrossRef1038
Wenfang Shi, Cunye Qu, Qijun Qian. (2007) Trends in therapeutic monoclonal antibodies of cancer. Expert Opinion on Therapeutic Patents 17:9, 1047-1059
CrossRef1039
Maryam B. Lustberg, Martin J. Edelman. (2007) Optimal Duration of Chemotherapy in Advanced Non-Small Cell Lung Cancer. Current Treatment Options in Oncology 8:1, 38-46
CrossRef1040
Thomas E. Stinchcombe, Mark A. Socinski, Christine M. Walko, Bert H. O’Neil, Frances A. Collichio, Anastasia Ivanova, Hua Mu, Michael J. Hawkins, Richard M. Goldberg, Celeste Lindley, E. Claire Dees. (2007) Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumors. Cancer Chemotherapy and Pharmacology 60:5, 759-766
CrossRef1041
Elwyn Cabebe, Heather Wakelee. (2007) Role of Anti-angiogenesis Agents in Treating NSCLC: Focus on Bevacizumab and VEGFR Tyrosine Kinase Inhibitors. Current Treatment Options in Oncology 8:1, 15-27
CrossRef1042
Giovanni Selvaggi, Giorgio Vittorio Scagliotti. (2007) Perspectives in adjuvant chemotherapy in NSCLC. Expert Review of Respiratory Medicine 1:1, 99-110
CrossRef1043
James R. Jett. (2007) Pulmonary toxicity of therapy. Journal of Thoracic Oncology 2:Supplement 4, S276-S277
CrossRef1044
Rakesh K. Jain, Emmanuelle di Tomaso, Dan G. Duda, Jay S. Loeffler, A. Gregory Sorensen, Tracy T. Batchelor. (2007) Angiogenesis in brain tumours. Nature Reviews Neuroscience 8:8, 610-622
CrossRef1045
David H. Johnson. (2007) Advances in Management of NSCLC - Advances in Chemotherapy. Journal of Thoracic Oncology 2:Supplement 4, S145-S146
CrossRef1046
Lloyd Kelland. (2007) The resurgence of platinum-based cancer chemotherapy. Nature Reviews Cancer 7:8, 573-584
CrossRef1047
Y Nieto, J Woods, F Nawaz, A Baron, R B Jones, E J Shpall, S Nawaz. (2007) Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy. British Journal of Cancer 97:3, 391-397
CrossRef1048
Gérard Tobelem. (2007) VEGF: a key therapeutic target for the treatment of cancer-insights into its role and pharmacological inhibition. Targeted Oncology 2:3, 153-164
CrossRef1049
Francesco Grossi, Marianna Aita. (2007) Bevacizumab and non-small-cell lung cancer. Expert Opinion on Biological Therapy 7:7, 1107-1119
CrossRef1050
Christopher G. Azzoli, Lee M. Krug, Vincent A. Miller, Naiyer A. Rizvi, Mark G. Kris, Megan Dunne, Amy Farmer, Barbara Pizzo, Leslie Tyson, Teresa Seeger, Barbara Coleman, Erin Moore, Lauren Lastinger, Ennapadam Venkatraman, Charles M. Rudin. (2007) A Phase II Tolerability Study of Cisplatin Plus Docetaxel as Adjuvant Chemotherapy for Resected Non-small Cell Lung Cancer. Journal of Thoracic Oncology 2:7, 638-644
CrossRef1051
Wah K. LAM, D Neil WATKINS. (2007) Lung cancer: Future directions. Respirology 12:4, 471-477
CrossRef1052
Quoc T. Ho, Calvin J. Kuo. (2007) Vascular endothelial growth factor: Biology and therapeutic applications. The International Journal of Biochemistry & Cell Biology 39:7-8, 1349-1357
CrossRef1053
T Kamba, D M McDonald. (2007) Mechanisms of adverse effects of anti-VEGF therapy for cancer. British Journal of Cancer 96:12, 1788-1795
CrossRef1054
C. G. Azzoli, M. G. Kris, D. G. Pfister. (2007) Cisplatin Versus Carboplatin for Patients With Metastatic Non-Small-Cell Lung Cancer--An Old Rivalry Renewed. JNCI Journal of the National Cancer Institute 99:11, 828-829
CrossRef1055
Lloyd Kelland. (2007) Broadening the clinical use of platinum drug–based chemotherapy with new analogues. Expert Opinion on Investigational Drugs 16:7, 1009-1021
CrossRef1056
P. Bonniaud. (2007) VEGF, une puissante molécule dans l’air du temps. Revue des Maladies Respiratoires 24, 18-19
CrossRef1057
Dan G. Duda, Tracy T. Batchelor, Christopher G. Willett, Rakesh K. Jain. (2007) VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. Trends in Molecular Medicine 13:6, 223-230
CrossRef1058
Young-Jae Cho, Septimiu D. Murgu, Henri G. Colt. (2007) Bronchoscopy for bevacizumab-related hemoptysis. Lung Cancer 56:3, 465-468
CrossRef1059
Paul J. Hesketh, Rogerio C. Lilenbaum, Kari Chansky, Afshin Dowlati, Patricia Graham, Robert A. Chapman, John J. Crowley, David R. Gandara. (2007) Chemotherapy in Patients ???80 with Advanced Non-small Cell Lung Cancer: Combined Results from SWOG 0027 and LUN 6. Journal of Thoracic Oncology 2:6, 494-498
CrossRef1060
Nathan A Pennell, Lecia V Sequist. (2007) Assessing the roles of EGFR gene copy number, protein expression and mutation in predicting outcomes in non-small-cell lung cancer after treatment with EGFR inhibitors. Biomarkers in Medicine 1:1, 203-207
CrossRef1061
Jhanelle Gray, John Murren, Anupama Sharma, Scott Kelley, Frank Detterbeck, Gerold Bepler. (2007) Perforated Viscus in a Patient with Non-small Cell Lung Cancer Receiving Bevacizumab. Journal of Thoracic Oncology 2:6, 571-573
CrossRef1062
T E Stinchcombe, M A Socinski. (2007) Bevacizumab in the treatment of non-small-cell lung cancer. Oncogene 26:25, 3691-3698
CrossRef1063
Sophie Sun, Joan H. Schiller. (2007) Angiogenesis inhibitors in the treatment of lung cancer. Critical Reviews in Oncology/Hematology 62:2, 93-104
CrossRef1064
T Macarulla, J Tabernero. 2007. Safety of targeted therapies. , 141-155.
CrossRef1065
Antonius A. Miller, Doug Case, Michele Harmon, Paul Savage, Glenn Lesser, David Hurd, Susan A. Melin. (2007) Phase I Study of Lenalidomide in Solid Tumors. Journal of Thoracic Oncology 2:5, 445-449
CrossRef1066
Sarita Dubey, Ravi Salgia. 2007. Antiangiogenic Therapy for Lung Cancer: Antibodies and Other Novel Agents. , 73-80.
CrossRef1067
Andrea Ardizzoni, Marcello Tiseo. (2007) Combination of Target Agents: Challenges and Opportunities. Journal of Thoracic Oncology 2:Supplement 1, S4-S6
CrossRef1068
Miguel Ángel Medina, Ramón Muñoz-Ch´puli, Ana R. Quesada. (2007) Challenges of antiangiogenic cancer therapy: trials and errors, and renewed hope. Journal of Cellular and Molecular Medicine 11:3, 374-382
CrossRef1069
P Hinnen, F A L M Eskens. (2007) Vascular disrupting agents in clinical development. British Journal of Cancer 96:8, 1159-1165
CrossRef1070
Jhanelle Gray, George Simon, Gerold Bepler. (2007) Molecular predictors of chemotherapy response in non-small-cell lung cancer. Expert Review of Anticancer Therapy 7:4, 545-549
CrossRef1071
Roy L Pañares, Agustin A Garcia. (2007) Bevacizumab in the management of solid tumors. Expert Review of Anticancer Therapy 7:4, 433-445
CrossRef1072
Suresh Ramalingam, Chandra P Belani. (2007) Role of bevacizumab for the treatment of non-small-cell lung cancer. Future Oncology 3:2, 131-139
CrossRef1073
(2007) Bevacizumab for Non–Small-Cell Lung Cancer. New England Journal of Medicine 356:13, 1373-1375
Full Text1074
Farbod Shojaei, Napoleone Ferrara. (2007) Antiangiogenesis to treat cancer and intraocular neovascular disorders. Laboratory Investigation 87:3, 227-230
CrossRef1075
Roy S Herbst, John V Heymach, Michael S O’Reilly, Amir Onn, Anderson J Ryan. (2007) Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opinion on Investigational Drugs 16:2, 239-249
CrossRef1076
Keisei TAKU, Narikazu BOKU. (2007) Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics 38:6, 393-400
CrossRef1077
Michael F Press, Heinz-Josef Lenz. (2007) EGFR, HER2 and VEGF Pathways. Drugs 67:14, 2045-2075
CrossRef1078
Manisha Gupta, James J. Lee, Edward Chu. (2007) Circulating Endothelial Cells and Circulating Endothelial Cell Progenitors as Surrogate Markers for Determining Response to Antiangiogenic Agents. Clinical Colorectal Cancer 6:5, 337-338
CrossRef1079
Uriel M. Malyankar. (2007) Tumor-Associated Antigens and Biomarkers in Cancer and Immune Therapy. International Reviews of Immunology 26:3-4, 223-247
CrossRef1080
Florian Schuetz, Christof Sohn, Andreas Schneeweiss. (2007) Bevacizumab in the Treatment of Metastatic Breast Cancer. Breast Care 2:2, 82-88
CrossRef
- Letters
